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Synthesis and Characterisation of Novel Long-Wavelength Phosphorescent Metal 
Complexes of Iridium(III) and Rhenium(I) 
By Kaitlin Alexandra Phillips 
The purpose of the work reported in this thesis was to develop novel phosphorescent transition 
metal complexes. These species are of importance due to the wide range of applications which 
will be discussed in further detail throughout this work. There is a clear need for the 
development of new red-emitting species which are of particular interest in the fields of OLEDs 
and bioimaging. 
Chapter 2 describes the effect of cyclometallating ligand substitution upon the photophysical 
properties of cationic iridium(III) complexes with an ancillary 2,2’-bipyridine ligand. A series of 
cyclometallating ligands based upon quinoxaline were synthesised and functionalised with 
electron withdrawing and donating groups. It was found that substitution was an effective 
method for the fine-tuning of emission wavelength and that the methylated species synthesised 
were excellent triplet-triplet annihilation upconversion donors. 
Chapter 3 utilises the same cyclometallating ligands from chapter two and describes the effect 
of ancillary ligand upon the overall photophysical properties. Picolinic acid and pyrazinoic acid 
were used as ancillary ligands to give a series of eleven novel complexes which all showed red 
emission and increased the total tuning range of emission wavelength.  
Chapter 4 describes the effect of conjugation upon the emission of cationic iridium(III) 
complexes. Four novel bis-cyclometallated iridium(III) complexes were synthesised with a series 
of benzo[g]quinoxaline ligands. Results showed near-infrared emission comparable to previous 
reports in literature but also showed visible green emission which previous reports has not 
observed. 
Chapter 5 describes the synthesis of four novel organic lumophores based upon a 
dicyanodibenzodioxin structure. It was shown that emission from these species is dominated by 
a charge transfer transition arising from the dicyanodibenzodioxin core of the compounds. 
Coordination of these compounds to rhenium(I) gave four novel neutral complexes that 
exhibited dual red and green emission. It was also noted that exchange of the axial halide ligand 
in the neutral species with acetonitrile gave a cationic species that showed green emission only. 
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1.1. Introduction  
The work in this thesis focuses upon the synthesis and characterisation of novel luminescent 
transition metal complexes. A large part of the analysis of these complexes is centred upon the 
photophysical properties that they exhibit. Therefore, this chapter provides an introduction to 
the phenomena of luminescence and phosphorescence as well as properties such as lifetime 
and quantum yield which are discussed in detail in later chapters. Furthermore, examples of 
well-known and more recent luminescent transition metal complexes will be discussed as well 
as their potential applications. 
1.2.  Luminescence 
1.2.1. The Jablonski Diagram 
The phenomenon of luminescence is described as the spontaneous emission of light from a 
substance and was first described in 1888.1 Luminescence can be split into two different 
categories – fluorescence and phosphorescence – depending upon the emitting state of the 
compound. The differences between these processes can be more clearly understood by use of 
a Jablonski diagram such as that shown in Figure 1.1. The Jablonski diagram was first proposed 
by Prof. Alexander Jablonski in 1935 and describes the absorption and emission processes that 
can occur in a luminescent species.2 
 
Figure 1.1: Jablonski diagram 
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The processes shown in the diagram include: 
 Absorption – The absorption of light excites an electron from the ground state, S0, into 
a higher energy excited state, S1 or S2. 
 Internal Conversion – A non-radiative process that involves the fast relaxation to the 
lowest energy vibrational level of S1. 
 Fluorescence – The emission of light from a singlet excited state, S1. 
 Intersystem Crossing – This is a spin conversion process from singlet state S1 to triplet 
state T1. 
 Phosphorescence – The emission of light from an excited triplet state, T1. 
In addition to these processes, it is also worth noting that there are additional non-radiative 
pathways in which an electron can relax back to the ground state S0.  
Fluorescence is a very fast process with lifetimes of typically 10-9 – 10-6 s. These short lifetimes 
are a consequence of the spin selection rule; as there is no change in quantum spin number from 
S1 to S0, fluorescence is formally spin-allowed and relaxation occurs rapidly.3 Conversely, 
phosphorescence lifetimes are relatively much longer and can extend to >100 s. This is because 
the spin selection rule is broken in phosphorescence as the spin quantum number must change 
between T1 and S0. 
1.2.2. The Stokes Shift 
The energy of luminescent emission from a species is lower than the energy of absorption. This 
is due to energy being lost through non-radiative processes such as internal conversion and 
intersystem crossing before the fluorescence or phosphorescence emission. The difference in 
energy between the absorption and emission is known as the Stokes shift and was first reported 
by G. G. Stokes in the mid nineteenth century.4 
 
Figure 1.2: Diagram showing the Stokes shift. 
1.2.3. Kasha’s Rule 
The processes of internal conversion and, where applicable, intersystem crossing cause emission 
only to occur from the lowest energy excited state of a luminescent molecule. As a result of this, 
emission profiles are usually independent of the wavelength of light used to excite the species, 
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meaning that the emission spectrum will look identical regardless of the energy of the incident 
light. This is known as Kasha’s rule, named for Michael Kasha who first reported the 
phenomenon in 1950.5 
Many exceptions to this rule have been reported through the years, however a recent study 
reassessed a number of these anomalies and found all but one of their studied compounds, 
azulene, do obey Kasha’s rule. The majority of the previously reported exceptions to the rule 
were found to be either impure samples or molecular systems in the gas phase with insufficiently 
coupled vibrational relaxation.6 
1.2.4. Quantum Yield and Luminescence Lifetime 
The photoluminescence quantum yield, Φ, is a measurement of how efficiently a luminescent 
molecule converts absorbed light into emitted light and is essentially the ratio of photons 
emitted to photons absorbed. The quantum yield is described in Equation 1.1. The equation 
shows that the quantum yield, Φ, is equal to the rate of emission, Γ, divided by the sum of 
emissive and non-emissive processes, knr.7 
 
𝛷 =  
𝛤
𝛤 + 𝑘௡௥
 
Equation 1.1 
Examples of compounds that exhibit very high quantum yield values include rhodamine dyes,8,9 
9,10-diphenylanthracene,10 and fluorescein.11 The structures of these compounds along with 
their quantum yield values are shown in Figure 1.3. 
 
Figure 1.3: The structures and quantum yields of fluorophores rhodamine 101,9 9,10-
diphenylanthracene,10 and fluorescein.11 
Another important property of a luminescent molecule is the luminescence lifetime, τ. This is 
the average amount of time that the compound spends in the excited state before relaxing back 
into the ground state.7 As fluorescence is a random process, not every molecule will spend the 
same amount of time in the excited state. The lifetime is related to the rate of fluorescence by 
the following equation: 
𝜏 =  
1
𝛤 + 𝑘௡௥
 
Equation 1.2 
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Once the rate of fluorescence, Γ, has been calculated or measured, it is possible to calculate the 
natural lifetime, τn, of the lumophore. The natural lifetime is the average amount of time spent 
in the excited state in the absence of any non-radiative processes, knr. 
𝜏௡ =  
1
𝛤
 
Equation 1.3 
The natural lifetime can also be calculated from the quantum yield value and the measured 
lifetime. This relationship is shown in Equation 1.4. 
𝜏௡ =  
𝜏
𝛷
 
Equation 1.4 
A high rate of internal conversion can lower the quantum yield of a luminescent molecule as it 
contributes to the non-radiative processes. In particular, aromatic compounds containing nitro 
groups typically have large knr values, and as a result, are weakly emissive. Also, heavy atoms, 
such as chlorine, can facilitate intersystem system crossing which also leads to lower rates of 
emission.7 
1.2.5. Luminescence Quenching 
Quenching is described as any process that decreases the intensity of luminescent emission from 
a species.7 The different forms of luminescence quenching are discussed below. 
1.2.5.1. Collisional Quenching 
Collisional quenching occurs when a luminescent molecule collides with another molecule, 
known as a quencher, in solution. The collisional quenching pathway is illustrated in the 
Jablonski diagram in Figure 1.4. 
 
Figure 1.4: Jablonski diagram illustrating the radiative and non-radiative processes involved in collisional 
quenching. Where FRET is fluorescence energy transfer to an acceptor molecule, A, and Σki is the sum of 
all non-radiative processes except for quenching, kq.  
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The process of collisional quenching is described in the Stern-Volmer equation, shown below 
(Equation 1.5). The terms F0 and F refer to the fluorescence intensity in the absence and in the 
presence of a quencher respectively, and [Q] is the concentration of the quencher species. The 
lifetime in the absence of quencher species is termed τ0 and kq is the rate of quenching. Together, 
these terms make up the Stern-Volmer quenching constant, K, and represent the sensitivity of 
a species towards a quencher. 
𝐹଴
𝐹
= 1 + 𝐾[𝑄] = 1 +  𝑘௤𝜏଴[𝑄] 
Equation 1.5 
Molecules that can act as collisional quenchers include oxygen,12–14 halogens,15,16 and amines.17–
19 The mechanisms of quenching differ between species, for example, heavy atoms such as 
halogens are good quencher species due to spin-orbit coupling.7 
1.2.5.2. Static Quenching 
Static quenching is a form of quenching that occurs in the ground state independently of 
diffusion or collisions. One such type of quenching occurs when the lumophore forms a non-
fluorescent complex with another compound.7,20 An example of this is observed in the 
interaction between the copper complex and the amino acid shown in Figure 1.5. The 
fluorescence from the dansyl(DNS)-amino acid on the right of the figure was found to be 
quenched upon binding to the copper complex on the left. This was reported by Corradini et al. 
in 1992.21 
 
Figure 1.5: The copper(II) complex on the left was found to quench the fluorescence of the dansyl(DNS)-
amino acid by static quenching.21 
1.2.6. Solvent Relaxation 
Molecules of solvent can also have an effect upon the wavelength of emission. Solvent 
molecules can arrange themselves around the excited state dipole of the lumophore (which is 
often larger than that in the ground state). This can stabilise the excited state, lowering the 
energy and causing a bathochromic shift in emission. 22 
 
1.2.7. Resonance Energy Transfer 
Resonance energy transfer, RET, is another non-radiative process that can occur. This happens 
when there is an overlap between the emission spectrum of the lumophore, known as the 
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donor, and the absorption spectrum of another molecule, known as the acceptor.23 The acceptor 
molecule does not need to be luminescent itself and the process does not involve the emission 
of light from the donor. Instead, a dipole-dipole interaction couples the donor and acceptor 
molecules. As a result of this, it is the distance between the donor and acceptor molecules that 
determines the extent of energy transfer. The rate of energy transfer, kT(r), is calculated using 
Equation 1.6 where R0 describes the spectral overlap between donor and acceptor, τD is the 
lifetime of the donor in the absence of the acceptor and r is the distance between the donor and 
acceptor molecules. 
𝑘்(𝑟) =  
1
𝜏஽
൬
𝑅଴
𝑟
൰
଺
 
Equation 1.6 
The efficiency of this process between a donor and acceptor molecule at a fixed distance apart 
is described in Equation 1.7. These equations clearly show that this process is highly dependent 
upon the factor r. 
𝐸 =  
𝑅଴଺
𝑅଴଺ +  𝑟଺
 
Equation 1.7 
This sort of energy transfer has been made use of in the field of analytical biochemistry. It allows 
for the measurement of distances between 10 - 100 Å and as such has been implemented as a 
“spectroscopic ruler” in determining the distance between important sites in proteins.24,25   
1.3. Luminescence Measurements 
Luminescent properties are measured using a luminescence spectrometer. There are two types 
of luminescent measurement that can be obtained from a fluorescence spectrometer, steady 
state and time-dependent measurements. 
1.3.1. Steady State Measurements 
Steady state measurements are the most common sort of measurements taken. They involve 
the constant illumination of the sample by light and the emission intensity is measured. Steady 
state of the sample is achieved almost instantaneously due the extremely short lifetimes 
associated with fluorescence.7 
1.3.2. Time Resolved Measurements 
During a time resolved measurement, the sample is exposed to a short pulse of light and the 
intensity decay of fluorescence is measured. Typically, the pulse width of the excitation light 
used is shorter than the time taken for fluorescence to decay. This means that a high-speed 
detector is required for the measurement of fluorescence on a nanosecond timescale. The 
fluorescence intensity of a molecule can be described using Equation 1.8 where I0 is the intensity 
at time t = 0 and τ is the lifetime of the lumophore.7 
𝐼(𝑡) =  𝐼଴ 𝑒
ି௧ ఛൗ  
Equation 1.8 
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It is also important to note that the steady state and time resolved measurements are linked as 
the steady state measurement is simply an average of the time resolved events. However, time 
resolved measurements can provide information that is lost in the averaging process of steady 
state. Through time resolved measurements it is possible to obtain information on quenching 
pathways, resonance energy transfer and molecular conformations. 
1.4. Recording Spectra 
Luminescence spectra are recorded using a luminescence spectrometer. Figure 1.6 shows the 
typical set up for a luminescence spectrometer. Common light sources that are available include 
arc xenon lamps, photodiodes and lasers. The optical filters and monochromators process the 
path of the light and the photomultiplier tube, PMT, detects the output light. 
 
Figure 1.6: Simplified diagram of luminescence spectrometer set-up. 
1.4.1. Emission Spectra 
To record an emission spectrum an appropriate excitation wavelength, λex, must first be chosen. 
Typically, the wavelength chosen matches the wavelength at which the molecule absorbs light, 
this can be observed in the UV-vis absorption spectrum which is usually recorded prior to 
luminescence measurements. Next, a scanning range is chosen using the emission 
monochromator. It is important to begin the scanning range at a higher wavelength than that 
used for excitation to avoid damaging the instrument. The spectra are produced as a plot of 
emission intensity vs. wavelength.  
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1.4.2. Excitation Spectra 
To record an excitation spectrum, the emission monochromator is set to the emission maximum, 
λem, which is determined from the emission spectrum. The excitation monochromator scans 
through wavelengths from around 250 nm up to around 15 nm λem. The peaks observed in the 
excitation spectrum are those wavelengths of light that are responsible for the emission peak 
observed. In general, the excitation spectrum will closely resemble the absorption spectrum of 
the lumophore.  
1.5. Types of Lumophores 
1.5.1. Organic Lumophores 
The majority of organic fluorophores are aromatic compounds. These compounds are good 
chromophores and their emission wavelengths can be altered with varying the functional groups 
and the amount of conjugation in the species. Examples of some polyaromatic lumophores are 
shown in Figure 1.7.  
 
Figure 1.7: Organic fluorophores with a polyaromatic structure. 
Due to the aromatic nature of these compounds, the absorption bands arise from a π-π* 
transition.26 The emission arises from a low-lying singlet π* state and is formally fluorescence. It 
is known that extending the conjugation of these molecules can bathochromically shift the 
emission. 
The compounds in Figure 1.7 show fluorescence in the UV to blue region of the visible spectrum. 
But it is known that extending the conjugation of organic fluorophores can cause a bathochromic 
shift in the emission wavelength. As such, new compounds have been developed to create 
organic fluorophores that emit at different wavelengths across the whole spectrum from UV to 
near infra-red wavelengths. 
The field of organic fluorophores is still expanding today, and some newer compounds are 
shown in Figure 1.8. The compound on the left of the image is an example from 2019 which 
showed emission at around 675 nm in the solid state. In addition to this, when the compound 
was incorporated into a polyethylene film and heated to different temperatures, the emission 
wavelength was found to decrease to around 550 nm at temperatures of 80 ˚C and higher.27 The 
compound on the right of the image was also reported in 2019. The dye was developed for use 
as a dopant in organic light emitting diodes, OLEDs, and showed an emission wavelength of 
around 600 nm in toluene, and a quantum yield value of 57%.28   
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Figure 1.8: Examples of new organic fluorophores. 
1.6. Transition Metal Complexes 
Transition metal complexes are attractive lumophores as it is possible to tune the electronic 
properties of these species by carefully choosing the ligand system and the metal to be used. 
This allows the emitting state of the complex to be pre-determined. The transitions typically 
expected for a transition metal complex are as follows: 
 Metal Centred (MC): These are transitions that occur between the d orbitals of the 
metal centre, also known as dd transitions. 
 Metal-to-Ligand-Charge-Transfer (MLCT): Transitions that involve the excitation of a 
metal centred electron to an anti-bonding (π*) orbital of the ligand. 
 Intra-Ligand (IL): The promotion of an electron in a π-bonding or non-bonding orbital of 
the ligand to an anti-bonding orbital of the same ligand. 
 Ligand-to-Metal-Charge-Transfer (LMCT): These transitions involve the movement of 
an electron from the ligand system to the metal centre.29 
Which of these states is the lowest-lying, and therefore the emitting state, can depend upon the 
metal centre, the ligand system and the geometry of the complex, making metal complexes ideal 
starting points for the design of new luminescent compounds for many applications.30 Some of 
these applications include chemosensing,31 biological imaging,32–34 organic light emitting 
diodes,35–37 and as dyes in solar cells.38–40 Some prominent examples are discussed below along 
with some newer developments. 
1.7. Phosphorescent Transition Metal Complexes 
1.7.1. First Row Transition Metal Complexes 
First row transition metals have weaker spin-orbit coupling effects and as such, 
phosphorescence is not commonly observed. While there have been reports of manganese(I) 
and manganese(II) complexes exhibiting phosphorescence in solid glasses at low 
temperatures,41,42 and weak phosphorescence from some nickel(0) complexes in solution,43,44 
the main examples of room temperature phosphorescence have been from complexes of 
chromium(III) and copper(I). 
The emission wavelengths of chromium(III) complexes are typically restricted to the red region 
of the spectrum due to the small energy gaps between ground and excited states in first row 
transition metals.45,46 In the case of copper(I) complexes, the emission is often weak and short-
lived. However, multi-nuclear complexes have shown significant room temperature 
phosphorescence.47 
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Shown in Figure 1.9 are some examples of phosphorescent chromium (III)  and copper(I) 
complexes. The chromium complex on the left of the figure was reported in 2017 by Barbour et 
al. and showed near infra-red emission at 796 nm. In addition to this, the complex also showed 
a long lifetime of 600 ns.48 The complex in the centre of Figure 1.9 is a dinuclear copper(I) 
complex which showed emission at 663 nm, with a lifetime of 16 ns. The authors also reported 
a low quantum yield value of 1x10-4.49 The final copper complex shown is a more recent example 
and was reported in 2018 by Liu et al. The mononuclear complex showed emission at 691 nm, 
with a lifetime of 750 ns.50 
 
Figure 1.9: Examples of phosphorescent chromium(III) and copper(I) complexes. 
More recently, an example of a phosphorescent iron(II) complex was reported by Vogler in 
2016.51 The tetrahedral Fe(II) complex with a binap (2,2’-bis(diphenylphosphino)-1,1’-
binaphthyl) ligand showed intraligand phosphorescent emission in the solid state at 505 nm. The 
structure of this complex is shown in Figure 1.10. Another example of a photoluminescent iron 
complex was reported by Chábera et al. in 2017.52 The octahedral low-spin d5 complex was 
synthesised using the carbene ligand btz (3,3’-dimethyl-1,1’-bis(p-tolyl)-4,4’-bis(1,2,3-triazol-5-
ylidene)) and showed emission at 600 nm with an emission lifetime of 100 ps. The emission was 
found to arise from an excited 3LMCT state. 
 
Figure 1.10: Left) Phosphorescent complex of Fe(II) reported by Vogler.51 Right) Phosphorescent complex 
of Fe(III) reported by Chábera et al.52 
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1.7.2. Second and Third Row Transition Metal Complexes 
The atoms in the second and third rows of the transition metals are heavier than those in the 
first row and, as a result, cause a stronger spin-orbit coupling effect. This helps to increase the 
rate of intersystem crossing from a singlet excited state to a triplet excited state. The 
consequence of this is that room temperature phosphorescence in solution and in the solid state 
is much more common for complexes of these metals than those of the first row. Furthermore, 
high quantum yields can be observed as the mixing of singlet and triplet states via spin-orbit 
coupling eliminates the spin-forbidden nature of the transition from T1  S0.29 Phosphorescent 
complexes of the 2nd and 3rd row transition metals can be characterised by the d electron 
configuration of the metal. 
1.7.2.1. d6 Configuration 
The metals that fall into this category include rhenium(I), ruthenium(II), osmium(II), rhodium(III) 
and iridium(III). Examples of rhenium(I) and iridium(III) complexes are discussed in detail in later 
chapters, and as such this introduction will focus only on ruthenium(II), osmium(II) and 
rhodium(III) complexes. 
Complexes of ruthenium(II) with simple polypyridine ligands, such as 2,2’-bipyridine and 1,10-
phenanthroline, have been well studied over the last few decades for their photophysical 
properties.53,54 It is known that phosphorescence from these complexes arises from a low-lying 
3MLCT state and that quantum yields for these complexes typically range between 10-1 – 10-3 
and lifetimes in the microsecond range. In addition to this, it has been noted that ligand tuning 
is largely inefficient and that the emission from these complexes is almost always in the orange-
red region of the spectrum.54 
Osmium(II) complexes with polypyridine ligands have also been extensively studied. Due to 
strong back-bonding to the ligands from the osmium centre, the emission lifetimes observed 
from these complexes are much shorter than from ruthenium(II) complexes and are generally in 
the order of 10-2 µs.55,56 However, the use of π-acid ligands such as phosphine or arsine alongside 
polypyridine ligands can extend the lifetime of phosphorescence up to tens of microseconds.57 
Ligand tuning has also been found to be more effective in changing the emission wavelength of 
Os(II) complexes than in Ru(II) complexes. While complexes such as [Os(bpy)3]2+ and 
[Os(phen)3]2+ emit in the red to near infra-red region,58,59 emission can be shifted into the green 
region of the spectrum by the use of phosphine ligands.57  
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Figure 1.11: Complexes of ruthenium(II) and osmium(II) with their photophysical properties.57,58 
Rhodium(III) and iridium(III) also have d6 electron configurations. Room temperature 
phosphorescence in solution is commonly observed in complexes of Ir(III), but  phosphorescence 
from complexes of Rh(III) is often only observed in low temperature glasses.60,61 This is due to 
rhodium(III) having weaker spin-orbit coupling than iridium(III). Exceptions to this are observed 
in cyclometallated complexes of rhodium(III) with diimine ligands. An example of such a complex 
is shown on the right of Figure 1.12; this complex was reported by Mandal et al. in 2014 and 
showed emission in solution at room temperature with a quantum yield value of 0.035 and a 
two-component lifetime, τ = 2.3 ns (83 %), 4.5 ns (17 %).62   
 
Figure 1.12: Structures and emission wavelengths of rhodium(III) complexes. Left and centre complexes 
recorded as ethanol: methanol glasses, right complex recorded in acetonitrile solution.61,62 
1.7.2.2. d8 Configuration 
There are fewer examples of phosphorescent d8 metal complexes than those with a d6 
configuration. There have been many reports of room temperature phosphorescence in solution 
from complexes of platinum(II). This is because the heavy platinum centre increases the rate of 
intersystem crossing which enhances phosphorescence. Three examples of such complexes are 
shown in Figure 1.13 along with some of their photophysical properties.  
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Figure 1.13: Phosphorescent complexes of platinum(II) along with photophysical properties.63–65 
The complex on the left was reported in 2003 by Williams et al. and at the time was only the 
second report of luminescence from a platinum(II) complex with an N^C^N cyclometallating 
ligand.63 The complex in the centre of the figure was reported in 2004 and is one of the earliest 
examples of a luminescent platinum(II) complex with an S^C^S pincer ligand. The complex 
showed long-lived phosphorescence at 595 nm and is air stable. These properties make the 
complex a good candidate for use in optoelectronic devices.64 The final complex shown is a much 
more recent example of a luminescent platinum complex. This species was reported as part of 
a series of eight cyclometallated complexes. While the lifetime and quantum yield of this 
complex in air are much lower than those reported for the other complexes in Figure 1.13, the 
emission wavelengths observed are much longer. The authors intend to incorporate these 
particular ligands into solid state lighting devices.65  
Phosphorescence from palladium(II) complexes is much rarer due to the weaker heavy atom 
effect when compared to platinum(II).29 The room temperature emission of many Pd(II) 
complexes has been due to fluorescence,66,67 with phosphorescence only observed at low 
temperatures.68,69 The most common ligand system in palladium(II) complexes is porphyrin. 
Metalloporphyrins of platinum and palladium typically show  red phosphorescence. Two 
examples of palladium(II) metalloporphyrins are shown in Figure 1.14. The complex on the left 
of the figure, meso-tetra (carbonyl phenyl) porphyrin palladium, is a well reported luminescent 
complex that shows near infra-red emission at 695 nm. In 2019, the complex was incorporated 
into a new hydrogel and used as an imaging agent.70 The complex on the right of the figure was 
reported by Łapok et al. in 2016 in addition to a platinum(II) complex with the same porphyrin 
ligand. The palladium complex exhibited emission at 1007 nm in air at room temperature with 
a lifetime of 15 µs.71 
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Figure 1.14: Phosphorescent palladium(II) metalloporphyrins. 
1.7.2.3. d10 Configuration 
Both silver(I) and gold(I) have d10 electron configurations. The photophysical properties  of 
silver(I) complexes have been much less well studied than other metal systems due to the light-
sensitivity of silver(I). Of the complexes that have shown phosphorescence, many exhibit similar 
structures to copper(I) complexes due to the similar bonding modes of these two metals. An 
example of this is the hexanuclear complex shown on the left of Figure 1.15. In a study where 
both the silver(I) and copper(I) analogues were synthesised; the silver complex showed room 
temperature phosphorescence in solution and in the solid state at 515nm. This was a substantial 
blue-shift from the copper(I) species which showed emission at 595 nm.72 The complex on the 
right of the figure is a silver metallocycle reported in 2018 that exhibits phosphorescence at low 
temperatures with an emission wavelength of 448 nm and a lifetime of 138 µs.73  
 
Figure 1.15: Examples of phosphorescent silver(I) complexes. 
In contrast, phosphorescent complexes of gold(I) are much more common. The geometry of 
gold(I) complexes is typically either two- or three-coordinate with the most common ligand 
systems being carbene, phosphine, thiolate and acetylide ligands. Gold(I) complexes have shown 
phosphorescence across the whole visible spectrum. Two recent examples of these complexes 
are shown in Figure 1.16. The complex shown on the left of the figure was reported in 2018 by 
Chen et al. and showed phosphorescence in the solid state. The complex showed emission at 
around 570 nm with a second, less intense emission at around 450 nm.74 The second complex is 
a dinuclear example of a gold(I) complex with carbene ligands that was reported in 2019. This 
complex also showed emission in the solid state, with an emission wavelength of 430 nm and a 
lifetime of 0.23 µs.75 
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Figure 1.16: Examples of phosphorescent gold(I) complexes. 
1.7.3. Fluorescent Transition Metal Complexes 
It is known that the singlet excited state lifetimes for transition metal complexes are extremely 
short. For example, the fluorescence lifetime of [Ir(ppy)3] has been reported at around 100 
fs,76,77 and that of [Ru(bpy)3]2+ has been recorded at 15 ± 10 fs.78 This is because the heavy metal 
atom in such complexes facilitates intersystem crossing which can have rates of around 1012 s-1, 
the result of this is that fluorescence is often very difficult to observe and the fluorescence 
quantum yields are very low, with that of [Ru(bpy)3]2+ reported at 9x10-5. 79 Despite this, there 
have been reports of transition metal complexes that exhibit fluorescence from a singlet excited 
state with lifetimes on the nanosecond timescale. Some examples of these complexes are shown 
in Figure 1.17. 
The rhodium complex on the left of the figure was reported in 2010 by Malder et al. The complex 
shown below was found to exhibit a long lived singlet excited state, this was found to be due to 
an unusually slow rate of intersystem crossing.80 The complex in the centre of the figure is an 
example of a fluorescent platinum complex first reported in 2010 as part of a series of platinum 
complexes with perylene-type ligands. The complex shown exhibited a fluorescence lifetime of 
1.9 ns and a quantum yield value of 0.43.81 The final complex in the figure is a fluorescent 
copper(I) complex. The complex shows fluorescence emission from a 1MLCT excited state, with 
a lifetime of 15 ps and an quantum yield value of 2.1x10-5. 82 
 
Figure 1.17: Examples of fluorescent transition metal complexes.80–82 
1.8. Summary 
As the above examples illustrate, transition metal complexes with conjugated organic ligands 
are a versatile group of compounds. The photophysical properties of these species can be 
manipulated with relative ease to give emission wavelengths across the whole of the visible 
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spectrum and even into the near infra-red. In addition to this, it is possible to adapt the quantum 
efficiency and lifetime to best serve individual applications. 
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2. Ligand-Tuneable, Red-Emitting Iridium(III) Complexes for Efficient 
Triplet–Triplet Annihilation Upconversion Performance 
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2.1. Introduction 
This chapter focuses on the design, synthesis and characterisation of cationic bis-
cyclometallated iridium(III) complexes. These types of complexes have been well studied over 
the past few decades for their photophysical properties and, as a result, their applications have 
become more and more diverse. The main applications of these species are discussed in detail 
below. 
2.1.1. Applications of Iridium(III) Complexes 
Cyclometallated octahedral complexes of iridium(III) have a large Δo value, and due to the strong 
σ character of the Ir-C cyclometallating bond, metal-to-ligand charge-transfer (MLCT) and 
ligand-to-ligand charge transfer (LLCT) are energetically more favourable than metal-centred 
(MC) transitions.1–3 As both the metal centre and the ligand are involved in emission, the 
emission wavelength can be tuned by making changes to the cyclometallating ligand. A property 
that is often exploited in iridium chemistry. 
2.1.2. Photocatalysts 
Transition metal complexes undergo an MLCT transition when excited by visible light and as a 
consequence, they can go through reductive and oxidative quenching pathways easily.1,4 In the 
case of ruthenium complexes, this has been utilised in the catalysis of organic transformations.5,6 
More recently, focus has moved to complexes of rhenium and iridium. Examples of some iridium 
complexes used as photocatalysts are shown in Figure 2.1. The complex on the left of the figure 
was first used as a catalyst by Stephenson et al. to break down lignin biomass substrates in a 
photoflow reactor.7 The same catalyst has since been used to catalyse a [4+2] ring-opening 
reaction in cyclobutylanilines with alkynes,8 and in a separate study was found to aid asymmetric 
azapinacol cyclization.9 The complex in the centre of the figure was found to perform selective 
C-H vinylation utilising vinyl sulfones. The reaction resulted in good yields and the methodology 
also extended to N-Boc α-amino acids.10 The final complex in the figure was reported in 2013 
and was found to be a highly efficient photocatalyst for CO2 reduction.11  
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Figure 2.1:Examples of iridium(III) complexes developed as photocatalysts. 
2.1.3. Photovoltaics 
Iridium complexes have also found use as light-harvesting molecules in photovoltaics; examples 
of these complexes are shown in Figure 2.2. The first complex in the figure was reported in 2015 
and was used to fabricate a bulk heterojunction solar cell. The device exhibited a power 
conversion efficiency of 0.25 %, which although low, showed that the complex was a good 
starting point for the design of complexes for photovoltaic applications.12 The central complex 
in the figure was reported in 2018 as part of an artificial FRET antenna with the complex used as 
the donor, and a BODIPY-type dye as an acceptor.13 The complex on the right side of the figure 
shows the general structure of a series of complexes reported in 2017 where an efficiency of up 
to 0.62 % was recorded when these species were incorporated into TiO2-based n-type dye-
sensitised solar cells.14  
  
Figure 2.2: Complexes developed for photovoltaic applications. 
2.1.4. Bioimaging 
One field where cationic iridium complexes have found particular use is bioimaging. Some of the 
most important requirements for cell imaging agents are low toxicity and preference for 
concentrating in a particular organelle.15,16 Metal complexes can be made to meet these 
requirements by the use of non-toxic, non-labile ligands with substituents that target specific 
organelles. In addition to this, metal complexes are particularly attractive due to their long-lived 
phosphorescence and large Stokes shifts.17–19  
The first report of cationic iridium(III) complexes used as stains in living cells came in 2008, these 
complexes are shown in the left and centre of Figure 2.3. The complex on the left of the image 
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is a green emitting species while the complex in the centre showed red emission, however both 
complexes selectively stained the cytoplasm of cells.20 The complex on the right of the figure is 
one of the most recent examples of an iridium based imaging agent. This complex was reported 
in 2019 as a detector for Cu2+ ions in cells. The complex shows green phosphorescence which is 
rapidly turned off in the presence of Cu2+ ions.21  
 
Figure 2.3: Iridium complexes synthesised as bioimaging agents. 
2.1.5. Triplet-Triplet Annihilation Upconversion 
Triplet-triplet annihilation upconversion (TTA UC) is a process whereby high energy light is 
produced from a low energy light input. One of the most promising applications of this 
phenomenon is to increase the efficiency of solar cells.22 The process involves the excitation of 
a donor molecule into a triplet excited state followed by triplet-triplet energy transfer to an 
appropriate acceptor molecule. Collision of two such acceptor molecules results in the 
population of a higher energy singlet level and produces upconverted delayed fluorescence 
exhibiting an anti-Stokes shift.23 
 
Figure 2.4: Schematic of triplet-triplet annihilation. Where D = donor molecule and A = acceptor 
molecule. 
Typically, the triplet acceptor molecules are commercial compounds used without further 
modification, but the criteria for a good acceptor is as follows: 1) The energy of the excited 
singlet state should be less than twice the energy of the excited triplet state (2 x ET1 > ES1) to 
allow population of the singlet state upon annihilation. 2) The compound should possess a high 
fluorescence quantum yield. 3) The T1 energy level should be tuneable, and 4) the acceptor must 
have good photochemical stability. Examples of common acceptor molecules include 
anthracene, 9,10-diphenylanthracene (DPA), perylene and boron-dipyrromethene (BODIPY). 
The structures of these compounds are shown in Figure 2.5.24 
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Figure 2.5: Examples of common triplet-triplet annihilation acceptor compounds. 
For efficient TTA UC, the donor molecule must exhibit efficient intersystem crossing, strong 
absorption in the visible region and long phosphorescent lifetimes.25 Late transition metal 
complexes have become well studied in this field because, in addition to the properties 
mentioned above, they also have large spin-orbit coupling constants and efficient intersystem 
crossing to the triplet state.24  
Ruthenium polyimine complexes have been studied for a long time for their upconversion 
efficiency. Figure 2.6 shows a ruthenium complex with a phenanthroline ligand that has a pyrene 
substituent. This complex was reported by Ji et al. in 2011 with an upconversion efficiency of 9.8 
%.26 Platinum and palladium porphyrin complexes have also been of interest. The complex in 
the centre of Figure 2.6 is a platinum porphyrin complex with a reported ΦUC value of 0.65 %.27 
One potential explanation for this relatively low value is the large size of the sensitiser molecule 
which may slow diffusion rate of the triplet state.28 The complex on the far right of the figure is 
a palladium complex which has a ΦUC = 4.00%.29 
 
Figure 2.6: Examples of transition metal complexes developed as triplet-triplet annihilation donors. 
Iridium(III) complexes are of particular interest in producing new sensitiser species for 
upconversion as they can have much higher ΦUC values. Some recent examples are shown in 
Figure 2.7. The tris-cyclometallated complex in the left of the image was reported by Peng et al 
in 2014 who found that when R2 was an alkyl chain, ΦUC = 0.26 %, but replacement of this group 
with a pyrene derivative caused this value to increase to 4.1 % .30 The complex in the middle of 
the figure is a bis-cyclometallated complex which uses a diimine ligand with a coumarin 
substituent to achieve a ΦUC value of 23.4 %. 31 The complex on the right of the figure was 
reported in 2016 and had the highest reported ΦUC value, at the time of this current work, for a 
triplet sensitiser species at 31.6 %.32  
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Figure 2.7: Examples of upconversion donor species based on iridium complexes. 
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2.2. Aims 
The aim of this chapter was to investigate the effects of cyclometallating ligand substituents 
upon the photophysical properties of their complexes. In this study, a series of seven 
cyclometallating complexes based upon quinoxaline derivatives have been synthesised that bear 
electron withdrawing and electron donating groups.  
These ligands were then coordinated to iridium along with a 2,2’-bipyridine ancillary ligand to 
give a series of cationic bis-cyclometallated iridium(III) complexes. The photophysical properties 
of these ligands were then fully investigated in an attempt to understand how ligand 
substituents can change the emission properties of organometallic complexes. In addition to 
this, DFT computational studies were performed in an effort to explain the experimental results 
observed. Also, the complexes were investigated for their potential use as upconversion 
sensitisers. 
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2.3. Results and Discussion 
2.3.1. Synthesis and Characterisation 
In this chapter of work, seven cyclometallating ligands were synthesised. These compounds 
were based upon quinoxaline and were differently functionalised to contain either electron 
withdrawing or electron donating groups. The substituents used were fluoro- and chloro- groups 
to induce an electron withdrawing effect, and methyl groups which have a weak electron 
donating effect. The general scheme for the synthesis of these ligands is shown in Scheme 2.1.  
 
Scheme 2.1: Synthesis scheme of ligands HL1-7 
The synthesis involves dissolving a phenyldiamine with benzil or 1-phenyl-1,2-propanedione in 
ethanol and heating to reflux in the presence of a catalytic amount of acetic acid. The ligands 
HL3-7 precipitated from the reaction mixture as solids after several hours and, after filtration 
and washing, required no further purification. However, the ligands HL1 and HL2 did not 
precipitate from the reaction mixture as solids. Instead, for these ligands, the solvent was 
removed under reduced pressure and the crude product taken up in dichloromethane and 
washed with dilute hydrochloric acid. The organic phase was then dried under reduced pressure 
to give the pure ligands as waxy solids.  
 
Figure 2.8: Assignment of proton NMR spectrum of ligand HL3. (300 MHz, CDCl3) 
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Figure 2.8 shows the proton NMR spectrum of ligand HL3. The two singlets at 8.23 and 8.18 ppm 
are assigned to the aromatic protons nearest to the chloro-substituents, and the singlet at the 
higher ppm value is that on the same side of the molecule as the phenyl substituent. They appear 
as two singlets due to the asymmetry of the molecule. The phenyl substituent is electron 
withdrawing and as a result this proton is slightly more de-shielded than the other. The 
multiplets at 7.64 and 7.53 ppm arise from the phenyl substituent and the singlet at 2.77 ppm 
corresponds to the methyl substituent.  
The electron withdrawing effect of the phenyl moiety can be seen more clearly in Figure 2.9, 
where the proton NMR spectra of the di-phenyl substituted ligand is overlaid with the 
corresponding phenyl-, methyl-substituted ligand. The protons corresponding to the two 
singlets seen at 8.23 and 8.18 ppm in the spectrum of HL3, are equivalent in HL6. Because of 
this, the two protons cause one singlet in the proton NMR at 8.29 ppm. The chemical shift of 
this singlet is higher than those seen in HL3 due to the extra electron withdrawing effect that 
occurs when there are two phenyl moieties in the molecule. 
 
 
Figure 2.9: Overlaid proton NMR sub-spectra of HL3 (red) and HL6 (black). (300 MHz, CDCl3) 
The ligands were also characterised by carbon NMR spectroscopy, high resolution mass 
spectrometry and, where applicable, fluorine NMR spectroscopy.  
The ligands were reacted with iridium trichloride, IrCl3.xH2O, to form the dimeric species [{Ir(L)2-
µ-Cl}2] as reported in literature.33 These reaction conditions have been shown to result in the  
cis-C,C and trans-N,N coordination mode of the cyclometallating ligand.34–36 This species was 
then used in the next step without further characterisation. The dimer was dissolved in 2-
ethoxyethanol with 2,2’-bipyridine and heated at reflux for 24 hours to give a series of cationic 
bis-cyclometallated iridium(III) complexes as chloride salts. 
Chapter 2  
30 
 
 
Scheme 2.2: General scheme for synthesis of cationic iridium(III) complexes. 
A saturated aqueous solution of ammonium hexafluorophosphate (NH4PF6) was added to the 
reaction flask to form the PF6 salt of the complex which precipitated from solution as a red solid. 
Where purification was required, this was carried out by column chromatography in DCM:MeOH 
(95:5). A pale-yellow band eluted first which was found to be free cyclometallating ligand, which 
was then followed by a red band. The red band was dried under reduced pressure and re-
precipitated from DCM and diethyl ether to give the pure cationic complex.  
  
Figure 2.10: Structures of seven cationic bis-cyclometallated iridium(III) complexes. 
The complexes were characterised by proton, carbon and where applicable, fluorine NMR 
spectroscopy. In addition to this, all complexes were also analysed by high resolution mass 
spectrometry, IR, UV-vis, transient absorption (TA) and luminescence spectroscopy. 
N
NR''
R''
R' IrCl3.xH2O
2-ethoxyethanol
N
N
N
N
Ir
R'
R'
R''
R''
R''
R''
N
N
N
N
Ir
R'
R'
R''
R''
R''
R''
Cl
Cl 2-ethoxyethanol
N N
N
N
N
N
Ir
R'
R'
R''
R''
R''
R''
N
N
N
N
N
N
N
N
Ir
N
N
N
N
N
N
Ir
Cl
Cl
Cl
Cl
N
N
N
N
N
N
Ir
F
F
F
F
N
N
N
N
N
N
Ir
F
F
F
F
N
N
N
N
N
N
Ir
Cl
Cl
Cl
Cl
N
N
N
N
N
N
Ir
N
N
N
N
N
N
Ir
PF6
C1a C2a C3a C4a
C5a C6a C7a
PF6 PF6 PF6
PF6 PF6 PF6
68 % 94 % 46 % 97 %
63 % 37 % 83 %
Chapter 2  
31 
 
 
Figure 2.11: Proton NMR spectrum of complex C4a. (400 MHz, acetone-d6) 
Figure 2.11 shows the proton NMR spectrum recorded for C4a. The circled signal at 6.81 ppm is 
a doublet which corresponds to the protons highlighted in red in the structure above. An upfield 
shift of the proton ortho- to the cyclometallating site on the phenyl moiety of the ligand is 
observed due to shielding by the ring currents of the aromatic moieties of adjacent ligands. 
The two fluoro- containing ligands, HL4 and HL7, and their corresponding complexes, C4a and 
C7a, were analysed by fluorine NMR spectroscopy and the data has been tabulated in Table 2.1. 
The chemical shifts of the fluorine atoms in the complexes shift upfield compared to those in 
the related free ligand. In the case of HL7, in addition to the upfield shift, the fluorine 
environments of the cyclometallating ligand become inequivalent upon coordination to the 
metal centre and two separate signals are observed. In both complexes, a signal is observed at 
-72.6 ppm which is not seen in the free ligand, due to the hexafluorophosphate anion. 
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Table 2.1: Fluorine NMR data including chemical shift values and coupling constants. 
Compound Ligand δ (3J(F,F)) [ppm] PF6- δ (1J(F,P)) [ppm] 
HL4 -130.4 (d, 21 Hz), -131.2 (d, 21 Hz)  
[Ir(L4)2(bpy)]PF6 -131.7 (d, 22 Hz), -133.7 (d, 22 Hz) -72.6 (d, 712 Hz) 
HL7 -129.9 (s)  
[Ir(L7)2(bpy)]PF6 -130.3 (d, 22 Hz), -132.7 (d, 22 Hz) -72.6 (d, 700 Hz) 
 
The data obtained from proton, carbon and fluorine NMR data confirm that each complex 
isolated was pure and only one isomer was present in each case.  
All of the complexes in this study were also characterised by high-resolution mass spectrometry. 
In all cases the molecular ion peak was present, and in some cases, a peak corresponding to a 
fragment containing both cyclometallating ligands but not the 2,2’-bipyridine ancillary ligand 
was also present. The isotope pattern was also consistent with an iridium-containing species. 
 
Figure 2.12: High-resolution mass spectrum of complex C2a with molecular ion peak. 
2.3.2. X-Ray Crystallography 
Single crystal X-ray data were obtained for complexes C2a, C5a and C7a. The crystals were grown 
via vapour diffusion of diethyl ether into saturated solutions of the complexes in acetonitrile. 
The crystal data was collected by the UK National Crystallography Service with the collection 
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parameters are reported in the experimental section of this chapter. The data show that the 
complexes have a distorted octahedral geometries around the iridium(III) centre and also 
confirms that the cyclometallating ligands chelate in a cis-C,C and trans-N,N manner. This also 
supports the theory that the trans influence of the phenyl group is stronger than that of the N-
heterocycle donors as .37–39  
 
Figure 2.13: X-ray structures of the cation in the complexes a) [Ir(L2)2(bpy)]PF6; b) [Ir(L5)2(bpy)]PF6 and c) 
[Ir(L7)2(bpy)]PF6. 
The structures also reveal that the ligand-Ir bond lengths match those expected for iridium(III) 
species. Additionally, it can be seen in the packing diagrams that there are intermolecular π-π 
interactions between the phenyl rings of quinoxaline ligands on neighbouring complexes. These 
rings are highlighted in blue in Figure 2.14. 
Table 2.2: Selected bonds lengths for complexes C2a, C5a and C7a. 
C2a C5a C7a 
Atom Atom Length/Å Atom Atom Length/Å Atom Atom Length/Å 
Ir1 N1 2.067(3) Ir1 N1 2.050(7) Ir1 N1 2.090(6) 
Ir1 N21 2.090(3) Ir1 N31 2.071(8) Ir1 N21 2.081(6) 
Ir1 N41 2.167(3) Ir1 N61 2.149(7) Ir1 N41 2.161(6) 
Ir1 N42 2.176(3) Ir1 N62 2.179(7) Ir1 N42 2.168(6) 
Ir1 C1 1.992(4) Ir1 C1 1.999(9) Ir1 C1 1.987(7) 
Ir1 C21 2.014(4) Ir1 C31 2.004(9) Ir1 C21 2.004(7) 
      Ir2 N51 2.083(7) 
      Ir2 N71 2.101(7) 
      Ir2 N91 2.143(6) 
      Ir2 N92 2.174(6) 
      Ir2 C51 1.984(8) 
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      Ir2 C71 1.985(7) 
 
Table 2.3: Selected bond angles for complexes C2, C5 and C7. 
C2a C5a C7a 
Atom Atom Atom Angle/° Atom Atom Atom Angle/° Atom Atom Atom Angle/° 
N1 Ir1 N21 170.94
(13) 
N1 Ir1 N31 173.2(3) N1 Ir1 N41 100.1(2) 
N1 Ir1 N41 102.78
(13) 
N1 Ir1 N61 100.3(3) N1 Ir1 N42 82.9(2) 
N1 Ir1 N42 84.10(
13) 
N1 Ir1 N62 81.5(3) N21 Ir1 N1 174.3(2) 
N21 Ir1 N41 82.80(
13) 
N31 Ir1 N61 84.6(3) N21 Ir1 N41 84.1(2) 
N21 Ir1 N42 104.35
(13) 
N31 Ir1 N62 104.3(3) N21 Ir1 N42 102.0(2) 
N41 Ir1 N42 75.46(
13) 
N61 Ir1 N62 75.8(3) N41 Ir1 N42 75.7(2) 
C1 Ir1 N1 79.48(
15) 
C1 Ir1 N1 80.1(3) C1 Ir1 N1 79.9(3) 
C1 Ir1 N21 96.25(
15) 
C1 Ir1 N31 95.7(3) C1 Ir1 N21 96.2(3) 
C1 Ir1 N41 170.06
(14) 
C1 Ir1 N61 172.2(3) C1 Ir1 N41 174.8(3) 
C1 Ir1 N42 95.29(
14) 
C1 Ir1 N62 96.7(3) C1 Ir1 N42 99.1(3) 
C1 Ir1 C21 87.66(
16) 
C1 Ir1 C31 88.2(3) C1 Ir1 C21 85.8(3) 
C21 Ir1 N1 92.62(
15) 
C31 Ir1 N1 95.2(3) C21 Ir1 N1 96.2(3) 
C21 Ir1 N21 79.15(
16) 
C31 Ir1 N31 79.4(4) C21 Ir1 N21 79.2(3) 
C21 Ir1 N41 101.82
(14) 
C31 Ir1 N61 99.5(3) C21 Ir1 N41 99.4(3) 
C21 Ir1 N42 175.10
(15) 
C31 Ir1 N62 173.5(3) C21 Ir1 N42 174.8(3) 
        N51 Ir2 N71 173.8(2) 
        N51 Ir2 N91 100.3(2) 
        N51 Ir2 N92 81.9(2) 
        N71 Ir2 N91 83.8(2) 
        N71 Ir2 N92 103.8(3) 
        N91 Ir2 N92 75.6(2) 
        C51 Ir2 N51 79.7(3) 
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C2a C5a C7a 
Atom Atom Atom Angle/° Atom Atom Atom Angle/° Atom Atom Atom Angle/° 
        C51 Ir2 N71 96.8(3) 
        C51 Ir2 N91 173.2(3) 
        C51 Ir2 N92 97.7(3) 
        C51 Ir2 C71 87.9(3) 
        C71 Ir2 N51 95.4(3) 
        C71 Ir2 N71 79.2(3) 
        C71 Ir2 N91 98.9(3) 
        C71 Ir2 N92 173.2(3) 
        N51 Ir2 N71 173.8(2) 
        N51 Ir2 N91 100.3(2) 
 
 
Figure 2.14: Packing diagram of complex C2a showing intermolecular π-π interactions of aromatic rings 
highlighted in blue. 
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Figure 2.15: Packing diagram of complex C5a 
Figure 2.16 shows the crystal structure of complex C5a overlaid with the computationally 
optimised structure. The computational work in this study was carried out by Thomas Stonelake 
and Dr Joseph Beames (Cardiff University). From the figure, it can be observed that the 
computational method used is able to adequately reproduce the crystal structure (RMSD < 0.5 
Ǻ), with the position of the methyl substituents introducing the major source of discrepancy 
which is likely from a combination of errors in both crystallography and DFT.  The methyl groups 
have low frequency vibrational motions associated with flexing and torsional motions which can 
account for this discrepancy.   
 
 
Figure 2.16: Overlay of the crystal structure (blue) and DF-DFT//B3LYP/6-31G*(SDD) optimised structures 
(brown) for [Ir(L5)2(bpy)]PF6. The structures exhibit an RMSD of 0.427 Å.  
There is also some discrepancy at the bipyridine position where the computationally optimised 
structure is closer to C2 symmetry. The RMSD value for complex C2a is < 0.2 Ǻ between the 
crystallography and computational geometry which also illustrates this effect. 
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2.3.3. Cyclic Voltammetry 
Cyclic voltammetry measurements were carried out upon the complexes in de-oxygenated 
dichloromethane. The cyclic voltammograms were measured by using a platinum disc electrode 
(scan rate υ = 200 mVs-1, 1x10-3 M solutions, 0.1 M [NBu4][PF6] as a supporting electrolyte). Each 
complex showed an irreversible oxidation process between + 1.4 and +1.6 V, which was assigned 
to a Ir3+ /4+ process. The lowest Eox values were observed for the methylated species C1, C2 and 
C5 which is consistent with the electron-donating ability of the quinoxaline ligands. The signal 
at around -0.9 V is irreversible and was assigned to a ligand centred reduction. An example 
voltammogram recorded for complex C4 is shown in Figure 2.17. 
 
Figure 2.17: Cyclic voltammograms recorded for complex C4 [(Ir(L4)2(bpy))(MeCN)][PF6]2 under argon. 
Voltammogram recorded in 0.25 M [NH4][PF6], scan rate υ = 200 mV/s with Fc/Fc+ couple at +0.46 for 
reference. 
2.3.4. Photophysical Properties 
The UV-vis absorption spectra of ligands HL1-7 are shown in Figure 2.18. All of the ligands absorb 
light in the UV region of the spectrum. The transitions shown arise from π-π* transitions in 
addition to n-π* transitions due to the heteroatom in the aromatic ring. 
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Figure 2.18: UV-vis absorption spectra of ligands HL1-7 recorded in chloroform (1x10-5 M) 
The spectra also show that the substituents on the ligands have an influence on the wavelength 
of light absorbed by the molecule. The unsubstituted ligand, HL1, has the lowest λmax value at 
325 nm, whilst the chloro-substituted ligand, HL6, has the highest value at 362 nm. It is also 
worth noting that the ligands with two phenyl substituents have longer absorption wavelengths 
than their counterparts with one phenyl and one methyl group.  
The steady state emission spectra of the free ligands were also recorded and the results are 
shown in Figure 2.19. All of the ligands emit light in the UV region of the spectrum and the 
emission profiles of the ligands match what would be expected from their absorption spectra, 
in that the ligand with the longest λmax value, HL6, has the longest emission wavelength at 408 
nm. Overall, there is an emission range of 45 nm across the series. 
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Figure 2.19: Steady state emission spectra of ligands HL1-HL7. Spectra recoded in chloroform, ex = 350 
nm. 
All of the complexes in this study were also characterised by UV-vis absorption spectroscopy and 
luminescence spectroscopy.  
The UV-vis absorption spectra of complexes C1a-7a were recorded in chloroform at a 
concentration of 1x10-5 M. The overlaid spectra of the complexes are shown in Figure 2.20 and 
show that each possesses three distinct features. The bands with high molar extinction 
coefficients between 260 and 400 nm are associated with ligand-centred transitions from the 
quinoxaline and bipyridine ligands. These are assigned as π-π* transitions; it is also likely that 
there are some n-π* transitions arising from the heteroatoms in the quinoxaline backbone. 
There is a weak, broad signal at between 474-498 nm with ε ~ 5000 M-1cm-1, that along with a 
stronger feature at 400-450 nm possess some metal-to-ligand charge transfer (MLCT) character. 
The exact position of these bands is dependent upon the substituents on the quinoxaline ligand 
with the halogenated species showing longer absorption wavelengths, and the methylated 
species having the shortest values. All complexes also showed a much weaker feature that 
extended to around 600 nm, which has typically been attributed to the spin-forbidden 3MLCT 
transition in iridium(III) species. 
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Figure 2.20: UV-vis absorption spectra of complexes C1a-7a. Recorded in CHCl3, 1x10-5 M 
A comparison of the absorption spectrum of HL1 and the absorption spectrum of C1a is shown 
in Figure 2.21. The feature at around 400-450 nm in the spectrum of the complex is not seen in 
the spectrum of the ligand, confirming that this transition does have some MLCT character. In 
addition to this, the absorption at 325 nm in the ligand, has red-shifted to 372 nm in the 
complex. 
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Figure 2.21: Comparison between absorption spectra of HL1 and C1a. 
2.3.5. Density Functional Theory 
All computational studies in this piece of work were carried out by Thomas Stonelake and Joseph 
Beames (Cardiff University). A more in-depth discussion of this work can be found in the 
publication in the appendix of this thesis.40 
The Kohn-Sham frontier orbitals of complex C1a were calculated and are shown in Figure 2.22. 
These calculations show that the occupied molecular orbitals have strong Ir 5d character while 
the unoccupied orbitals are more ligand centred. The contributions to the HOMO are equally 
split between the metal (33 %) and the two quinoxaline ligands (33 and 33 %), with a negligible 
contribution from the 2,2’-bipyridine ligand (1 %). However, the LUMO is predominantly 
quinoxaline ligand centred (48 and 47 %). Table 2.4 shows the contributions for each complex in 
the series. 
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Figure 2.22: Isosurfaces of the Kohn-Sham [Ir(L1)2(bpy)]PF6 frontier molecular orbitals (DFT//B3LYP/6-
31G*) 
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Table 2.4: Excitation contributions to the lowest lying singlet excited states of complex C1. Only single 
electron excitation contributions greater than 10 % are shown. Q1 and Q2 pertain to the two quinoxaline 
ligands. 
 Moiety Contribution to Molecular Orbital (%) 
Orbital Ir (5d) Bpy Q1 Q2 
LUMO + 4 1 67 16 16 
LUMO + 3 2 79 9 9 
LUMO + 2 2 97 0 1 
LUMO + 1 4 1 47 48 
LUMO 3 2 48 47 
HOMO 33 2 33 33 
HOMO – 1 3 1 48 48 
HOMO – 2 10 1 44 45 
HOMO – 3 22 3 38 37 
HOMO - 4 17 0 43 40 
For complex C1a, the longest wavelength singlet excitation was predicted to be at 405 nm and 
does not account for the broad feature observed at around 475 nm in the absorption spectrum. 
This feature is typically assigned to the formally spin forbidden T1  S0 transition but may 
become weakly allowed due to spin-orbit coupling effects (Table 2.5). This is also in agreement 
with the energy of the T1 state which corresponds to a predicted 3MLCT band at 514 nm. Figure 
2.23 shows that these values compare qualitatively with the observed UV-vis spectrum of C1a. 
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Figure 2.23: Bottom) Experimental absorption spectrum of complex C1a. Top) TD-DFT//CAM-B3LYP/6-31 
G*(SDD) convoluted absorption spectrum. 
These calculations suggest that the low-energy transition at between 400-450 nm, formerly 
assigned as having MLCT character, is not purely MLCT. In fact, the major contribution to this 
transition is ligand centred, which can explain why the energy of this transition depends upon 
the ligand substituents. This is also supported by the experimental steady state emission data, 
discussed below. 
Due to the favourable correlation between the experimental and computed UV-vis absorption 
spectra, the relative band positions of all complexes have been calculated and are displayed in 
Table 2.5. 
Table 2.5: Computed spectral properties for all complexes; experimentally observed band positions are 
given in parentheses. Values in italic are those calculated for an adiabatic system. The experimental spin-
allowed absorption band positions are taken from the band onsets, whereas the spin-forbidden 
parameters are λmax value. (a) Recorded in chloroform. (b) Recorded in chloroform; λex = 355 nm.  
 
The steady state emission spectra were also recorded for each complex. The species with the 
longest emission wavelength is the chlorinated complex C6a, with λem = 642 nm. The shortest 
Compound(a) S1  S0 / nm(a) T1  S0 / nm(b) T1  S0 / nm(b) 
C1a 405 (372) 541 (477) 691, 607 (627) 
C2a 402 (402) 533 (474) 698, 605 (617) 
C3a 419 (406) 565 (500) 708, 630 (634) 
C4a 409 (394) 552 (480) 692, 612 (624) 
C5a 406 (417) 540 (479) 723, 618 (624) 
C6a 423 (428) 572 (501) 730, 642 (645) 
C7a 414 (418) 555 (483) 716, 626 (632) 
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emission wavelength recorded was 616 nm for complex C2a, the trimethylated species. In 
general, the emission profiles of the complexes follow the same trend seen in the emission 
spectra of the free ligands, with the halogenated species recording longer wavelengths than the 
methylated and unsubstituted species. The bathochromic shift observed upon chlorination is a 
result of changing electronic character of the system, which is clearly shown by the 
reproducibility of this trend in the T1  S0 TD-DFT calculations in Table 2.5. 
 
Figure 2.24: Overlaid steady state emission spectra for complexes C1a-7a. ex = 450 nm. 
Time resolved measurements were also carried out on the complexes. The luminescence 
lifetime of each complex was measured in chloroform and the results are tabulated below. The 
lifetimes of the complexes range from 307 - 539 ns with the longest value recorded for the 
fluorinated complex, C7a, and the shortest value recorded for the chlorinated complex, C6a. The 
cause of the reduced emission lifetime for the chlorinated species cannot be explained through 
a mixture of electronic and relativistic effects. It is most likely due to an increase in intersystem 
crossing rates, which is supported by the particularly high kr value calculated for the chlorinated 
complex, C6a. Further computational studies were able to confirm that chlorine substitution of 
the quinoxaline ligands leads to an increase in S0/T1 spin-orbit coupling (SOC), which leads to a 
shorter T1 lifetime value. 
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Table 2.6: Photophysical data for complexes C1a-7a. 
Complex A τ/ ns B Φ/ % knr/ 106 s-1 kr/ 105 s-1 
C1a 459 5.7 2.05 0.79 
C2a 453 5.1 2.09 1.18 
C3a 337 1.8 2.91 0.53 
C4a 396 6.0 2.37 1.51 
C5a 440 6.6 2.12 1.50 
C6a 307 6.4 3.05 2.08 
C7a 539 7.8 1.71 1.45 
 
The recorded lifetimes showed mono-exponential decay character in each case which is 
consistent with a single emitting state. The length of the lifetimes also suggest that the nature 
of the emission is phosphorescent in character for all complexes. The complexes also showed 
sensitivity to quenching by triplet oxygen (3O2), as lifetimes extending into the microsecond 
domain were observed upon degassing the samples. Therefore, all of the photophysical data 
recorded are consistent with an emitting state that possesses a significant 3MLCT contribution. 
2.3.6. Transient Absorption Spectroscopy 
Transient absorption spectra of the complexes were measured by Thomas Stonelake and Joseph 
Beames (Cardiff University). As in the case of the DFT calculations, a more detailed discussion is 
provided in the appendix of this work.40 
The TA spectrum of complex C1a is shown in Figure 2.25 and is illustrative of the spectra 
collected for all complexes. The main features in the spectrum are a ground state bleaching at 
355 nm, shown by a negative ΔOD value, two features at around 430 and 560 nm, which 
correspond to triplet-triplet absorptions, and a long wavelength transition which has been 
attributed to the spin-forbidden T1  S0 transition. These features are all consistent with the 
computational calculations discussed earlier.  
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Figure 2.25: Left) Transient absorption spectrum of complex C1a shown in black, overlaid with the 
emission spectrum of the same complex shown in red. Right) Transient absorption lifetime 
measurements made at selected wavelengths, highlighted as grey bars in the left hand figure. The red 
traces indicate mono-exponential fits to these measurements with corresponding lifetimes displayed in 
each panel. Recorded in chloroform, λex = 355 nm. 
 
Each feature in the spectrum exhibits a similar TA lifetime which suggests that they all relate to 
the same photoexcitation, ISC process and deactivation. This has been attributed to the 
formation of the lowest triplet state and compares relatively well with the observed lifetime 
from time-resolved emission measurements.41 Figure 2.26 shows a comparison of TA spectra for 
the complexes C1a, C5a and C6a. It can be seen that each spectrum has similar features with the 
exception of the ground state bleaching which appears as a doublet in the case of C5a and C6a, 
and does not show the same spectral shape as complex C1a.  
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Figure 2.26: Transient absorption spectra of complexes C1a, C5a and C6a. The spectra show qualitatively 
similar features. Recorded in chloroform; λex = 355 nm.  
2.3.7. Triplet-Triplet Annihilation Upconversion Measurements 
Triplet-triplet annihilation upconversion luminescence experiments were carried out by Kepeng 
Chen, Yuqi Hou and Prof. Jianzhang Zhao (Dalian University of Technology).  
These experiments were carried out in degassed toluene, using the complexes as the donor and 
9,10-diphenylanthracene (DPA) as the acceptor. Figure 2.27 shows the emission spectra 
recorded in degassed toluene. The graphs show overlaid emission spectra of the complex alone 
in solution and a mixture of the complex and DPA following excitation at 510 nm. The DPA triplet 
excited state lies below the triplet emitting levels of all the complexes in the series.  
When a solution of DPA is irradiated at 510 nm, no emission is observed. In contrast to this, in 
the majority of cases irradiation of a mixture of complex and DPA at the same wavelength 
produced an emission at 400-500 nm arising from the DPA. This is indicative of an upconversion 
process. This was most pronounced in complexes C1a, C2a and C5a which showed significant 
quenching of the 3MLCT emission band.  
These findings were also supported by the measured quantum yields for upconversion shown in 
Table 2.7. The results varied across the series, but by far the best performing species were the 
methylated complexes C1a and C2a. These complexes displayed quantum efficiencies of 26 and 
39 % respectively, with the latter being the highest recorded value for TTA upconversion with a 
triplet sensitiser. 
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Figure 2.27: Clockwise from top left: The upconversion fluorescence of C1a, C2a, C7a and C5a as 
photosensitisers in toluene. DPA was used as the acceptor. excitation was achieved with a continuous 
laser at l = 510 nm and power density of 5.2 mW under a deaerated atmosphere. c(sensitiser) = 1.0x10-5 
M; c(DPA) = 1.6x10-3, 1.6x10-3, 2.6x10-4 and 2.0x10-4 M, respectively; 20 ˚C.  
The poorest performing complexes were the chlorinated species C3a and C6a. Previous reports 
have suggested that high molar absorption coefficients in the visible region and long triplet 
excited-state lifetimes are necessary for efficient triplet sensitisers.42 As noted earlier, the 
chlorinated species have some of the shortest lifetimes in the series which goes some way to 
explaining their low upconversion efficiencies. 
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Table 2.7: Emission and upconversion data of the complexes recorded in toluene. (a) Recorded in air. (b) 
Recorded in deaerated toluene. (c) diiodi-BODIPY used as standard (ΦF = 0.027 in acetonitrile) 
Compound em (nm) τobsd (µs)(a) τobsd (µs)(b) ΦUC (%)(c) 
C1a 618 0.41 2.2 25.9 
C2a 609 0.38 2.3 39.3 
C3a 656 0.38 0.8 0.1 
C4a 638 0.39 1.6 2.0 
C5a 617 0.37 2.0 9.6 
C6a 660 0.35 1.8 1.0 
C7a 646 0.38 1.3 4.0 
 
When recorded in toluene, the luminescence measurements showed a larger range in emission 
properties. The methylated species display the highest emission energies and longest lifetime 
values, while the chlorinated complexes show the longest emission wavelength and the shortest 
lifetimes. Figure 2.28 shows a visual representation of the upconversion process. This 
photograph shows the best performing complexes, C1a and C2a. 
 
Figure 2.28: Photographs of the emission of selected triplet donors C1a, C2a and C5a alone and the 
upconversion with DPA in toluene. Excitation was achieved with a continuous laser of λ = 510 nm and 
power density of 5.2 mW under a deaerated atmosphere. c(sensitisers) = 1x10-5 M; c(DPA) = a) 1.6x10-3, 
b) 1.6x10-3 and c) 2.0x10-4 M; 20 ˚C.  
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2.4. Conclusion 
In this chapter of work, seven cationic bis-cyclometallated iridium(III) complexes have been 
successfully synthesised using (poly)substituted quinoxaline ligands. Photophysical studies have 
shown that the ligand substituents have an effect upon the emission wavelength and lifetimes 
of these species. This was also confirmed by computational studies which suggest that the 
emissive state is not purely MLCT in nature but has a significant ligand-centred contribution. 
Of the complexes synthesised, the methylated species C1a and C2a have shown particularly high 
upconversion efficiency when used as sensitisers in triplet-triplet annihilation upconversion. The 
higher energy and longer-lived excited state triplet emission are two factors that enhance 
performance. In contrast, the chlorinated complexes show much shorter lifetimes and this is 
reflected in their poor performance in upconversion experiments. This may be attributed to 
enhanced ISC which is facilitated by the chlorine substituents, leading to a faster non-radiative 
deactivation of the 3MLCT state.  
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2.5. Experimental 
All reactions were performed with the use of vacuum line and Schlenk techniques. Reagents 
were commercial grade and were used without further purification. 1H and 13C{1H} NMR spectra 
were measured on NMR-FT Bruker 300 or 400 spectrometers and recorded in CDCl3. Low-
resolution mass spectra were obtained by the staff at Cardiff University. High-resolution mass 
spectra were carried out by at the EPSRC National Mass Spectrometry Service at Swansea 
University. UV-Vis studies were performed on a Shimadzu UV-1800 as chloroform solutions (10-
5 M). Photophysical data were obtained on a JobinYvon-Horiba Fluorolog spectrometer fitted 
with a JY TBX picosecond photodetection module as MeCN solutions. Emission spectra were 
uncorrected and excitation spectra were instrument corrected. The pulsed source was a Nano-
LED configured for 372 nm output operating at 1 MHz. Luminescence lifetime profiles were 
obtained using the JobinYvon-Horiba FluoroHub single photon counting module and the data 
fits yielded the lifetime values using the provided DAS6 deconvolution software. 
Synthesis of 2-methyl-3-phenylquinoxaline HL1 1-phenyl-1,2-propanedione (2.0 mL, 15 mmol) 
and 1,2-diaminobenzene (1.60 g, 15 mmol) were dissolved in ethanol (30 mL) with acetic acid (1 
mL). The reaction mixture was heated at reflux for 24 hours under a nitrogen atmosphere. The 
mixture was cooled to room temperature and the solvent removed in vacuo. The crude product 
was taken up in dichloromethane (20 mL) and washed with hydrochloric acid (0.1 M, 2x 20 mL). 
The organic phase was dried over MgSO4 and dried in vacuo to yield a low melting-point, yellow 
solid (Yield = 3.26 g, 81 %). 1H NMR (400 MHz; CDCl3): δH 8.10 (1H, d, JHH = 8.37 Hz, Ar), 8.05 (1H, 
d, JHH = 8.37 Hz, Ar), 7.67-7.75 (3H, m, Ar), 7.65 (2H, d, JHH = 7.15 Hz, Ar), 7.44-7.54 (3H, m, Ar), 
2.77 (3H, s, Me), 2.51 (3H, s, Me) ppm. 13C{1H} NMR (75 MHz, CDCl3): C 155.7, 153.3, 142.0, 
141.7, 139.8, 130.5, 130.0, 129.8, 129.7, 129.3, 129.1, 25.2 ppm. HRMS (ESI) found m/z 
220.1072, calcd m/z 220.1073 for C15H12N2; UV vis. (CHCl3) max (ε / dm3mol-1cm-1):  325 (9400) 
nm. IR (solid)  / cm-1 : 3061, 3032, 2961, 1952, 1813, 1686, 1611, 1578, 1557, 1508, 1495, 1483, 
1443, 1431, 1395, 1375, 1341, 1248, 1217, 1188, 1132, 1117, 1074, 1030, 1005, 993, 974, 950, 
921, 897, 868, 818, 797, 708, 679, 619, 608, 575, 559, 496, 467, 436, 409, 401. 
Synthesis of HL2 As L1 but with 1-phenyl-1,2-propanedione (246 mg, 1.7 mmol) and 1,2-
diamino-4,5-dimethylbenzene ( 250 mg, 1.8 mmol). Product collected as a low melting-point, 
brown solid. (Yield = 361 mg, 86 %). 1H NMR (300 MHz, CDCl3): H 7.85 (s, 1H), 7.80 (s, 1H), 7.64 
– 7.62 (m, 2H), 7.53 – 7.44 (m, 3H), 2.74 (s, 3H), 2.50 (s, 3H), 2.48 (s, 3H) ppm. 13C{1H} NMR (101 
MHz, CDCl3): C 153.92, 151.29, 140.27, 139.97, 139.62, 139.32, 128.97, 128.76, 128.49, 128.28, 
127.33, 24.20, 20.44, 20.34 ppm. HRMS (ESI) found m/z 249.1385, calcd m/z 249.1386 for 
C17H16N2. UV vis. (CHCl3) max (ε / dm3mol-1cm-1): 339 (11200), 269 (11400), 262 (21800) nm. IR 
(solid)  / cm-1 : 3060, 3030, 2961, 1654, 1483, 1445, 1398, 1373, 1337, 1252, 1217, 1204, 1157, 
1123, 1076, 1024, 1003, 988, 920, 876, 870, 858, 785, 768, 739, 706, 696, 644, 629, 610, 559, 
532, 494, 478, 440, 420, 403. 
Synthesis of HL3 As L1 but with 1-phenyl-1,2-propanedione (190 mg, 1.3 mmol) and 1,2-
diamino-4,5-dichlorobenzene (250 mg, 1.4 mmol). Upon cooling to room temperature, a white 
precipitate formed and was collected by filtration. The precipitate was washed with methanol 
to yield the product as a white solid. (Yield = 283 mg, 73 %). 1H NMR (300 MHz, CDCl3): H 8.22 
(s, 1H), 8.17 (s, 1H), 7.66 – 7.62 (m, 2H), 7.58 – 7.52 (m, 3H), 2.77 (s, 3H) ppm. 13C{1H} NMR (75 
MHz, CDCl3): δC 155.92, 154.01, 139.97, 139.77, 138.27, 133.69, 129.47, 129.12, 128.91, 128.69, 
109.99, 24.54 ppm. HRMS (ESI) found m/z 291.0268, calcd m/z 291.0264 for C15H10Cl2N2. UV vis. 
(CHCl3) max (ε / dm3mol-1cm-1): 342 (12800), 268 (30700) nm. IR (solid)  / cm-1 : 3088, 1753, 
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1697, 1587, 1543, 1491, 1441, 1412, 1389, 1371, 1325, 1246, 1209, 1180, 1169, 1107, 1078, 
1022, 1005, 993, 976, 955, 930, 897, 878, 845, 795, 768, 748, 706, 658, 635, 629, 613, 594, 550, 
509, 490, 461, 428, 417. 
Synthesis of HL4 As for L1 but with 1-phenyl-1,2-propanedione (230 mg, 1.6 mmol) and 1,2-
diamino-4,5-difluorobenzene (250 mg, 1.7 mmol). Upon cooling to room temperature, a white 
precipitate formed and was collected by filtration and washed with methanol. Product collected 
as a white solid. (Yield = 225 mg, 55 %). 1H NMR (300 MHz, CDCl3): H 7.87 – 7.77 (m, 2H), 7.65 – 
7.62 (m, 2H), 7.56 – 7.49 (m, 3H), 2.76 (s, 3H) ppm. 13C{1H} NMR (101 MHz, CDCl3): C 138.44, 
129.29, 128.88, 128.66, 114.78, 114.03, 24.29 ppm. 19F {1H} NMR (376 MHz, CDCl3): δF -130.38 
(d, J = 21.2 Hz), -131.17 (d, J = 21.2 Hz) ppm.  HRMS (ESI) found m/z 257.0888, calcd m/z 
257.0885. UV vis. (CHCl3) max (ε / dm3mol-1cm-1): 326 (13000) nm. IR (solid)  / cm-1 : 3030, 1630, 
1572, 1553, 1497, 1450, 1373, 1356, 1339, 1256, 1227, 1200, 1142, 1078, 1015, 1005, 988, 928, 
897, 874, 866, 791, 772, 752, 712, 706, 667, 619, 611, 584, 544, 484, 447, 419, 405. 
Synthesis of HL5 Benzil (357 mg, 1.7 mmol) and 1,2-diamino-4,5-dimethylbenzene (250 mg, 1.8 
mmol) were dissolved in ethanol (15 mL) and acetic acid (1 mL). The reaction mixture was heated 
at reflux under a nitrogen atmosphere for 24 hours. The mixture was then cooled to room 
temperature and a white precipitate was collected by filtration and washed with methanol. 
(Yield = 413 mg, 78 %). 1H NMR (300 MHz, CDCl3): H 7.92 (s, 2H), 7.51 – 7.48 (m, 4H), 7.35 – 7.31 
(m, 6H), 2.49 (s, 6H) ppm. 13C{1H} NMR (75 MHz, CDCl3): C 152.50, 140.55, 140.21, 139.37, 
129.84, 128.53, 128.21, 109.99, 20.50 ppm. HRMS (ESI) found m/z 311.1542, calcd m/z 311.1543 
for C22H18N2. UV vis. (CHCl3) max (ε / dm3mol-1cm-1): 356 (13900), 281 (24600), 269 (31800), 254 
(44900) nm. IR (solid)  / cm-1 : 2974, 1749, 1549, 1531, 1493, 1474, 1460, 1445, 1416, 1400, 
1375, 1346, 1335, 1263, 1211, 1179, 1153, 1074, 1059, 1022, 1003, 966, 932, 870, 849, 814, 783, 
773, 762, 741, 725, 691, 633, 608, 598, 556, 530, 519, 492, 476, 436, 413. 
Synthesis of HL6 As L5 but with benzil (273 mg, 1.3 mmol) and 1,2-diamino-4,5-dichlorobenzene 
(250 mg, 1.4 mmol). Product collected as a white solid. (Yield = 367 mg, 80 %). 1H NMR (300 
MHz, CDCl3): H 8.29 (s, 2H), 7.52 – 7.49 (m, 4H), 7.37 – 7.35 (m, 6H) ppm. 13C{1H} NMR (101 
MHz, CDCl3): C 154.49, 139.95, 138.39, 134.43, 129.80, 129.29, 128.37 ppm. HRMS (ESI) found 
m/z 351.0450, calcd m/z 351.0450 for C20H12Cl2N2. UV vis. (CHCl3) max (ε / dm3mol-1cm-1): 362 
(19400), 254 (61300) nm. IR (solid)  / cm-1 : 3067, 3024, 2980, 1589, 1535, 1491, 1452, 1439, 
1393, 1337, 1254, 1190, 1109, 1074, 1061, 1020, 999, 964, 920, 883, 874, 831, 814, 766, 733, 
719, 692, 640, 621, 606, 598, 546, 511, 488, 480, 444, 426, 419, 409. 
Synthesis of HL7 As L5, but with benzil (336 mg, 1.6 mmol) and 1,2-diamino-4,5-difluorobenzene 
(250 mg, 1.7 mmol). Product collected as an orange solid. (Yield = 296 mg, 58 %). 1H NMR (300 
MHz, CDCl3): H 7.91 (td, JHH = 1.37, 9.35 Hz, 2H), 7.51 – 7.48 (m, 4H), 7.41 – 7.31 (m, 6H) ppm. 
13C{1H} NMR (75 MHz, CDCl3): C 154.31, 154.07, 153.69, 150.89, 150.66, 138.51, 138.48, 129.77, 
129.13, 128.37, 114.72 ppm. 19F{1H} NMR (376 MHz, CDCl3): δF -129.86 ppm. HRMS (ESI) found 
m/z 319.1044, calcd m/z 319.1041 for C20H12F2N2. UV vis. (CHCl3) max (ε / dm3mol-1cm-1): 343 
(14900), 261 (16800) nm. IR (solid)  / cm-1 : 3051, 1597, 1568, 1541, 1456, 1435, 1352, 1342, 
1246, 1217, 1194, 1175, 1152, 1142, 1082, 1072, 1055, 1022, 1001, 972, 939, 918, 872, 818, 785, 
772, 760, 752, 719, 700, 677, 623, 610, 573, 542, 521, 498, 438, 424, 419. 
Synthesis of  [{Ir(L)2(µ-Cl)}2] IrCl3.xH2O (1 eq.) and ligand, L (2 eq.) were dissolved in 2-
ethoxyethanol (10 mL) and the reaction mixture heated at reflux for 48 hours. The reaction was 
then cooled to room temperature and water (30 mL) was added to form a dark brown 
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precipitate. The solid was collected by filtration to yield [{Ir(L)2(μ-Cl}2] and was used in 
subsequent steps without further characterisation or purification. 
Synthesis of C1a [{Ir(L1)2(μ-Cl)}2] (100 mg, 0.075 mmol) and 2,2-bipyridyl (0.025 g, 0.16 mmol) 
were dissolved in 2-ethoxyethanol (10 mL) and heated at reflux for 24 hours under a nitrogen 
atmosphere. The reaction mixture was then cooled to room temperature and a saturated 
solution of aqueous ammonium hexafluorophosphate was added. Upon formation of a red 
precipitate, the mixture was filtered and the precipitate washed with water and diethyl ether to 
yield the product as a red solid. (Yield = 80 mg, 68 %). 1H NMR (300MHz, CDCl3): δH 8.39 (2H, d, 
JHH= 8.3Hz, Ar), 8.24 (2H, d, J= 8.3Hz, Ar), 8.17 (2H, d, JHH= 5.3Hz, Ar), 8.01 (2H, app.t, JHH= 7.9Hz, 
Ar), 7.90 (2H, d, JHH= 8.3Hz Ar), 7.45-7.57 (4H, m, Ar), 7.16-7.24 (2H, m, Ar), 7.00 (2H, app.t, JHH= 
7.7Hz, Ar), 6.86 (2H, app. t, JHH= 7.7Hz, Ar), 6.61 (2H, d, JHH= 7.6Hz, Ar), 3.36 (6H, s, Me) ppm. 
13C{1H} NMR (101MHz; CDCl3): δC 163.7, 155.1, 152.6, 152.0, 146.6, 144.0, 140.4, 140.0, 139.7, 
135.1, 130.9, 130.5, 130.4, 130.1, 129.2, 127.6, 124.8, 123.6, 123.2, 27.5 ppm. HRMS (ESI) found 
m/z 787.2148, calculated m/z  787.2158 for C40H30IrN6. UV vis. (CHCl3): λmax/nm (ε/dm3 mol-1 
cm-1) 477 (2500), 372 (13200), 253 (27900) nm. IR (solid)  / cm-1 : 1605, 1578, 1530, 1449, 
1427, 1387, 1348, 1261, 1215, 1196, 1165, 1130, 1016, 1001, 897, 837, 770, 750, 731, 704, 660, 
627, 592, 557, 459, 420, 415, 405. 
Synthesis of C2a As C1a, but with [{Ir(L2)2(μ-Cl)}2] (104 mg, 0.07 mmol) and 2,2-bipyridyl (25 mg, 
0.15 mmol). Product collected as a red solid (Yield = 133 mg, 94 %). 1H NMR: (400 MHz, Acetone-
d6): δ H 8.57 – 8.54 (2 H, m), 8.49 (2 H, dd, JHH = 8.3, 1.2), 8.41 (2 H, dt, JHH = 8.2, 1.0), 8.16 (2 H, 
ddd, JHH = 8.3, 7.6, 1.6), 7.86 – 7.81 (2 H, m), 7.66 (2 H, s), 7.24 (2 H, ddd, JHH = 8.3, 7.1, 1.3), 7.17 
(2 H, s), 6.86 – 6.79 (2 H, m), 6.70 (2 H, dd, J HH  = 7.7, 1.3), 3.34 (6 H, s), 2.30 (6 H, s), 1.81 (6 H, 
s) ppm. 13C {1H} (101 MHz, Acetone): δ C 164.56, 156.84, 154.00, 153.38, 149.62, 146.39, 142.69, 
142.14, 141.53, 140.70, 140.05, 136.48, 132.09, 131.63, 130.00, 129.66, 125.61, 125.24, 124.33, 
28.18, 20.36, 20.11 ppm. HRMS (ESI) found m/z 843.2783 calculated m/z 843.2784 for 
C44H38IrN6. UV-vis (CHCl3) max (ε / dm3mol-1cm-1):  474 (4800), 391 (22100), 376 (23900), 309 
(19300), 390 (32300), 268 (47200) nm. IR (solid)  / cm-1 : 1601, 1582, 1560, 1526, 1483, 1445, 
1396, 1375, 1342, 1323, 1267, 1219, 1171, 1134, 1063, 993, 835, 795, 768, 737, 702, 660, 627, 
556, 474, 434, 420, 403. 
Synthesis of C3a As C1a but with [{Ir(L3)2(μ-Cl)}2]  (100 mg, 0.06 mmol) and 2,2’-bipyridine (20 
mg, 0.1 mmol). Product collected as a red solid. (Yield = 61 mg, 46 %). 1H NMR (400 MHz, 
Acetone-d6): δH 8.60 (2 H, d, JHH = 8.4), 8.50 (2 H, d, JHH = 8.0), 8.51 (2 H, d, JHH = 8.0 ), 8.26 – 8.18 
(2 H, m), 8.13 (2 H, d, JHH = 1.2), 7.92 – 7.83 (2 H, m), 7.59 (2 H, s), 7.31 (2 H, dd, JHH = 8.3, 6.7), 
6.97 – 6.89 (2 H, m), 6.85 (2 H, d, JHH = 8.0), 3.41 (6 H, s) ppm. 13C {1H} NMR (126 MHz, DMSO): 
δC 165.56, 155.14, 154.80, 153.75, 147.29, 143.91, 140.79, 138.80, 138.42, 135.28, 133.16, 
132.60, 132.14, 131.53, 129.82, 129.31, 125.05, 124.96, 123.41, 27.34 ppm. HRMS (ESI) found 
m/z 925.0548, calculated m/z 925.0558 for C40H26Cl4IrN6. UV vis. (CHCl3) max (ε / dm3mol-1cm-1): 
500 (4500), 383 (23700), 298 (28900), 266 (48200) nm. IR (solid)  / cm-1 : 1603, 1576, 1528, 
1464, 1447, 1381, 1315, 1265, 1188, 1165, 1132, 1113, 1061, 1026, 1009, 962, 895, 870, 843, 
824, 772, 739, 729, 673, 664, 646, 637, 608, 556, 467, 428, 419, 403. 
Synthesis of C4a As C1a, but with [{Ir(L4)2(µ-Cl)}2] (101 mg, 0.07 mmol) and 2,2’-bipyridyl (23 
mg, 0.15 mmol). Product collected as a red solid. (Yield = 133 mg, 97 %). 1H NMR (400 MHz, 
Acetone-d6): δH  8.58 (2 H, dd, JHH = 8.3, 1.2), 8.54 (2 H, ddd, JHH = 5.5, 1.6, 0.8), 8.47 (2 H, dt, JHH 
= 8.2, 1.0), 8.25 – 8.18 (2 H, m), 7.92 – 7.81 (4 H, m), 7.34 – 7.20 (4 H, m), 6.95 – 6.88 (2 H, m), 
6.82 – 6.80 (2 H, d, JHH = 8.0), 3.39 (6 H, app. S) ppm. 13C {1H} NMR (101 MHz, Acetone-d6): δC 
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155.55, 152.77, 147.77, 144.41, 140.52, 135.29, 131.51, 131.13, 128.91, 124.79, 123.34 ppm. 19F 
NMR (376 MHz, Acetone-d6): δF -72.63 (d, J = 711.7 Hz), -131.73 (d, J = 21.9 Hz), -133.10 (d, J = 
21.9 Hz) ppm. HRMS (ESI) found m/z 859.1780, calculated m/z 859.1781 for C40H26F4IrN6. UV vis. 
(CHCl3) max (ε / dm3mol-1cm-1): 480 (2400), 375 (13200), 311(11800), 288 (15400), 262 (25800) 
nm. IR (solid)  / cm-1 : 1065, 1578, 1533, 1501, 1447, 1341, 1331, 1252, 1233, 1196, 1128, 1063, 
1036, 997, 878, 841, 795, 772, 741, 731, 689, 660, 638, 586, 557, 476, 451, 428, 422, 407. 
Synthesis of C5a As C1a but with [{Ir(L5)2(µ-Cl)}2] (150 mg, 0.09 mmol) and 2,2’-bipyridine (29 
mg, 0.2 mmol). Product collected as a red solid. (Yield = 124 mg, 63%). 1H NMR (400 MHz, 
Acetone-d6): δH 9.10 (2 H, dt, JHH = 5.1, 2.2), 8.61 – 8.52 (2 H, m), 8.34 – 8.25 (2 H, m), 8.24 – 8.15 
(2 H, m), 7.96 (4 H, dt, JHH = 6.7, 2.7), 7.78 (2 H, s), 7.74 – 7.65 (6 H, m), 7.34 (2 H, s), 7.18 (2 H, 
ddd, JHH = 8.2, 2.9, 1.5), 6.78 – 6.72 (2 H, m), 6.69 – 6.63 (2 H,m), 6.61 – 6.54 (2 H, m), 2.35 (6 H, 
s), 1.94 (6 H, s) ppm. 13C {1H} NMR (101 MHz, Acetone-d6): δC 162.58, 156.09, 153.60, 152.81, 
149.26, 144.93, 142.80, 141.53, 140.81, 140.42, 139.91, 139.43, 135.23, 131.40, 130.46, 130.06, 
129.58, 129.44, 129.21, 124.84, 123.98, 122.37, 19.43, 18.99 ppm. HRMS (ESI) found m/z 
967.3086, calcd m/z 967.3099 for C54H42IrN6. UV vis. (CHCl3) max (ε / dm3mol-1cm-1): 479 (6500), 
400 (29300), 362 (24800), 297 (49000), 269 (71300) nm. IR (solid)  / cm-1 : 1603, 1580, 1479, 
1447, 1348, 1321, 1234, 1207, 1159, 1134, 1074, 1024, 1001, 974, 833, 810, 775, 748, 737, 729, 
700, 658, 640, 608, 577, 557, 542, 446, 432, 415. 
Synthesis of C6a As C1a, but with [{Ir(L6)2(µ-Cl)}2] (100 mg, 0.05 mmol) and 2,2’ – bipyridine (19 
mg, 0.1 mmol). Product collected as a red solid. (Yield = 48 mg, 37 %). 1H NMR (300 MHz, 
Acetone-d6): δH 8.98 (2 H, ddd, JHH = 5.5, 1.7, 0.7), 8.60 (2 H, dt, JHH = 8.2, 1.0), 8.30 (2 H, td, JHH = 
7.9, 1.6), 8.23 – 8.15 (4 H, m), 7.99 – 7.90 (4 H, m), 7.69 (8 H, q, JHH = 2.2, 1.8), 7.25 – 7.15 (2 H, 
m), 6.81 – 6.62 (6 H, m) ppm. 13C {1H} NMR (101 MHz, Acetone-d6): δC 166.36, 157.25, 156.93, 
155.10, 149.90, 145.27, 142.19, 141.00, 140.74, 140.57, 136.52, 136.16, 133.44, 132.75, 131.91, 
131.67, 130.77, 130.55, 126.65, 126.43, 123.84 ppm. HRMS (ESI) found m/z 1049.0839, 
calculated m/z 1049.0872 for C50H30Cl4IrN6. UV vis. max/ nm (CHCl3) 501(7300), 404 (35300), 299 
(54600), 268 (87500) nm. IR (solid)  / cm-1 : 1603, 1576, 1524, 1493, 1445, 1433, 1406, 1383, 
1342, 1317, 1258, 1186, 1165, 1132, 1115, 1072, 1045, 1026, 1001, 961, 880, 839, 826, 766, 734, 
698, 673, 648, 635, 606, 577, 557, 532, 517, 486, 474, 451, 434, 419. 
Synthesis of C7a As C1a but with [{Ir(L7)2(µ-Cl)}2] (100 mg, 0.06 mmol) and 2,2’-bipyridine (19 
mg, 0.1 mmol). Product collected as a red solid. (Yield = 108 mg, 83 %). 1H NMR (400 MHz, 
Acetone-d6): δH 9.10 – 9.06 (2 H, m), 8.63 (2 H, d, JHH = 8.2), 8.35 (2 H, tt, JHH = 8.0, 1.4), 8.22 (2 
H, m), 8.01 (6 H, tt, JHH = 8.5, 4.4), 7.79 – 7.68 (6 H, m), 7.46 – 7.37 (2 H, m), 7.28 – 7.20 (2 H, m), 
6.87 – 6.79 (2 H, m), 6.77 – 6.72 (2 H, m), 6.69 (2 H, dt, JHH = 7.8, 1.3) ppm. 13C {1H} NMR (101 
MHz, Acetone-d6): δC 157.50, 150.05, 142.41, 140.79, 136.71, 133.25, 132.55, 131.76, 130.75, 
126.56, 124.00, 117.87 ppm. 19F{1H} NMR (376 MHz, Acetone-d6): δF -72.64 (d, J = 699.9 Hz), -
130.30 (d, J = 21.7 Hz), -132.66 (d, J = 22.2 Hz) ppm. HRMS (ESI) found m/z 983.2088, calculated 
m/z 983.2095 for C50H30F4IrN6. UV vis. (CHCl3) max (ε / dm3mol-1cm-1): 483 (4500), 396 (21600), 
367 (20200), 297 (33100), 265 (48600) nm. IR (solid)  / cm-1 : 1603, 1578, 1503, 1447, 1429, 
1335, 1275, 1260, 1223, 1204, 1163, 1126, 1072, 1043, 1026, 980, 874, 835, 810, 758, 739, 700, 
660, 640, 623, 615, 557, 536, 498. 
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Crystal data collection parameters 
[Ir(L2)2(bpy)][PF6] 
Formula  C46H44F6IrN6OP  Z'  1  
Dcalc./ g cm-3  1.675  Wavelength/Å  0.71075  
µ/mm-1  3.368  Radiation type  MoKα  
Formula Weight  1034.04  Θmin/°  1.722  
Colour  red  Θmax/°  27.483  
Shape  block  Measured Refl.  44265  
Size/mm3  0.100×0.055×0.03
5  
Independent Refl.  9342  
T/K  100(2)  Reflections Used  7210  
Crystal System  monoclinic  Rint  0.0408  
Space Group  P21/n  Parameters  588  
a/Å  13.7693(2)  Restraints  51  
b/Å  20.6315(4)  Largest Peak  2.313  
c/Å  14.5942(3)  Deepest Hole  -1.250  
α/°  90  GooF  1.036  
β/°  98.480(2)  wR2 (all data)  0.0867  
γ/°  90  wR2  0.0794  
V/Å3  4100.61(13)  R1 (all data)  0.0548  
Z  4  R1  0.0366  
 
 
 
 
 
 
 
[Ir(L5)2(bpy)][PF6] 
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Formula  C54H42F6IrN6P  Z'  1  
Dcalc./ g cm-3  1.513  Wavelength/Å  0.71075  
µ/mm-1  2.834  Radiation type  MoKα  
Formula Weight  1112.10  Θmin/°  1.635  
Colour  dark red  Θmax/°  25.028  
Shape  cut block  Measured Refl.  38931  
Size/mm3  0.060×0.025×0.01
0  
Independent Refl.  8623  
T/K  100(2)  Reflections Used  5823  
Crystal System  monoclinic  Rint  0.1029  
Space Group  P21/n  Parameters  617  
a/Å  14.5802(8)  Restraints  639  
b/Å  22.2820(11)  Largest Peak  2.304  
c/Å  16.1754(9)  Deepest Hole  -1.142  
α/°  90  GooF  1.040  
β/°  111.734(7)  wR2 (all data)  0.1480  
γ/°  90  wR2  0.1308  
V/Å3  4881.4(5)  R1 (all data)  0.1049  
Z  4  R1  0.0646  
 
 
 
 
 
 
 
 
[Ir(L7)2(bpy)][PF6] 
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Formula  C54H40F10IrN6OP  Z'  2  
Dcalc./ g cm-3  1.706  Wavelength/Å  0.71075  
µ/mm-1  2.975  Radiation type  MoKα  
Formula Weight  1202.09  Θmin/°  1.817  
Colour  red  Θmax/°  27.486  
Shape  cut block  Measured Refl.  113221  
Size/mm3  0.060×0.025×0.00
5  
Independent Refl.  21466  
T/K  100(2)  Reflections Used  11036  
Crystal System  monoclinic  Rint  0.1871  
Space Group  P21/c  Parameters  1339  
a/Å  17.0632(5)  Restraints  1349  
b/Å  22.3096(6)  Largest Peak  3.828  
c/Å  24.9163(8)  Deepest Hole  -1.303  
α/°  90  GooF  0.967  
β/°  99.205(3)  wR2 (all data)  0.1519  
γ/°  90  wR2  0.1223  
V/Å3  9362.8(5)  R1 (all data)  0.1507  
Z  8  R1  0.0627  
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3. Neutral Iridium(III) Complexes Incorporating Cyclometallated 
Quinoxaline Ligands: Synthesis, Characterisation and Luminescence 
Properties 
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3.1. Introduction 
The work presented in this chapter focuses on the photophysical properties of bis-
cyclometallated complexes of iridium(III). Unlike the work of the previous chapter, the 
complexes in this study have an overall neutral charge due to one of the coordination sites of 
the ancillary ligands bearing a formal negative charge. 
The potential applications of neutral iridium(III) complexes are similar to those of cationic 
iridium complexes in that their uses can include imaging agents,1,2 and catalysts.3 But by far, the 
most widespread application of bis-cyclometallated iridum(III) complexes is in the field of 
phosphorescent organic light emitting diodes (PhOLEDs). One reason that neutral species are 
preferred in the manufacturing of OLED devices is that they can be sublimed more easily than 
cationic species. In this chapter, the background of this field and examples of iridium complexes 
used as dopants in electroluminescent devices are discussed in detail. 
3.1.1. OLEDs 
In recent years, organic light emitting diodes (OLEDs) have become increasingly popular as they 
have high brightness and fast response times.4–7 OLEDs also open up the possibility of flexible 
displays and lighting.8 
An OLED device is typically made up of a series of thin organic layers sandwiched between an 
anode, such as indium tin oxide, and a metallic cathode. Figure 3.1 illustrates an example of such 
a device. The organic layers include a hole transport layer, an electron transport layer and, in 
newer devices, an exciton blocking layer which improves quantum efficiency.9–11 The organic 
emitter is either deposited between the conducting layers or doped into the electron transport 
layer. The first OLED devices used small fluorescent molecules as dopants,12 but focus has since 
switched to phosphorescent materials as a means to increase the luminous efficiency of these 
devices.13 
 
Figure 3.1: Typical structure of an OLED device.13 
Phosphorescence is emission of light from a triplet excited state, in which the electron in the 
excited state has the same spin value as that in the ground state. As a result, transitions to the 
ground state are spin-forbidden and emission rates are slow, meaning that emission lifetimes 
can reach milliseconds to seconds.14 
The factors to be considered when designing phosphorescent materials for OLEDs include 
emission wavelength (λem), luminescence lifetime (τ) and quantum yield (Φ). Emission 
wavelength determines the colour output, and in full-colour displays, red, green and blue 
Chapter 3  
63 
 
emitters are required. A long luminescence lifetime is detrimental to the performance of an 
OLED device as the length of time a molecule spends in the triplet state is a limiting factor in the 
conversion of electrical energy to photon energy, therefore an ideal lifetime should fall between 
5-50 µs at room temperature. In addition to this, the efficiency of the OLED device is directly 
linked to the quantum yield of the emitter and as such, the Φ value should be as close to unity 
as possible. In reality, this is very difficult to achieve, but it is generally accepted that a 
phosphorescent emitter should have a quantum yield value of at least 0.25 at room 
temperature.13  
Organic phosphorescent molecules typically have very long emission lifetimes, meaning they are 
not ideal for use in OLED devices. Instead, transition metal complexes are often employed as 
their phosphorescent lifetimes are generally much shorter. This is due in part to the metal-to-
ligand charge transfer transition (MLCT) that occurs in these species, which involves an 
electronic transition from a metal-centred d orbital to a ligand centred π* orbital.15 These occur 
most often in late-transition metal complexes where the metal is in a low oxidation state. 
Emission from triplet MLCT (3MLCT) states is formally phosphorescence, but as these states are 
shorter lived than typical phosphorescent states, they have much shorter lifetime values; 
normally on the scale of microseconds, which are much more applicable to OLED devices.14 
 
Figure 3.2: Jablonksi diagram illustrating the transition from a 3MLCT state to the ground state.14 
Organometallic complexes of late-transition metals are most often used as dopants in OLED 
devices because the heavy metal centre helps to facilitate intersystem crossing to the 3MLCT 
state through strong spin-orbit coupling.16,17 Metals such as osmium, iridium, ruthenium and 
platinum have been most commonly used as phosphorescent emitters.18 Examples of osmium, 
ruthenium and platinum complexes developed as phosphors for OLED devices are shown in 
Figure 3.3.  
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Figure 3.3: Examples of transition metal complexes used as dopants in OLED devices.19–21 
The complex on the left of the figure is a near-infra red-emitting osmium species reported in 
2015 with an emission wavelength of 717 nm and a photoluminescent quantum yield of 8.8 %. 
19 The ruthenium complex in the centre was synthesised as part of a series of complexes with 
differently functionalised ligands. An OLED device was synthesised incorporating this complex 
and showed strong saturated red emission with excellent efficiency.20 The platinum species was 
reported as part of a series of complexes that showed emission between 600-750 nm in the solid 
state. The complex shown in the figure was used as a co-dopant in an OLED device and showed 
red emission at a wavelength of 661 nm.21 
3.1.2. Iridium Complexes 
The first tris-cyclometallated iridium complex, fac-[Ir(ppy)3], was reported in the 1980s as a by-
product of the synthesis of another iridium complex. 22 However, it wasn’t until 1999 that this 
complex was used in an OLED device, when Baldo et al. created a green emitting device using 
fac-[Ir(ppy)3] as a dopant.23 Emission from this species is believed to arise from a mixed state 
possessing both MLCT and intra-ligand IL π-π* character.24–26 Molecular orbital theory suggests 
that the LUMO and HOMO of the phenylpyridine ligand are partially situated on the pyridyl 
moiety and the phenyl moiety respectively meaning that the ligand can be selectively 
functionalised to tune the emission wavelength.27 Functionalisation of the pyridyl ligand can 
alter the level of the LUMO, whilst the HOMO remains unchanged as long as the phenyl moiety 
remains un-functionalised. A typical way in which this strategy is employed is in the substitution 
of a carbon atom in the pyridyl part of the ligand with a nitrogen atom to create a pyrazine 
moiety.28 The addition of this nitrogen atom decreases the LUMO level resulting in a reduction 
in the energy gap for both the 3π-π* and 3MLCT emission. 
 
Figure 3.4: Structure and emission properties of fac-[Ir(ppy)3] 
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In an effort to further manipulate the photophysical properties of phosphorescent iridium(III) 
complexes, design has since moved away from homoleptic tris-cyclometallated complexes and 
toward heteroleptic species.  
A common ancillary ligand used in iridium chemistry is acetylacetonate (acac) which is formed 
by deprotonation of acetylacetone (Hacac). A study published by Lamansky et al. in 2001 
reported a large series of bis-cyclometallated iridium complexes with a variety of functionalised 
acac ancillary ligands in an investigation into the emissive state of bis-cyclometallated 
complexes.29 In another paper by the same authors, a series of bis-cyclometallated complexes 
were synthesised with three different ancillary ligands: acac, picolinate (pic) and N-
methylsalicyliminate (sal) and it was found that the bis-cyclometallated species showed very 
similar emission profiles to their tris-cyclometallated counterparts.30 The structure and binding 
modes of these ligands are shown in Figure 3.5. 
 
Figure 3.5: Ancillary ligands used in bis-cyclometallated iridium complexes.30 Top) L-R) Acetylacetonate, 
picolinate and N-methylsalicyliminate. Bottom) Substituted acetylacetonate ligands.29 
The same study found that the ancillary ligand did have a small effect upon emission wavelength. 
It was reported that the emission wavelength increased in the order pic < sal ~ acac which is 
proportional to the electron donating strengths of the ligands. 
Some of the most recent neutral iridium(III) complexes reported are shown in Figure 3.6. The 
complex on the left of the figure was synthesised by Han et al. as part of a series of green 
emitting complexes which showed photoluminescent efficiency of up to 94%.31 The central 
complex has a more unusual bis(diphenylphorothioyl)amide ancillary ligand. This complex, along 
with two similar species, when used as dopants in OLED devices, showed strong green emission 
at turn-on voltages as low as 2.8 V and quantum yields as high as 98%.32 
 
Figure 3.6: Recent neutral iridium(III) complexes synthesised for OLED applications. 
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The complex on the right of the figure was published as part of a study comparing acac and pic 
ancillary ligands. A series of six complexes were synthesised, three with pic ligands and three 
with acac, all with yellow to orange emission. The study reported very high quantum yields for 
the complexes of between 64 – 90%, but the study also noted that solid-state luminescence 
properties were much improved when a picolinic acid ligand was used.33 
3.1.3.  Picolinic Acid 
Picolinic acid is a small organic molecule also known as pyridine-2-carboxylic acid. It is often used 
as a bi-dentate ligand in metal systems as it can coordinate through the nitrogen atom in the 
aromatic ring and through the oxygen in the carboxylic acid group.  
 
Figure 3.7: Transition metal complexes with a picolinic acid ligand. 
Figure 3.7 shows two examples of picolinate used as a ligand in transition metal systems. The 
cobalt complex was reported in 2019, along with an analogous complex with methylated 
picolinate ligands, the complex shown above exhibited good activity as an inhibitor of α-
glucosidase.34 The platinum complex was reported along with a series of di-nuclear platinum 
complexes using functionalised picolinic acid ligands to link two platinum centres.35 
As discussed previously, picolinate has also been used as a ligand in complexes of iridium(III). It 
is most often used as an ancillary ligand in bis-cyclometallated systems. One of the earliest 
reports of the use of picolinate in an iridium(III) complex was in 2001, discussed earlier, which 
investigated the effects of ancillary ligands derived from picolinic acid, acetylacetone and N-
methylsalicylimine, upon a series of iridium complexes with different cyclometallating ligands.30 
More recent examples of iridium complexes with picolinate ligands are shown in Figure 3.8. The 
left-most complex is a blue-emitting species reported in 2017 as part of a series of 
diphenylphosphoryl-substituted bis-cyclometallated iridium complexes investigated for their 
oxygen-sensing properties.36 The central complex has a carbazole-functionalised benzimidazole 
cyclometallating ligand and shows strong green emission in solution, but was shown to have a 
lower wavelength emission and poorer efficiency in electrochemical devices than its acac 
analogue.37  
Examples of red-emitting iridium complexes with a picolinic acid ligand are much less well known 
than blue- and green-emitting complexes. The complex shown on the right of Figure 3.8 is the 
only known example at time of writing. The complex has a 2-(thiophen-2-yl)quinoline 
cyclometallating ligand and shows emission at 647 nm.38 
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Figure 3.8: From left to right) Blue-, green- and red-emitting complexes of iridium(III) with a picolinate 
ligand.36–38 
Red emission from neutral species is essential for applications such as high-quality white OLEDs 
(WOLEDs) and as such, demand is growing.39 Picolinic acid could provide a convenient route to 
neutral red-emitting species as the synthetic route to these complexes uses the same iridium 
starting materials as the red-emitting cationic complexes reported in the previous chapter. 
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3.2. Aims 
The aim of the work presented in this chapter was to build upon the results reported in chapter 
2, where an emission tunability range of 30 nm was recorded across a series of seven bis-
cyclometallated cationic iridium(III) complexes. In this study, a series of related neutral bis-
cyclometallated complexes were synthesised bearing the same cyclometallating ligands used in 
the previous chapter, but with an anionic ancillary ligand replacing the neutral 2,2’-bipyridine 
ligand used in the cationic species.  
The two anionic ligands utilised in this chapter were derived from picolinic acid, of which there 
are many reports in the literature, and the closely related pyrazinoic acid which has not 
previously been reported as an ancillary ligand in iridium(III) coordination chemistry. The 
photophysical properties of these complexes were studied and compared to their cationic 
analogues to investigate the effect of the ancillary ligand upon the emission wavelength of the 
complex. 
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3.3. Results and Discussion 
3.3.1.  Synthesis 
The synthesis of the cyclometallating ligands used in this study has been previously reported 
and was discussed in further detail in chapter 2.40 The general scheme for the synthesis of these 
ligands is shown below.  
 
Scheme 3.1: Synthesis of cyclometallating ligands used in this study. 
From these ligands, a series of chloro-bridged iridium(III) dimer compounds of formula [{Ir(L)2(µ-
Cl)}2] were synthesised according to a method first published by Nonoyama.41 The dimeric 
species were then used as starting materials for the synthesis of a series of neutral complexes. 
The proposed synthetic route to these complexes is shown in Scheme 3.2. 
The synthesis is similar to that used for the cationic species, in that the iridium(III) dimer species 
is dissolved in 2-ethoxyethanol with a stoichiometric amount of ancillary ligand. However, for 
the synthesis of neutral complexes, two molar equivalents of potassium carbonate and silver 
nitrate were added to the reaction flask. The purpose of the potassium carbonate is to 
deprotonate the carboxylic acid group of the ancillary ligand, and the silver nitrate abstracts the 
chloride ions produced when the dimer species is split.  
 
Scheme 3.2: Synthesis of neutral bis-cyclometallated complexes from chloro-bridged iridium(III) dimer 
species. 
The ancillary ligands used in this study were picolinic acid and pyrazinoic acid. The first ligand to 
be investigated was picolinic acid and, following the procedure shown in Scheme 3.2, a series of 
seven novel neutral iridium(III) complexes was synthesised and the structure and yield of each 
complex is presented in the Figure 3.9. The yields of the isolated product vary from 12 – 97 %, 
suggesting that the reaction conditions may not be optimised for each species.  
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Figure 3.9: Structures of neutral bis-cyclometallated iridium(III) complexes of formula [Ir(L)2(pic)] 
The analogous synthetic approach was undertaken using pyrazinoic acid. For this series, four of 
the seven available starting materials were chosen to synthesise four novel neutral iridium(III) 
complexes show in Figure 3.10. 
 
Figure 3.10:Structures of neutral bis-cyclometallated iridium(III) complexes of formula [Ir(L)2(pyz)] 
The yields recorded for this set of complexes are overall lower than those for the picolinic acid 
complexes. In fact, it was not possible to isolate complex C2c in a significant yield when following 
the proposed synthetic route outlaid in Scheme 3.2. 
An alternative route to cationic bis-cyclometallated iridium(III) complexes that has been 
reported involves first splitting the chloro-bridged dimer with acetonitrile, before addition of 
the ancillary ligand.42 Scheme 3.3 shows this method along with the alterations made to obtain 
a neutral product.  
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Scheme 3.3:Alternative synthetic route to complex C2c. 
The advantage of this synthetic route is that the acetonitrile ligands on the cationic species 
formed from splitting the dimer in the presence of a silver salt are much more labile than the 
bridging chloride ligands of the dimer species.43,44 This then makes the coordination of the 
pyrazinoic acid ligand more facile than in the previous synthesis. The second step of the new 
synthesis route uses chloroform as a solvent as it is very weakly coordinating so should not 
compete with the pyrazinoic acid.45 Following this method, complex C2c was isolated in a yield 
comparable to that of the other pyrazinoate complexes suggesting that this route may result in 
higher yields if applied to other complexes in the series. 
3.3.2. Characterisation 
The complexes synthesised in this study were characterised by proton, carbon and fluorine NMR 
spectroscopy, in addition to high-resolution mass spectrometry. All of the complexes 
synthesised showed good solubility in organic solvents including chloroform, acetonitrile and 
acetone.  
3.3.2.1. NMR Spectroscopy 
One notable difference that can be observed in the NMR spectra of these complexes when 
compared with their cationic counterparts is increase in number of signals, arising from  the loss 
of symmetry in the complex. As the anionic ancillary ligand is non-symmetrical, unlike 2,2’-
bipyridine, the two cyclometallating ligands therefore become inequivalent. As a result, the 
proton NMR spectra of the neutral complexes are more complicated than those recorded for 
the cationic species.  
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Figure 3.11: Comparison of the proton NMR spectra of C1b (black) and a cationic complex from chapter 2 
bearing the same C^N ligand (red). 
In Figure 3.11, the black trace spectrum is that recorded for the neutral complex C1b and the 
red spectrum is that recorded for the corresponding cationic complex, C1a, [Ir(L1)2(bipy)][PF6]. 
The inset of the figure shows the aliphatic region of the same spectra. The cationic complex 
shows a singlet as the methyl group of each cyclometallating ligand is equivalent. In the neutral 
complex, C1b, the signal splits into two singlets due to the difference in the environments caused 
by the non-symmetrical picolinate. 
Other characteristic features that confirm coordination of the ligand to the metal centre include 
the doublet at 6.26 ppm which corresponds to the proton ortho- to the cyclometallating carbon 
atom on the quinoxaline ligand. As discussed in chapter 2, this is due to shielding caused by ring 
currents in adjacent ligands, however, as the complexes presented in this chapter are non-
symmetrical, this effect is more pronounced in one cyclometallating ligand than the other. 
Therefore, a different signal is seen for each ligand with the doublet corresponding to the other 
cyclometallating ligand arising at 6.93 ppm. 
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Figure 3.12: Inequivalency of protons ortho- to cyclometallating site. Circled signals correspond to proton 
highlighted in red. 
The four fluorine-containing complexes were analysed by fluorine NMR and the data collected 
is tabulated below alongside the data collected for the corresponding cationic species, and the 
free ligands. 
Table 3.1: Tabulated proton decoupled fluorine NMR data for fluorinated complexes C4b, C7b, C4c and 
C7c compared with free ligand and cationic counterparts. 
 
 
 
 
 
 
 
The free ligands each show a single fluorine environment. In the case of ligand HL7, this is 
because the compound is symmetrical; ligand HL4 is not symmetrical but the two fluorine atoms 
are not significantly influenced by the non-symmetrical part of the ligand as they are too far 
Compound δF/ ppm Compound δF/ ppm 
HL4 -130.4 HL7 -130.0 
[Ir(L4)2(bipy)][PF6] -131.7, -133.7 [Ir(L7)2(bipy)][PF6] -130.3, -132.7 
[Ir(L4)2(pic)] 
-131.8, -132.9, -133.7, 
-134.0 
[Ir(L7)2(pic)] 
-130.8, -131.5, -133.1, 
-133.6 
[Ir(L4)2(pyr)] 
-125.01, -129.0, -129.5, 
-130.9 
[Ir(L7)2(pyr)] 
-123.5, -128.1, -128.5, 
-130.5 
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away. Two signals are observed in each cationic species as the fluorine environments become 
inequivalent upon coordination of the ligand to the metal centre. The number of signals 
observed then increases to four for each of the neutral species as each cyclometallating ligand 
becomes inequivalent meaning each fluorine atom in the complex is now in a unique 
environment. 
The fluorine NMR chemical shifts in the complexes with a pyrazinoate ligand showed a higher δF 
value than the other complexes. This suggests that the ancillary ligand in these species is less 
electron donating to the metal centre, leaving the fluorine environments less shielded than 
those in the cationic species and those in the picolinate species. 
3.3.2.2. Mass Spectrometry 
All complexes in this study were also characterised by high-resolution mass spectrometry. In 
each case, the molecular ion peak was present with an isotope pattern consistent with iridium, 
and in some cases a fragment was present that contained both cyclometallating ligands, but 
without the ancillary ligand. 
 
Figure 3.13: High-resolution mass spectrum recorded for C4c. Spectrum shows molecular ion peak, 
fragments and a sodium adduct. 
The spectrum shown in Figure 3.13 is that recorded for complex C4c. The peak at 827.1365 amu 
is the protonated molecular ion peak, the peak at 849.1181 amu is an adduct formed from the 
molecular ion and a sodium ion present in the spectrometer. The peak at 703.1088 amu is a 
fragment that does not contain the ancillary ligand. 
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3.3.3. Electrochemistry 
Cyclic voltammograms were recorded for each complex in the series to investigate the 
electrochemical properties. Each sample was dissolved in deoxygenated dichloromethane (1x10-
3 M) and measured using a platinum disc electrode (scan rate 200 mV s-1, 0.1 M [NBu4][PF6] used 
as electrolyte). The results are shown in Table 3.2. 
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Table 3.2: Redox potentials for picolinate complexes C1b-7b and pyrazinoate complexes C2c,4c, 5c and 
7c. Cyclic voltammogramms recorded in DCM with NH4PF6 as an electrolyte. Scanning rate of 200 mV s-1 
used. Values reported relative to Ag/Ag+ electrode with ferrocene as a reference. 
Complex Eox/ V Ered/ V Complex Eox/ V Ered/ V 
C1b +1.16 -1.42    
C2b +1.11 -1.51 C2c +1.18 -0.98 
C3b +1.27 -1.17    
C4b +1.26 -1.05, -1.27 C4c +1.24 -1.06 
C5b +1.09 -1.25 C5c +1.19 -1.04, -1.42 
C6b +1.31 -1.12    
C7b +1.30 -1.24 C7 +1.39 -1.15 
 
The table shows that in the majority of cases, there is one oxidative process and one reductive 
process. The oxidative process was found to be irreversible and was attributed to the Ir3+/4+ 
couple. As expected, the neutral complexes have lower oxidation potentials than their cationic 
counterparts [Ir(L)2(bipy)][PF6]. It is observed that the complexes with a pyrazonoate ligand have 
a more positive reduction potential than their picolinate counterparts while the substituents of 
the quinoxaline cyclometallating ligand also have an effect upon the redox potentials within 
each series of complexes. The halogenated species have higher oxidation potentials than those 
with methylated substituents. This could be due to the electron-withdrawing effects of these 
atoms reducing the electron density at the metal centre. Furthermore, the pyrazinoate species 
exhibit a more positive oxidation potential that the corresponding picolinate complexes, 
suggesting that the ancillary ligand also has a subtle effect upon the electrochemical properties. 
Ligand-based processes are assumed to be responsible for the reduction features observed. 
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Figure 3.14: Cyclic voltammogram recorded for complex C1b in DCM with NH4PF6 as electrolyte. Potential 
reported relative to Ag/Ag+ electrode. Fc/Fc+ used as internal reference at +0.46 V. Scanning rate of 200 
mV s-1. 
3.3.4. Photophysical Studies 
3.3.4.1. UV-vis Absorption Spectra 
The UV-vis absorption spectra of all complexes were recorded as solutions in chloroform at a 
concentration of 10-5 M.  The results are collected in Table 3.3. 
Table 3.3: UV-vis absorption data collected for all complexes, in CHCl3 at 1x10-5 M. 
Complex λabs (ε) / nm (M-1cm-1) Complex λabs (ε) / nm (M-1cm-1) 
C1b 491 (3700), 373 (17300)   
C2b 
507 (3700), 381 (26000), 276 
(116200) 
C2c 
480 (5100), 380 (27100), 267 
(50200) 
C3b 
538 (2300), 389 (12500), 371 
(11500), 300 (11500), 273 (21500) 
  
C4b 
501 (4000), 377 (26300), 361 
(23900), 272 (113200) 
C4c 
490 (4900), 374 (31000), 262 
(50900) 
C5b 
501 (4700), 387 (28900), 300 
(34200), 262 (50000) 
C5c 
489 (4400), 386 (24000), 271 
(49000) 
C6b 528 (4100), 396 (29800), 273 (90600)   
C7b 505 (3100), 387 (23100), 277 (3400) C7c 
494 (2900), 383 (15500), 272 
(41200) 
Figure 3.15 shows the spectra recorded for the picolinate complexes, while Figure 3.16 shows 
those recorded for the pyrazinoate complexes. In both sets of spectra, three distinct features 
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can be seen; a peak at around 500 nm arising from a metal-to-ligand charge transfer (MLCT) 
transition and features at around 375 and 275 nm from π-π* transitions. 
 
Figure 3.15: Left) UV-vis absorption spectra recorded for complexes C1b-7b. All samples recorded in 
chloroform at 10-5 M. 
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Figure 3.16: UV-vis absorption spectra recorded for complexes C2c, 4c, 5c and 7c. All samples recorded in 
chloroform at 10-5M. 
The molar extinction coefficients of the MLCT and the n-π* transitions have similar values across 
both series of complexes, however the value for the π-π* transition varies widely from around 
20000 to 120000  M-1cm-1. 
Figure 3.17 shows the MLCT absorption bands for three complexes with the same 
cyclometallating ligand, this shows the effect of the ancillary ligand upon this transition. There 
are subtle differences between the three species. In particular, this absorption band is slightly 
blue-shifted and appears less broad in the cationic species. The two neutral complexes have very 
similarly shaped absorption peaks, but the pyrazinoate complex shows a higher molar 
absorption coefficient at this peak than the picolinate complex. 
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Figure 3.17: UV-vis spectra showing the effect of ancillary ligand on MLCT band. Overlaid spectra of 
cationic complex C2a, picolinate complex C2b and pyrazinoate complex C2c all recorded in chloroform at 
1x10-5M. 
3.3.4.2. Emission Data 
The emission properties of the complexes were also investigated. Figure 3.18 shows the 
emission spectra of the picolinate complexes, while Figure 3.19 shows the spectra recorded for 
the pyrazinate complexes, all recorded in aerated chloroform. An excitation wavelength of 495 
nm was used which corresponds to population of the MLCT excited states. The complexes with 
a picolinate ligand show an emission range of around 40 nm, with the species with ligand L2 
having the shortest emission wavelength at 635 nm, and the longest emission wavelength of 
677 nm arising from the complex with ligand L6. 
400 500 600 700
0
5000
10000
15000
/
 M
-1
cm
-1
Wavelength/ nm
 C2a
 C2b
 C2c
Chapter 3  
81 
 
 
Figure 3.18: Normalised emission spectra recorded for complexes C1b-7b in aerated CHCl3, ex = 495 nm. 
 
Figure 3.19: Normalised emission spectra recorded for complexes C2c, 4c, 5c and 7c in aerated CHCl3, λex 
= 495 nm. 
The complexes with the pyrazinoate ligands show a modest range of emission wavelengths. The 
three complexes C2c, C4c and C5c all emit at 635 nm, whilst the complex C11 emits at 646 nm. 
For comparison, the emission spectra of three complexes bearing the same C^N ligand, L2, are 
shown in Figure 3.20. This figure shows that the ancillary ligand also has a subtle affect upon the 
wavelength of light emitted by the complex.  The cationic complex bearing a 2,2’-bipyridine 
ancillary ligand shows the shortest emission wavelength at 615 nm, with both neutral complexes 
showing emission at around 635 nm.  
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Figure 3.20: Overlaid absorption spectra of complexes bearing L2 with different ancillary ligands. 
Figure 3.21 shows the absorption spectrum of C1b overlaid with the emission spectrum of the 
same complex to illustrate the Stokes’ shift. The Stokes’ shift occurs because the energy of 
emission is always less than that of absorption and can be measured by the difference in 
wavelength between the absorption maximum and the emission wavelength.14 This complex 
shows a Stokes’ shift of 157 nm. Large Stokes shifts are consistent with phosphorescence. 
 
Figure 3.21: Absorption and emission spectra for complex C1b illustrating the Stokes shift. 
Red light has a wavelength of between 622 – 780 nm.46 All of the complexes synthesised in this 
chapter emit light in this range of the visible spectrum over a range of 42 nm. When these results 
are combined with the red-emitting complexes discussed in chapter 2, a total emission range of 
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60 nm is achieved across a series of 18 complexes. This means that it is possible to tune the 
emission of a complex to a particular ‘shade’ of red by careful selection of cyclometallating 
ligand substituents and ancillary ligand. 
 
Figure 3.22: Overlaid emission spectra of all neutral complexes in this chapter, combined with the 
emission spectra of all cationic complexes from chapter 2. 
3.3.4.3. Luminescence Lifetime 
The luminescence lifetimes of the complexes studied in this chapter are tabulated below. Across 
each series, the cyclometallating ligand has an effect upon emission lifetime. For the picolinate 
complexes, the two methylated ligands, L2 and L5, gave the longest lifetime values of 333 and 
321 ns respectively, whilst the chlorinated ligands, L3 and L6, give the shortest lifetime values at 
275 and 294 ns. This is likely due to the heavy atom effect induced by the chlorine atoms, which 
can increase the rate of intersystem crossing. 
However, in the pyrazinoate complex series, it is the fluorinated ligands L4 and L7 that give the 
longest-lived emission, with lifetime values of 402 and 454 nm respectively. In addition to this 
observation, the lifetimes recorded for the complexes with pyrazinoate ligands show longer 
values than those recorded for the corresponding picolinate complexes. 
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Table 3.4: Luminescent lifetimes recorded for neutral iridium(III) complexes. λex = 295 nm, recorded in 
aerated CHCl3 
Complex τ/ ns Complex τ/ ns 
C1b 308   
C2b 333 C2c 350 
C3b 275   
C4b 321 C4c 402 
C5b 323 C5c 370 
C6b 294   
C7b 323 C7c 454 
 
Table 3.5 shows the collated data for both sets of neutral complexes compared with their 
cationic counterparts. While there is no distinct trend over the three series of complexes that 
links the cyclometallating ligand with the length of emission lifetime, there is a trend linking the 
ancillary ligand with emission lifetime. Overall, the cationic species have the longest emission 
lifetimes with the longest lifetime in the table being recorded for the cationic species with the 
fluorinated ligand, L7, at 539 ns. The complexes with a picolinate ligand generally have the 
shortest lifetimes in the series, with the chlorinated species, L4, having a lifetime of 321 ns 
Table 3.5: A table listing the effect of ancillary ligand upon the luminescence lifetime of complexes with 
the same cyclometallating ligands. Λex = 295 nm, all samples recorded in CHCl3 
Complex τ/ ns Complex τ/ ns Complex τ/ ns 
C2b 333 C2c 350 C2a 453 
C4b 321 C4c 402 C4a 396 
C5b 323 C5c 370 C5a 440 
C7b 323 C7c 454 C7a 539 
 
3.3.4.4. Quantum Yield  
The quantum yield of each complex was measured, and the results are shown in Table 3.6. The 
measurements were recorded in aerated chloroform using [Ru(bpy)3][PF6]2 as a standard.  
There is no clear trend in the data that links either the cyclometallating ligand or the ancillary 
ligand to the quantum efficiency of the complex. The highest and lowest quantum yield values 
were recorded for pyrazinoate complexes with fluorinated cyclometallating ligands. The 
complex with L4, C4c, gave the highest value over both series at 8.9 %; whilst the complex C7c 
has the lowest quantum yield at 1.3 %. The picolinate complexes with these same ligands have 
the same quantum yield value and sit at halfway between the values recorded for their 
pyrazinoate analogues. 
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Table 3.6: Quantum yield values for all complexes with [Ru(bpy)3][PF6]2 as a standard. (ΦΔ = 0.018 in 
acetonitrile.47 
Complex Φ/ % Complex Φ/ % Complex Φ/ % 
C1b 4.1   C1a 5.7 
C2b 6.8 C2c 5.9 C2a 5.1 
C3b 3.6   C3a 1.8 
C4b 4.8 C4c 8.9 C4a 6.0 
C5b 3.2 C5c 2.9 C5a 6.6 
C6b 2.7   C6a 6.4 
C7b 4.8 C7c 1.3 C7a 7.8 
 
The last two columns of the table list the quantum yield values of the cationic complexes. These 
values also show no correlation between cyclometallating ligand and quantum yield. There is 
also no apparent trend when comparing the same cyclometallating ligand across a series of 
differing ancillary ligands. 
Photoluminescent quantum yields of neutral red-emitting phosphors in solution reported in the 
literature are typically low. Many of these complexes have cyclometallating ligands based on 
phenylquinoline, with the highest quantum yield value recorded for methyl-substituted 
phenylquinoline complexes of iridium(III) with an acetylcacetone (acac) ligand recorded 14 %.39 
However, in 2015, a fluorine-substituted phenylquinoline complex with a picolinate ligand was 
synthesised which exhibited a quantum yield value of 65 %.48 Although the complexes in this 
study have much lower values, this could be due to quenching by triplet oxygen in solution as 
these values were measured in aerated solvents, while the literature examples are unclear on 
whether the samples were de-aerated or not. 
Table 3.7 shows the lifetime and quantum yield for each complex in this chapter alongside the 
calculated values for the rates of radiative, kr, non-radiative, knr, decay. This table shows that the 
kr values are relatively consistent across the series of complexes whilst the knr value shows much 
more variation. From this, it can be inferred that the photophysical properties of these 
complexes are dominated by non-radiative processes. 
Table 3.7: Photophysical data collected for all neutral comlexes. 
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3.3.4.5. Solvent Studies  
The complex C2c was chosen to investigate the effect of solvent upon the absorption and 
emission spectra of the pyrazinoic acid complex series. The extra heteroatom in the aromatic 
ring of the pyrazinoic acid could make the absorption and emission properties of the molecule 
more susceptible to solvent effects such as polarity and hydrogen bonding. 
Figure 3.23 shows the UV-vis absorption spectra of C2c recorded in a variety of solvents with 
differing polarity and dielectric constant. The position of the MLCT absorption band does not 
change depending on the solvent, however the extinction coefficient of this peak does vary 
marginally, but not in line with polarity or dielectric constant of the solvent. 
Complex A τ/ ns B Φ/ % Knr. 106 s-1 Kr/ 105 s-1 
C1b 308 4.1 3.11 1.33 
C2b 333 6.8 2.80 2.04 
C3b 275 3.6 3.51 1.31 
C4b 321 4.8 2.97 1.50 
C5b 323 3.2 3.00 0.99 
C6b 294 2.7 3.31 0.92 
C7b 323 4.8 2.95 1.49 
C2c 350 5.9 2.69 1.69 
C4c 402 8.9 2.27 2.21 
C5c 370 2.9 2.62 0.78 
C7c 454 1.3 2.17 0.29 
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Figure 3.23: UV-vis absorption spectra recorded for complex C2c in different solvents. All spectra 
recorded at a concentration of 10-5 M. 
The emission spectrum of the same complex was also recorded in different solvents. Unlike the 
absorption spectra, the position of the emission peak does change depending upon the solvent. 
The longest wavelength emission was observed in methanol at 662 nm and the shortest 
wavelength was recorded in toluene at 622 nm. As the emission wavelength increases with 
increasing polarity of the solvent, the complex is undergoing positive solvatochromism. 
 
Figure 3.24: Emission spectra recorded for complex C2c in different solvents, showing positive 
solvatochromism. ex = 495 nm. 
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The 3MLCT excited state from which the complex emits creates a dipole moment in the molecule 
and depending upon the dielectric constant (ε) of the solvent, the solvent molecules arrange 
themselves around this dipole to varying degrees. The polar solvents stabilise this state, 
lowering the energy gap between the excited and ground states, leading to a bathochromic shift 
in emission. The change in emission wavelength between solvents is relatively small, at around 
40 nm, suggesting that the excited state dipole is spread across the ligands and not concentrated 
on any particular one. 
The hydrogen bonding ability of a solvent can also have an impact upon the emission 
wavelength. Methanol has a lower dielectric constant (see Table 3.8) than DMSO, but causes a 
larger bathochromic shift in emission wavelength, as its better ability to hydrogen-bond further 
stabilises the excited state. The most likely site of this hydrogen bonding is to one of the 
heteroatoms not involved in coordination.  
In addition to this, the lifetime of the complex is also affected by a change in solvent. The general 
trend is that the luminescence lifetime increases with increasing dielectric constant of the 
solvent. However, the exception to this trend is acetonitrile, which despite having the second-
highest dielectric constant, gives the shortest lifetime value. This may be attributed to the 
combination of high solubility of oxygen in acetonitrile and the low viscosity of the solvent.49–51 
These factors could help facilitate quenching of the luminescence lifetime by triplet oxygen, 3O2. 
Table 3.8: Emission and lifetime data recorded for complex C2c in different solvents along with their 
dielectric constants. a - ex = 495 nm, b - ex = 295 nm. 
Solvent  λem/ nma  τ/ nsb Dielectric constant, ε 
Chloroform 630 350 4.81 
Dichloromethane 626 468 8.93 
Toluene 622 253 2.38 
Dimethyl sulfoxide 636 695 46.7 
Acetonitrile 632 66 37.5 
Methanol 662 630 32.7 
 
3.3.5. Computational Studies 
Extensive computational studies have been carried out upon ten of the eleven complexes 
reported in this chapter. This work was carried out by Thomas Stonelake and Dr Joseph Beames 
of Cardiff University and the findings are summarised below.  
Density functional theory (DFT) calculations were found to support the experimental findings in 
this chapter. DFT was used to calculate the contribution of each moiety in the molecule to the 
HOMO and LUMO and these results are shown in Table 3.9. In the case of complex C1b, the 
quinoxaline ligands were responsible for 36 and 59 % of the contribution to the LUMO each, 
while the iridium centre and the picolinate ligand contributed only 4 and 1% respectively. These 
differ from the results calculated for the corresponding cationic complex, [Ir(L1)2(bipy)][PF6], as 
the asymmetric picolinic acid ligand introduces inequivalency between the quinoxaline ligands. 
It was observed that where the complexes possessed a picolinate ligand, the quinoxaline ligands 
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formed pseudo-degenerate pairs. For example, the complex C2b showed LUMO contributions 
of 34 % and 60 % from quinoxaline ligands Q1 and Q2 respectively, whilst the LUMO+1 shows 
the opposite  (Q1 = 60 %, Q2 = 34 %). These pseudo-degenerate pairs were not observed in the 
pyrazinoate complexes. Overall, the calculations suggest that the emissive state is almost 
entirely ligand-centred in character and not MLCT as previously supposed. 
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Table 3.9: A summary of the calculated percentage contributions to each MO from each part of the 
complex. Q1 and Q2 refer to the inequivalent quinoxaline ligands 
Complex 
Ir 5d Q1 Q2 pic/pyz 
HOMO-1 HOMO LUMO LUMO+1 LUMO LUMO+1 LUMO+2 
C1b 43 40 36 59 59 36 96 
C2b 37 39 34 60 60 34 96 
C3b 41 39 40 55 55 40 94 
C4b 40 39 39 56 56 39 96 
C5b 21 38 38 57 57 38 94 
C6b 21 38 42 53 53 41 6 
C7b 16 38 41 54 54 41 90 
C2c 28 38 48 47 38 39 77 
C5c 10 37 41 35 47 48 76 
C7c 8 37 44 46 49 46 89 
 
The absorption spectrum of each complex was simulated and compared with that recorded 
experimentally. Figure 3.25 shows the results obtained for complex C1b and it can be seen that  
qualitatively, the simulated spectra are in good agreement with experiment, each featuring 
three components in decreasing intensity with increasing wavelength. However, the absolute 
energy of each transition is underestimated in the simulation as presented in Table 3.10. 
 
Figure 3.25: Comparison of experimental emission spectrum (red) and simulated emission spectrum 
(black) of complex C1b.  
The calculations predict that there are no singlet transitions that occur above 500 nm and in 
each complex, there is a singlet-triplet absorption feature between 550 – 620 nm which 
corresponds well with the broad, low intensity feature observed experimentally. 
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The effect of ligand substitution was also studied. It is known that electron withdrawing groups 
of the cyclometallating ligands stabilise the HOMO, while electron donating groups have the 
opposite effect.52–54 Here, it was calculated that complexes with fluoro- and chloro- substituted 
quinoxaline ligands exhibited lower energy values for frontier orbitals, with the HOMO typically 
being less stabilised than the LUMO. It has been suggested that this effect could be due to the 
quinoxaline rings contributing more to the LUMO than the HOMO. The result of this effect is 
that the HOMO – LUMO gap is slightly different depending upon the ligand substituents; the 
electron withdrawing substituents decrease this gap, while the electron donating methyl 
substituents lead to an increase. In addition to this, it was observed that the phenyl-substituted 
ligands have similar HOMO values to the methyl-substituted ligands, but have lower LUMO 
values. 
Table 3.10: Absorption and emission values calculated for each complex. Experimental values for T1  S0 
are written in parentheses 
Complex S0  S1 (nm) S0  T1 (nm) T1  S0 (nm) 
C1b 424 578 697 (646) 
C2b 419 568 689 (640) 
C3b 440 608 739 (667) 
C4b 428 586 710 (651) 
C5b 425 579 705 (648) 
C6b 445 618 751 (675) 
C7b 434 597 722 (659) 
C2c 416 563 685 (632) 
C5c 422 573 703 (641) 
C7c 431 589 714 (651) 
 
The ancillary ligand also shows a similar effect. Both picolinate and pyrazinoate are electron 
withdrawing ligands, however the pyrazinoate has a slightly stronger effect due to the additional 
nitrogen atom in the aromatic ring. These electron withdrawing effects stabilise the HOMO and 
the LUMO, but the pyrazinoate ligand stabilises the HOMO more than the LUMO in comparison 
with picolinate. As a result of this, complexes with a pyrazinoate ligand exhibit slightly blue-
shifted emission compared to their picolinate counterparts. The large metal contribution to the 
HOMO may be responsible for the differences in HOMO vs. LUMO stabilisation. 
3.3.6. Transient Absorption Studies 
Transient absorption studies were also carried out by Thomas Stonelake and Dr Joseph Beames 
of Cardiff University.  
The transient absorption (TA) spectra recorded show three distinct features. The first of these 
features occurs at around 350 – 400 nm in all complexes which is attributed to the ground state 
bleach, the depletion of the 1MLCT absorption band. The second of these features is a positive 
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going signal at between 400 – 500 nm which, in most cases, consists of two peaks. As the lifetime 
of this feature closely matched that of the T1  S0 emission decay kinetics, this was assigned as 
a triplet-triplet transition. This assignment was also supported by time dependent DFT 
calculations. The third feature observed is a broad, positive going feature at around 600 nm 
which was relatively weak. This was also assigned to a triplet-triplet transition. 
 
Figure 3.26: Left) TA spectra recorded for picolinate complexes C1b-7b. Right) TA spectra recorded for 
pyrazinoate complexes C2c, C5c and C7c 
As mentioned previously, the LUMO of the picolinate complexes exhibits pseudo-degeneracy. 
This can be observed in the TA spectra as the structured absorption profiles in the 400 – 500 nm 
range. It is of note that these features were not observed in the previously reported spectra 
recorded for the cation species, [Ir(L)2(bipy)][PF6]. In addition to this, all complexes showed a 
red-shift relative to the complex C1, with the size of the shift depending upon quinoxaline 
substituents. Also, diphenyl substitution results in a greater red-shift than phenyl, methyl-
substitution. 
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3.4. Conclusion 
In this chapter of work, eleven novel neutral bis-cyclometallated iridium(III) complexes have 
been synthesised and fully characterised. The complexes utilised a series of seven 
cyclometallating ligands based upon quinoxaline, and two different ancillary ligands derived 
from picolinic acid and pyrazinoic acid. 
These complexes showed emission between 635 and 677 nm in the red region of the spectrum, 
with the picolinate complexes showing a greater range in emission wavelength than the 
pyrazinoate analogues. When considered in combination with the structurally related cationic 
complexes synthesised in chapter two, the total emission range in the red region is over 60 nm. 
In addition to this, the emission wavelength of each complex can be tuned to a lesser degree by 
changing the solvent used in the emission experiments. More polar solvents stabilise the 3MLCT 
emitting state leading to a bathochromic shift in emission wavelength. This effect is much 
smaller than the effect of ligand substituents as the emitting state of these complexes is not 
purely MLCT in character as supported by DFT calculations. 
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3.5. Experimental 
1H and 13C{1H} NMR spectra were recorded on an NMR-FT Bruker 500 and 400 MHz spectrometer 
and recorded in CDCl3, acetone-d6, acetonitrile-d3 and DMSO-d6. 1H and 13C{1H} NMR chemical 
shifts (δ) were determined relative to residual solvent peaks with digital locking and are given in 
ppm. Low-resolution mass spectra were obtained by the staff at Cardiff University. High-
resolution mass spectra were carried out at the EPSRC National Mass Spectrometry Facility at 
Swansea University. UV-Vis studies were performed on a Shimadzu UV-1800 spectrophotometer 
as CHCl3 solutions (1 × 10-5 M). Photophysical data were obtained on a JobinYvon–Horiba 
Fluorolog spectrometer fitted with a JY TBX picosecond photodetection module as CHCl3 
solutions. Emission spectra were uncorrected and excitation spectra were instrument corrected. 
The pulsed source was a Nano-LED configured for 459 nm output operating at 1 MHz. 
Luminescence lifetime profiles were obtained using the JobinYvon–Horiba FluoroHub single 
photon counting module and the data fits yielded the lifetime values using the provided DAS6 
deconvolution software. Quantum yield measurements were obtained on aerated CHCl3 
solutions of the complexes using [Ru(bpy)3](PF6)2 in aerated MeCN as a standard (Φ = 0.016). 
For synthesis of ligands L1-L7 see chapter 2. 
Synthesis of [Ir(L1)2(pic)] C1b [{Ir(L1)2(μ-Cl)}2] (100 mg, 0.08 mmol) and 2-picolinic acid (2 eq., 18 
mg, 0.16 mmol) were dissolved in 2-ethoxyethanol (10 mL) along with potassium carbonate (2 
eq., 22 mg, 0.16 mmol) and silver nitrate (4 eq., 51 mg, 0.32 mmol). The reaction mixture was 
heated at reflux under a nitrogen atmosphere in a covered flask for 24 hours. The reaction 
mixture was then cooled to room temperature before the addition of cold water (20 mL) to form 
a dark red precipitate. The solid was collected by filtration to yield the product as a red powder 
(Yield = 107 mg, 97%). 1H NMR (400 MHz, CDCl3): δH  8.55 (1H, d, JHH = 8.56 Hz), 8.39 (1H, d, JHH = 
8.56 Hz), 8.21 (1H, d, JHH = 8.56 Hz), 7.97 – 7.87 (4H, m), 7.77 (1H, d, JHH = 7.79 Hz), 7.64 (1H, t, 
JHH = 7.42 Hz), 7.61 – 7.55 (1H, m), 7.54 – 7.48 (1H, m), 7.42 (1H, t, JHH = 7.20 Hz), 7.34 – 7.30 (1H, 
m), 7.17 (1H, t, JHH = 7.20 Hz), 7.02 (1H, t, JHH = 7.20 Hz), 6.93 (1H, d, JHH = 7.57 Hz), 6.90 – 6.85 
(1H, m), 6.80 (1H, t, JHH = 7.20 Hz), 6.66 (1H, t, JHH = 7.53 Hz), 6.26 (1H, d, JHH = 7.77 Hz), 3.35 
(6H,overlapping s) ppm. 13C {1H} NMR (100 MHz, CDCl3): δC  145.5, 138.2, 137.1, 135.2, 131.1, 
130.1, 129.9, 129.7, 129.5, 129.4, 128.9, 128.7, 127.9, 127.6, 127.5, 127.1, 124.5, 122.4, 121.7, 
27.6 ppm. HRMS (ESI) found m/z 754.1789, calculated m/z 754.1790 for [C36H26IrN5O2]H+. UV 
vis. (CHCl3) max (ε / dm3mol-1cm-1): 491 (3700), 373 (17300) nm. IR (solid) υmax = 3723, 2962, 
1630, 1507, 1578, 1564, 1526, 1481, 1451, 1425, 1387, 1334, 1321, 1289, 1260, 1219, 1194, 
1165, 1015, 907, 841, 795, 758, 739, 662, 627, 592, 552, 407 cm-1. 
Synthesis of [Ir(L2)2(pic)] C2b  as C1 but with [{Ir(L2)2(μ-Cl)}2] (100 mg, 0.07 mmol). Purified by 
column chromatography using DCM: MeOH (96:4) and product collected as first red band. Red 
solid (Yield = 13 mg, 12 %). 1H NMR (400 MHz, CDCl3): δH 8.36 (1 H, d, JHH = 1.1 Hz), 8.36 – 8.31 
(1 H, m), 8.19 (1 H, d, JHH = 8.2 Hz), 7.96 – 7.92 (1 H, m), 7.83 (1 H, app. ddd), 7.69 (1 H, s), 7.66 
– 7.62 (4 H, m), 7.32 (1 H, app. ddd), 7.13 (1 H, app. ddd), 7.03 (1 H, s), 6.99 (1 H, app. ddd), 6.86 
(1 H, app. dd), 6.79 – 6.71 (1 H, m), 6.65 – 6.60 (1 H, m), 6.28 – 6.18 (1 H, m), 2.38 – 2.36 (6 H, 
overlapping s), 2.32 (6 H, s), 2.29 – 2.27 (6 H, overlapping s) ppm. 13C{1H} NMR (101 MHz, CDCl3): 
δC 142.1, 137.8, 129.7, 129.4, 128.5, 127.6, 127.1, 126.3, 124.4, 122.0, 121.4, 27.9, 27.5, 20.3, 
20.0, 19.7, 19.6 ppm. HRMS (ESI) found m/z 810.2415, calculated m/z 810. 2417 for 
[C40H34IrN5O2]H+. UV vis. (CHCl3) max (ε / dm3mol-1cm-1): 507 (3700), 381 (26000), 276 (116200) 
nm. IR (solid) υmax = 3362, 2915, 1655, 1601, 1578, 1562, 1526, 1483, 1408, 1335, 1321, 1287, 
Chapter 3  
95 
 
1269, 1219, 1163, 1121, 1059, 1047, 1034, 1024, 991, 903, 878, 839, 795, 758, 743, 733, 702, 
691, 658, 629, 567, 476, 430 cm-1. 
Synthesis of [Ir(L3)2(pic)] C3b as C1 but with [{Ir(L3)2(μ-Cl)}2]  (100 mg, 0.06 mmol). Purified by 
column chromatography using DCM: MeOH (95:5) and product collected as first red band. Red 
solid (Yield = 20 mg, 18%). 1H NMR (400 MHz, CDCl3): δH 8.83 (1 H, d, JHH = 12.5 Hz), 8.42 (1 H, d, 
JHH = 8.3 Hz), 8.29 – 8.19 (1 H, m), 8.06 (2 H, s), 8.04 (1 H, s), 7.96 – 7.90 (1 H, m), 7.84 (1 H, t, JHH 
=  6.4 Hz), 7.76 (1 H, app. dt), 7.46 – 7.39 (1 H, m), 7.38 (1 H, s), 7.24 – 7.16 (1 H, m), 7.06 – 7.02 
(1 H, m), 6.87 (1 H, d, JHH = 3.8 Hz), 6.76 – 6.66 (1 H, m), 6.17 (1 H, app. dd), 3.47 – 3.23 (6 H, 
overlapping s) ppm. 13C{1H} NMR (126 MHz, CDCl3): δC 171.2, 164.3, 154.8, 154.3, 152.5, 152.3, 
151.8, 145.5, 145.0, 143.8, 139.5, 139.2, 139.1, 138.8, 138.7, 136.6, 136.3, 134.9, 134.7, 134.2, 
133.2, 131.0, 130.6, 130.3, 130.0, 128.7, 128.4, 128.2, 127.8, 125.4, 122.7, 122.2, 28.0, 27.7 ppm. 
HRMS (ESI) found m/z 892.0191, calculated m/z 892.0195 for [C36H22Cl4IrN5O2]H+. UV vis. (CHCl3) 
max (ε / dm3mol-1cm-1): 538 (2300), 389 (12500), 371 (11500), 300 (11500), 273 (21500) nm. IR 
(solid) υmax = 3407, 3060, 1655, 1599, 1578, 1524, 1460, 1431, 1316, 1190, 1163, 1115, 1049, 
1009, 963, 882, 855, 758, 725, 671, 646, 610, 556, 469, 436, 417 cm-1. 
Synthesis of [Ir(L4)2(pic)] C4b as C1 but with [{Ir(L4)2(μ-Cl)}2] (80 mg, 0.05 mmol). Purified by 
column chromatography, DCM used to elute ligand followed by DCM:MeOH (9:1) to elute 
product as red band. The product was then recrystallised from chloroform and hexane to give a 
red solid. (Yield = 27 mg, 30 %). 1H NMR (400 MHz, CDCl3): δH 8.81 (1H, d, JHH =  0.4 Hz), 8.42 (1H, 
dd, JHH =  8.3, 1.0 Hz), 8.25 – 8.21 (1H, m), 8.06 (1H, d, JHH =  0.4 Hz), 8.04 (1H, d, JHH =  0.4 Hz), 
7.96 – 7.93 (1H, m), 7.83 – 7.78 (1H, m), 7.76 (1H, app. td), 7.44 – 7.40 (1H, m), 7.38 (1H, d, JHH =  
0.4 Hz), 7.23 – 7.17 (1H, m), 7.07 – 7.03 (1H, m), 6.86 (2H, d, JHH =  3.9 Hz), 6.71 (1H, app. dt), 
6.19 – 6.16 (1H, m), 3.33 (6H, overlapping s) ppm. 13C{1H} NMR (101 MHz, CDCl3): δC 171.1, 153.9, 
152.0, 145.4, 145.2, 144.1, 138.8, 136.7, 134.7, 130.7, 130.2, 129.9, 128.2, 128.0, 122.8, 122.2, 
114.3, 31.6, 27.7, 27.5, 22.7, 14.2 ppm. 19F{1H} NMR (376 MHz, CD3CN): δ F -131.81 (d, 3JFF = 22.6 
Hz), -132.90 (d, 3JFF = 22.6 Hz), -133.67 (d, 3JFF = 18.8 Hz), -134.03 (d, 3JFF = 18.8 Hz) ppm. HRMS 
(ESI) found m/z 826.1416, calculated m/z 826.1413 for [C36H22F4IrN5O2]H+. UV vis. (CHCl3) max 
(ε / dm3mol-1cm-1): 501 (4000), 377 (26300), 361 (23900), 272 (113200) nm. IR (solid) υmax = 3410, 
3001, 1634, 1601, 1578, 1530, 1501, 1414, 1327, 1294, 1256, 1233, 1196, 1163, 1125, 1051, 
1034, 995, 880, 843, 793, 758, 743, 729, 706, 694, 660, 637, 586, 476, 459, 434 cm-1. 
Synthesis of [Ir(L5)2(pic)] C5b as C1 but with [{Ir(L5)2(μ-Cl)}2] (100 mg, 0.06 mmol). 
Product purified by column chromatography using DCM:MeOH as the eluent. Product 
collected as the first red band and recrystallised from DCM and hexane to give a red 
solid. (Yield = 25 mg, 23 %). 1H NMR (400 MHz, CDCl3): δH 8.50 (1 H, s), 8.39 (1 H, d, 
JHH = 5.3 Hz), 8.03 – 7.87 (3 H, m), 7.82 (1 H, s), 7.76 (3 H, m), 7.66 – 7.54 (6 H, m), 
7.54 – 7.45 (3 H, m), 7.15 (1 H, s), 7.10 – 7.02 (1 H, m), 7.02 – 6.94 (1 H, m), 6.75 – 6.41 
(4 H, m), 6.16 (1 H, d, JHH = 7.5 Hz), 2.32 (6 H, s), 1.84 (6H, s) ppm. 13C{1H} NMR (101 
MHz, CDCl3): δC 145.7, 144.3, 139.5, 134.5, 130.5, 129.6, 129.4, 128.9, 128.0, 127.3, 
124.2, 121.3, 20.7, 20.0, 19.9, 19.7 ppm. HRMS (ESI) found m/z 934.2731, calculated 
m/z 934.2731 for [C50H38IrN5O2]H+. UV vis. (CHCl3) max (ε / dm3mol-1cm-1): 501 (4700), 
387 (28900), 300 (34200), 262 (50000) nm. IR (solid) υmax = 3053, 1640, 1599, 1578, 
1547, 1508, 1481, 1443, 1348, 1317, 1263, 1234, 1209, 1171, 1157, 1132, 1117, 1071, 
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1047, 1024, 1003, 974, 922, 876, 843, 833, 810, 774, 762, 743, 733, 698, 660, 640, 621, 
608, 579, 540, 498, 490, 460, 440, 421 cm-1. 
 
Synthesis of [Ir(L6)2(pic)] C6b  as C1 but with [{Ir(L6)2(μ-Cl)}2]. Product purified by column 
chromatography using DCM:MeOH as the eluent. Product collected as the first red band and 
recrystallised from DCM and hexane to give a red solid (Yield = 37 mg, 34%). 1H NMR (400 MHz, 
CDCl3): δH 8.94 (1 H, s), 8.32 (1 H, d, JHH = 4.8 Hz), 8.20 (1 H, s), 8.16 (1 H, s), 8.08 (1 H, d, JHH = 7.2 
Hz), 7.98 (2 H, s), 7.86 (1 H, app. td), 7.79 (2 H, s), 7.67 (3 H, d, JHH = 2.2 Hz), 7.64 – 7.60 (4 H, m), 
7.52 (1 H, s), 7.20 – 7.14 (1 H, m), 7.07 (1 H, d, JHH = 8.0 Hz), 6.77 – 6.71 (1 H, m), 6.70 – 6.78 (2 
H, m), 6.65 – 6.54 (2 H, m), 6.11 – 6.09 (1 H, m) ppm. 13C{1H} NMR (126 MHz, CDCl3): δC 171.3, 
165.7, 163.7, 155.7, 154.4, 154.1, 152.6, 145.7, 144.6, 143.5, 139.8, 139.4, 139.3, 139.2, 139.1, 
139.0, 139.0, 137.0, 136.2, 135.2, 134.9, 134.5, 133.5, 131.5, 131.2, 131.0, 130.8, 130.5, 130.4, 
130.2, 129.5, 129.1, 128.9, 128.5, 128.3, 127.7, 125.3, 122.1, 121.6 ppm. HRMS (ESI) found m/z 
1017.0534, calculated m/z 1017. 0537 for [C46H26Cl4IrN5O2]H+. UV vis. (CHCl3) max (ε / dm3mol-
1cm-1): 528 (4100), 396 (29800), 273 (90600) nm. IR (solid) υmax = 3410, 3000, 1632, 1597, 1578, 
1562, 1543, 1508, 1458, 1443, 1429, 1406, 1387, 1346, 1317, 1256, 1198, 1163, 1132, 1115, 
1069, 1044, 1022, 997, 959, 887, 878, 845, 808, 758, 745, 735, 725, 696, 673, 665, 652, 633, 606, 
571, 515, 488, 476, 436, 415, 403 cm-1. 
Synthesis of [Ir(L7)2(pic)] C7b  as C1 but with [{Ir(L7)2(μ-Cl)}2] (90 mg, 0.05 mmol). Product 
collected as a red solid. (Yield = 39 mg, 40 %). 1H NMR (400 MHz, CDCl3): δH 8.67 (1H, app. dd), 
8.41 (1H, d, JHH =  5.4 Hz), 8.06 -8.04 (1H, m), 8.01 – 7.97 (2H, m), 7.90 – 7.84 (2H, m), 7.81 (2H, 
app. dd), 7.70 – 7.59 (8H, m), 7.22 – 7.18 (1H, m), 7.18 – 7.14 (1H, m), 7.07 – 7.03 (1H, m), 6.76 
– 6.72 (1H, m), 6.70 – 6.68 (2H, m), 6.64 – 6.55 (2H, m), 6.10 – 6.07 (1H, m) ppm. 13C {1H} NMR 
(126 MHz, DMSO): δC 171.4, 153.5, 152.7, 151.8, 145.6, 145.1, 143.9, 139.1, 139.0, 136.4, 134.6, 
131.1, 130.7, 130.6, 130.4, 130.2, 130.1, 129.1, 128.9, 128.4, 128.2, 122.2, 121.6 ppm. 19F{1H} 
NMR (376 MHz, CD3CN): δF -130.18 (d, 3JFF = 22.6 Hz), -131.51 (d, 3JFF = 22.6 Hz), -133.10 (d, 3JFF 
= 18.8 Hz), -133.59 (d, 3JFF = 18.8 Hz) ppm. HRMS (ESI) found m/z 950.1726, calculated m/z 
950.1728 for [C46H26F4IrN5O2]H+ . UV vis. (CHCl3) max (ε / dm3mol-1cm-1): 505 (3100), 387 (23100), 
277 (3400) nm. IR (solid) υmax = 3412, 3042, 1649, 1601, 1578, 1522, 1499, 1445, 1427, 1327, 
1294, 1273, 1258, 1227, 1165, 1126, 1069, 1044, 1024, 980, 874, 841, 808, 758, 745, 725, 700, 
662, 640, 623, 615, 596, 530, 500, 488, 421 cm-1. 
Synthesis of [Ir(L2)2(pyz)] C2c [Ir(L2)2(MeCN)2] (250 mg, 0.325 mmol), pyrazine carboxylic acid 
(50 mg, 0.4 mmol) and K2CO3 (55 mg, 0.4 mmol) were dissolved in a mixture of chloroform (20 
mL) and ethanol (5 mL). The reaction mixture was heated at reflux for 48 hours. The reaction 
mixture was then filtered and a red solid collected. The solid was purified by silica gel 
chromatography (dichloromethane:methanol, 95:5) and collected as the first red band. 
Reprecipitation from DCM and Et2O gave the product as a red solid. (Yield = 32 mg, 12 %); 1H 
NMR (400MHz, CDCl3): δH 8.93 ( 1H, d, JHH = 1.1 Hz), 8.53 ( 1H, d, JHH = 3.0 Hz), 8.29 (1H, d, JHH = 
7.8 Hz), 8.22 (1H, s), 8.12 (1H, d, JHH = 7.7 Hz), 7.84 (1H, dd, JHH = 3.0, 1.2Hz), 7.65 (1H, s), 7.61 
(1H, s), 7.13-7.06 (1H, m), 6.97-6.90 (1H, m), 6.83 (1H, s), 6.80 (1 H, dd, JHH = 7.8, 1.1 Hz), 6.75-
6.69 (1H, m), 6.61-6.56 (1H, m), 6.13 (1H, dd, JHH = 7.7, 1.0 Hz), 3.26 (3H, s), 3.24 (3H, s), 2.32 
(3H, s), 2.25 (3H, s), 2.23 (3H, s), 1.72 (3H, s) ppm. 13C{1H} NMR (126MHz, CDCl3): δC 170.0, 163.6, 
161.5, 151.7, 151.2, 150.1, 149.8, 149.5, 148.3, 146.0, 145.7, 144.6, 142.5, 141.2, 140.1, 139.6, 
139.5, 139.4, 139.0, 138.7, 136.7, 129.9, 129.5, 129.5, 129.1, 128.9, 127.4, 126.1, 123.9, 122.4, 
122.0, 27.8, 27.5, 20.3, 20.00, 19.7 ppm. HRMS (ESI) found m/z of 811.2367, calculated m/z 
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811.2367 for [C35H21F4IrN6O2]H+. UV-vis (CHCl3) max (ε /dm3mol-1cm-1) 480 (5100), 380 (27100), 
267 (50200) nm. IR (solid) υmax = 3408, 3050, 2918, 1649, 1578, 1524, 1483, 1449, 1406, 1344, 
1319, 1217, 1163, 1034, 991, 870, 847, 793, 760, 723, 700, 627, 567, 473, 403 cm-1. 
Synthesis of [Ir(L4)2(pyz)] C4c [{Ir(L4)2(µ-Cl)}2] (174 mg, 0.118 mmol), pyrazine carboxylic acid 
(28 mg, 0.236 mmol), potassium carbonate (33 mg, 0.236 mmol) and silver nitrate (80 mg, 0.472 
mmol) were dissolved in 2-ethoxyethanol (10 mL). The reaction mixture was heated at reflux for 
24 hours in the absence of light. The reaction mixture was cooled to room temperature and 
water (40 mL) added to form a brown precipitate. The precipitate was collected by filtration and 
purified by silica gel chromatography (dichloromethane:methanol, 95:5). First red band 
collected and dried in vacuo to yield [Ir(L4)2pyr] as a red solid (Yield = 35mg, 18%). 1H NMR (400 
MHz, CDCl3): H 9.02 (1H, d, JHH = 1.3 Hz), 8.63 (1H, d, JHH = 3.0 Hz), 8.42-8.3 (2H, m), 8.15 (1H, d, 
JHH = 7.6 Hz), 7.79 (1H, dd, JHH = 3.0, 1.3 Hz), 7.75-7.62 (2H, m), 7.19-7.14 (1H, m), 7.04-6.98 (1H, 
m), 6.88 (1H, dd, JHH = 11.7, 7.7 Hz) 6.85-6.79 (2H, m), 6.06 (1H, dd, JHH = 7.7, 1.0 Hz), 3.28 (3H, 
s), 3.26 (3H, s) ppm. 13C{1H} NMR (101 MHz, CDCl3): C 167.0, 152.2, 151.8, 149.9, 149.2, 145.5, 
145.0, 144.0, 138.9, 136.8, 134.6, 131.0, 130.5, 130.4, 129.9, 123.2, 122.7, 116.1, 115.9, 114.00, 
110.8, 27.6, 27.5 ppm. 19F{1H} NMR (376 MHz, CDCl3): F -125.01 (d, 3JFF = 21.7 Hz), -128.95 (d, 
3JFF = 22.0 Hz), -129.51 (d, 3JFF = 22.0 Hz), -130.85 (d, 3JFF = 21.7 Hz) ppm. HRMS found m/z 
827.1365, calculated m/z 827.1365 for [C35H21F4IrN6O2]H+. UV-vis (CHCl3) max (ε /dm3mol-1cm-1) 
490 (4900), 374 (31000), 262 (50900) nm. IR (solid) υmax = 3456, 3057, 1655, 1578, 1501, 1449, 
1414, 1327, 1258, 1223, 1165, 1126, 1034, 995, 928, 876, 793, 731, 660, 637, 586, 474cm-1. 
Synthesis of [Ir(L5)2(pyz)] C10 as [Ir(L4)2(pyz)] but with [{Ir(L5)2(µ-Cl)}2] (200 mg, 0.118 mmol), 
pyrazine carboxylic acid (28 mg, 0.236 mmol), potassium carbonate (0.033g, 0.236mmol) and 
silver nitrate (80 mg, 0.472 mmol) were dissolved in 2-ethoxyethanol (10 mL). Product purified 
by silica gel chromatography (dichloromethane:methanol, 99:1), followed by 
(dichloromethane:methanol, 95:5) to elute red band, solvent was removed in vacuo, then 
reprecipitated from DCM and Et2O to give [Ir(L5)2pyr] as a red solid (Yield = 25 mg, 11 %). 1H 
NMR (400 MHz, CDCl3): H 9.15 (1H, d, JHH = 1.1Hz), 8.78 (1H, d, JHH = 2.9Hz), 8.44 (1H, s), 8.31 
(1H, dd, JHH = 3.0, 1.3Hz), 7.98-7.73 (6H, m), 7.67-7.56 (6H, m), 7.08 (1H, dd, JHH = 8.1, 1.1 Hz), 
7.02 (1H, s), 7.00 (1H, dd, JHH =8.0, 1.3 Hz), 6.75-6.61 (3H, m), 6.60-6.50 (2H, m), 6.13 (1H, dd, JHH 
= 7.5, 1.1 Hz) 2.41 (3H, s), 2.41 (3H, s), 2.33 (3H, s), 1.89 (3H, s) ppm. 13C{1H} NMR (101 MHz, 
CDCl3): δC 170.1, 163.0, 160.8, 153.5, 152.2, 150.7, 150.0, 149.9, 148.3, 146.6, 145.2, 144.1, 
143.5, 141.5, 130.2, 129.9, 129.8, 129.5, 129.4, 128.9, 128.3, 126.1, 123.7, 121.8, 121.4, 20.8, 
20.1, 20.0, 19.8 ppm. HRMS found m/z 935.2684, calculated m/z 935.2683 for [C49H37IrN6O2]H+. 
UV-vis (CHCl3) max (ε /dm3mol-1cm-1) 489 (4400), 386 (24000), 271 (49000) nm. IR (solid) υmax = 
3422, 3057, 1578, 1549, 1508, 1481, 1445, 1408, 1348, 1319, 1236, 1211, 1159, 1072, 1047, 
1024, 1003, 974, 849, 810, 802, 762, 746, 731, 698, 642, 608, 579, 540, 492, 444 cm-1. 
Synthesis of [Ir(L7)2(pyz)] C11 As [Ir(L4)2(pyz)] but [{Ir(L7)2(µ-Cl)}2] (250 mg, 0.145 mmol), 
pyrazine carboxylic acid (41 mg, 0.290 mmol), potassium carbonate (42 mg, 0.290 mmol) and 
silver nitrate (98 mg, 0.58 mmol) were dissolved in 2-ethoxyethanol (10 mL). Product purified 
by silica gel chromatography (dichloromethane:methanol, 99:1) to elute yellow band, followed 
by (dichloromethane:methanol, 95:5) to elute red band, solvent was removed in vacuo to yield 
the product as a purple solid. Product was dissolved in DCM and recrystallised from hexane to 
give the product as a purple crystalline solid (Yield = 22 mg, 8 %). 1H NMR (400 MHz, CDCl3): H 
9.16 (d, J=1.2Hz, 1H), 8.85 (d, J=3.0Hz, 1H), 8.53 (dd, J=12.1, 8.1Hz, 1H), 8.30 (dd, J=3.0, 1.3Hz, 
1H), 7.93 (dd, J=6.9, 2.7Hz, 2H), 7.88-7.74 (m, 4H), 7.65-7.53 (m, 6H), 7.14-6.97 (m, 3H), 6.74-
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6.62 (m, 3H), 6.60-6.49 (m, 2H), 5.98 (dd, J=7.6, 1.0Hz, 1H); 13C NMR (101 MHz, CDCl3): δC 171.4, 
165.7, 160.6, 154.0, 152.3, 151.6, 150.1, 148.2, 147.3, 143.1, 141.1, 139.9, 132.7, 131.5, 129.3, 
128.2, 127.1, 125.2, 123.6, 121.7, 120.3 ppm. 19F NMR (376 MHz, CDCl3): F -123.47 (d, 3JFF = 
22.2 Hz), -128.13 (d, 3JFF = 21.7 Hz), -128.54 (d, 3JFF = 22.2 Hz), -130.53 (d, 3JFF = 21.7 Hz) ppm. 
HRMS found m/z 951.1677, calculated m/z 951.1677 for [C45H25F4IrN6O2]H+. UV-vis (CHCl3) max 
(ε /dm3mol-1cm-1): 494 (2900), 383 (15500), 272 (41200) nm. υmax = 3422, 3044, 1649, 1576, 
1501, 1329, 1227, 1163, 1126, 1069, 1045, 980, 874, 847, 808, 797, 758, 725, 700, 662, 640, 
5 3 0 ,  4 1 9  c m - 1 . 
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4. Dual Visible/ Near-IR Emission from Organometallic Iridium(III) 
Complexes 
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4.1. Introduction 
Chapters 2 and 3 have discussed the development of red-emitting bis-cyclometallated 
iridium(III) complexes and the fine-tuning of their emission wavelength. In this chapter, the focus 
is placed on the use of organic ligands that possess a higher degree of conjugation than those 
previously investigated, in an attempt to create a much larger bathochromic shift in emission 
wavelength. 
4.1.1. Near Infrared 
The near-infrared (NIR) region of the spectrum is commonly defined as 750-1500 nm.1 In recent 
years, there has been a drive to develop compounds that emit in this range due to the many 
potential applications. Recently, NIR operating broadband light sources have been used clinically 
in ophthalmology and skin disease diagnosis,2,3 as well as in the field of bioimaging with a 
particular focus on fluorescence spectroscopy.4–6  Near-infrared wavelengths are advantageous 
in the fields of cellular and tissue imaging due to the low absorption of molecules in this region.7 
In addition to this, organic compounds with near-infrared emission have already found 
applications in the fields of night vision displays, sensors and optical communication.8,9 The 
development of near-infrared emitting species is still continuing to expand, with the one of the 
main focuses now on the synthesis of long wavelength emitting inorganic complexes.  
 
Figure 4.1: Illustration of electromagnetic spectrum from ultraviolet to infrared region. 
In chapters 2 and 3 it was discussed that the number of red-emitting iridium complexes reported 
in the literature was much lower than those with green or blue emission, and it follows that the 
number of reports of iridium complexes with near-infrared emission is lower still. One of the 
earliest reports of a NIR emitting iridium complex was in 2006. Williams et al. synthesised a 
phosphorescent OLED using the iridium complex shown in the left of Figure 4.2 which exhibited 
emission at 720 nm.10 The complex in the centre of the image was also developed with OLED 
applications in mind, this complex reported an emission peak at 716 nm, with a shoulder at 792 
nm.11 The final complex in the image has the longest reported emission wavelength of the three 
shown. This complex utilises a highly conjugated perylene diimide derived compound as the 
coordinating ligand and the reported emission wavelength was found to be 736 nm with 
another, less intense, peak at 824 nm when recorded as a film.12 
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Figure 4.2: Examples of NIR-emitting iridium(III) complexes with OLED applications.10–12  
The complexes shown in Figure 4.2 have relatively large, highly conjugated ligands. The rationale 
behind this is that increasing the conjugation of a cyclometallating ligand has been shown to 
bathochromically shift the emission wavelength of a complex.13 The increased conjugation 
lowers the energy of the LUMO, whilst the position of the HOMO remains around the same, as 
a result there is a smaller energy gap leading to lower energy emission.14,15 
 
Figure 4.3: Conjugation and addition of heteroatoms results in a bathochromic shift in  in emission 
wavelength.8  
However, the literature suggests that it is not necessary to have quite as high a level of 
conjugation as seen in the previous examples as near-IR emission has been observed from 
complexes with simpler ligands. Figure 4.4 shows three examples of such complexes all of which 
have cyclometallating ligands based upon benzo[g]quinoxaline. The first complex in the figure 
was reported in 2012 by Tao et al. The cyclometallating ligands used in this complex are methyl-
, phenyl-substituted benzo[g]quinoxaline with a di-phenylphenanthroline ancillary ligand and 
the complex showed a maximum emission wavelength of 935 nm.16 The complex in the centre 
of the figure uses a benzo[g]quinoxaline ligand with two aryl substituents and a 2,2’-biquinoline 
ancillary ligand. This complex exhibited an emission wavelength of 852 nm.17 The final complex 
shown has a very similar structure to the centre complex except that the cyclometallating ligand 
does not have methyl groups on the aryl substituent and the 2,2’-biquinoline ligand is replaced 
with 2-(quinolin-2-yl)quinoxaline (quqo) ligand. These small structural changes lead to a large 
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shift in emission wavelength as this complex emits at 970 nm, this latter work published after 
completion of the work described herein.18 
 
Figure 4.4: Near-IR emitting complexes with simpler cyclometallating ligands.16,18,19 
The benzo[g]quinoxaline ligand is simply a more conjugated version of quinoxaline. Quinoxaline-
based ligands have been the focus of chapters 2 and 3, and their complexes have shown 
emission in the red region. Therefore, complexes bearing benzo[g]quinoxaline-based ligands 
would form an appropriate comparison species and should undergo a bathochromic shift in 
respect to their quinoxaline counterparts. 
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4.2. Aims 
Over the previous two chapters, series of complexes have been synthesised with quinoxaline-
based cyclometallating ligands and the effects of substituents and ancillary ligands have been 
studied. The aims of this chapter were to investigate the effect of ligand conjugation and 
substituents in bis-cyclometallated iridium complexes. 
In this study, four ligands based upon benzo[g]quinoxaline were synthesised and characterised. 
From these ligands, a series of cationic bis-cyclometallated iridium complexes were synthesised. 
These complexes were fully characterised and their photophysical properties investigated to 
understand the influence of an extended aromatic system on absorption and emission 
properties. 
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4.3. Results and Discussion 
4.3.1. Synthesis of Ligands 
The ligands used in this study were based upon benzo[g]quinoxaline and were synthesised via a 
condensation reaction between 2,3-diaminonaphthalene and a benzil derivative. Four different 
benzil derivatives were used to introduce electron-donating and electron withdrawing groups 
into the system; in addition to benzil these included 4,4’-dimethyl benzil, 4,4’-dibromobenzil and 
4,4’-dimethoxy benzil. The general reaction scheme for the synthesis of these compounds was 
based upon the synthesis of pyrido-[2,3-b]pyrazine ligands, and is shown in Scheme 4.1.20 
 
Scheme 4.1: Synthesis scheme for ligands HL1-4. 
This synthetic route was used to isolate ligands HL1-3, but in the case of HL4 the solvent was 
substituted with tetrahydrofuran, with all other conditions retained. In all cases, the product 
formed as a yellow-brown precipitate which was collected by filtration and washed with 
methanol and used without further purification. High yields were recorded for all ligands at 
between 64 – 80 % suggesting that these conditions are an efficient route for condensation 
reactions. 
Figure 4.5 shows the proton NMR spectrum recorded for the methoxy-substituted ligand, HL4. 
Some of the more interesting signals have been highlighted in the figure. The doublet at 6.90 
ppm (highlighted in green) corresponds to the aromatic protons nearest to the methoxy group. 
The position of these protons varies from ligand to ligand as they experience the most influence 
from the functional group on the phenyl moiety. This signal is shifted most upfield in L4 due to 
the electron donating character of the functional group. In contrast to this, this signal is observed 
at its most downfield position in ligand HL3, at 7.45 ppm, due to the electron withdrawing 
bromo- substituent. The singlet highlighted in red  in the spectrum arises from the aromatic 
protons at the centre of benzo[g]quinoxaline backbone. These appear as a singlet as the ligands 
are symmetrical and there are no nearby protons to cause splitting. The position of this signal 
varies by only 0.05 ppm across the series and in each case,  this is the most downfield signal due 
to the close proximity of the electron-withdrawing nitrogen atoms in the adjacent aromatic ring. 
Finally, the singlet highlighted in blue at 3.85 ppm corresponds to the methyl groups of the 
methoxy substituent; these are downshifted from those in ligand HL2, which appear at 2.39 
ppm, due to the electron withdrawing effect of the oxygen atom in the methoxy group. 
NH2
NH2
O
R
R
O N
N
R
R
HL1: R = H
HL2: R = Me
HL3: R = Br
HL4: R = OMe
EtOH
AcOH (cat.)
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Figure 4.5: Proton NMR spectrum recorded for ligand HL4 in CDCl3. Selected proton assignments are 
shown in circles. 
For ligand HL3, it was possible to grow good quality, orange, blade-shaped single crystals via 
slow evaporation of a concentrated chloroform solution. These crystals were submitted to the 
University of Southampton for diffraction studies with the collection parameters reported in the 
experimental section of this chapter. The structure was refined in the 𝑃2భ
೙
 space group and it 
was observed that there is a single molecule in the asymmetric unit. The data collected 
confirmed the proposed structure of the ligand and the packing arrangement showed some 
long-range π-π interactions. Figure 4.7 shows the crystal structure, while Figure 4.6 shows the 
packing diagram. Furthermore, Table 4.1 and Table 4.2 show the bond lengths and bond angles 
recorded respectively. 
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Table 4.1: Selected bond length data for compound HL3. 
Atom Atom Length/Å Atom Atom Length/Å 
Br1 C16 1.900(3) C8 C9 1.362(5) 
Br2 C22 1.902(3) C9 C10 1.425(5) 
N1 C1 1.305(5) C10 C11 1.396(5) 
N1 C12 1.377(4) C11 C12 1.387(5) 
N2 C2 1.310(4) C13 C14 1.398(5) 
Figure 4.2: X-ray structure of ligand HL3. Ellipsoids drawn at 50 % probability. Crystal data: 
C24H14Br2N2, Mr = 490.19, monoclinic, P21/n (No. 14), a - 5.7963(2) Ǻ, b = 21.8021(9) Ǻ, c = 
15.1661(6) Ǻ, β = 91.211(3)˚, α = γ = 90 ˚, V = 1916.15(13) Ǻ3, T = 100(2) K, Z = 4, Z’ = 1, µ(MoKα) = 
4.243 mm-1, 19907 reflections measured, 4396 unique (Rint = 0.0501) which were used in all 
calculations. The final wR2 was 0.1219 (all data) and R1 was 0.0491 (I>2(I)). 
Figure 4.1: Packing diagram for ligand HL3 obtained from crystal data. Ellipsoids are drawn at 50 % 
probability. 
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N2 C3 1.385(4) C13 C18 1.395(5) 
C1 C2 1.463(5) C14 C15 1.391(5) 
C1 C13 1.497(4) C15 C16 1.383(5) 
C2 C19 1.490(5) C16 C17 1.389(5) 
C3 C4 1.393(5) C17 C18 1.390(5) 
C3 C12 1.431(5) C19 C20 1.401(5) 
C4 C5 1.399(5) C19 C24 1.390(5) 
C5 C6 1.430(4) C20 C21 1.383(5) 
C5 C10 1.442(5) C21 C22 1.381(5) 
C6 C7 1.368(5) C22 C23 1.385(5) 
C7 C8 1.422(5)    
 
Table 4.2: Selected bond angles for compound HL3. 
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Atom Atom Atom Angle/° Atom Atom Atom Angle/˚ 
C1 N1 C12 118.2(3) N1 C12 C3 120.4(3) 
C2 N2 C3 117.4(3) N1 C12 C11 119.1(3) 
N1 C1 C2 121.1(3) C11 C12 C3 120.4(3) 
N1 C1 C13 115.4(3) C14 C13 C1 117.7(3) 
C2 C1 C13 123.5(3) C18 C13 C1 123.0(3) 
N2 C2 C1 121.9(3) C18 C13 C14 118.9(3) 
N2 C2 C19 116.8(3) C15 C14 C13 121.1(3) 
C1 C2 C19 121.1(3) C16 C15 C14 118.7(3) 
N2 C3 C4 120.2(3) C15 C16 Br1 118.8(3) 
N2 C3 C12 120.4(3) C15 C16 C17 121.5(3) 
C4 C3 C12 119.5(3) C17 C16 Br1 119.6(3) 
C3 C4 C5 120.5(3) C16 C17 C18 119.2(3) 
C4 C5 C6 122.4(3) C17 C18 C13 120.6(3) 
C4 C5 C10 119.6(3) C20 C19 C2 119.0(3) 
C6 C5 C10 118.0(3) C24 C19 C2 121.7(3) 
C7 C6 C5 120.8(3) C24 C19 C20 119.3(3) 
C6 C7 C8 120.9(3) C21 C20 C19 120.6(3) 
C9 C8 C7 120.1(3) C22 C21 C20 119.1(3) 
C8 C9 C10 121.0(3) C21 C22 Br2 118.5(3) 
C9 C10 C5 119.2(3) C21 C22 C23 121.7(3) 
C11 C10 C5 119.3(3) C23 C22 Br2 119.8(3) 
C11 C10 C9 121.5(3) C22 C23 C24 119.0(3) 
C12 C11 C10 120.5(3) C19 C24 C23 120.4(3) 
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4.3.2. Synthesis of Complexes 
These compounds were then used as cyclometallating ligands with iridium(III). Firstly, the 
dimeric species [{Ir(L)2(µ-Cl)}2] was again prepared following the method first proposed by 
Nonoyama.21 This dimeric species was then dissolved in 2-ethoxyethanol along with the 
appropriate cyclometallating ligand and heated at reflux for 24 hours. Upon cooling, a saturated 
aqueous solution of ammonium hexafluorophosphate was added to the reaction mixture 
causing the complex to crash out of solution as a hexafluorophosphate salt. Each complex was 
collected as a red solid and where further purification was required, this was carried out by 
column chromatography using a DCM/methanol mixture as an eluent. The general synthetic 
scheme is shown below.  
 
Scheme 4.2: Synthesis of bis-cyclometallated iridium(III) complexes. 
Following this synthesis route, four complexes cationic bis-cyclometallated iridium(III) 
complexes were isolated as red solids. The structures and yields are shown in Figure 4.8. 
 
Figure 4.8: Structures and yields of complexes synthesised in this study. 
Of the complexes synthesised, C2, C3 and C4 are novel with complex C1 first being reported in 
2006,22 and once more shortly after the completion of this work.18 The complexes were 
characterised by proton NMR, carbon NMR spectroscopy and high-resolution mass 
spectrometry.  Mass spectrometry was able to confirm the presence of the molecular ion peak 
and the correct isotope pattern in each case; an example spectrum is shown in Figure 4.9 while 
Figure 4.10 shows a comparison with theoretical data. The complexity of the peak cluster arises 
from the four bromine atoms, with bromine having two isotopes, 79Br and 81Br, in a 1:1 ratio 
abundance. 
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Figure 4.9: High-resolution mass spectrum recorded for complex C3. 
 
Figure 4.10: Observed mass spectrometry data for complex C3 compared with theoretical data for the 
same complex. 
As discussed in chapters 2 and 3, proton NMR spectroscopy can be useful in determining the 
coordination of the ligand to the metal centre. The signal circled in red in Figure 4.11 relates to 
the proton adjacent to the cyclometallating site of the ligand. This signal experiences a large 
upfield shift due to experiencing the effects of the ring currents of the adjacent aromatic rings. 
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Figure 4.11: Proton NMR spectrum recorded for complex C1 showing the signal arising from proton 
adjacent to cyclometallating site. Recorded in CDCl3, 400 MHz. 
4.3.3. UV-Vis and Luminescence Spectroscopy 
The ligands and complexes in this study were characterised by UV-vis absorption spectroscopy 
as well as luminescence spectroscopy and the results are discussed below. 
Figure 4.12 shows the absorption spectra recorded for ligands HL1-4. All spectra were recorded 
as chloroform solutions at a concentration of 1x10-5 M and compare well with similar ligand 
systems in literature.13,22–24 Each ligand shows strong π-π* transitions at 200 - 400 nm in the UV 
region. There is also a shoulder feature which extends beyond 450 nm and this is attributed to 
weak π-π* transitions as well as some n-π* transitions. It is also clear that the phenyl substituent 
effects the positions of these bands with the ligand L4 exhibiting the longest wavelength 
absorption, possibly due to the strong electron-donating character of the OMe groups. 
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Figure 4.12: UV-Vis absorption spectra recorded for ligands HL1-4. Recorded in CHCl3 at  
1x10-5 M. 
The emission spectra were also recorded for each ligand in the series. Luminescence in the 
visible region of the spectrum was observed for each species at between 400-550 nm, with some 
vibronic structure visible in the peak shape. The position of the emission peak varies depending 
upon the substituent, as observed in the absorption spectra. The ligand HL3 has the longest 
emission wavelength, while the ligand HL4 has the shortest. The lifetimes recorded for these 
species were all recorded at < 5 ns, which is in accordance with that expected from a π-π*  
fluorescent emitting state. The emission spectra are shown in Figure 4.13.  
 
Figure 4.13: Emission spectra recorded for ligands HL1-4. Recorded as chloroform solutions, ex = 400 
nm. 
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The UV-vis absorption spectra of the complexes are shown in Figure 4.14 and show absorption 
signals in both the UV and visible regions. The peaks seen at 250-450 nm are ligand centred 
transitions that, upon coordination to the Ir(III) centre, become perturbed. It is also likely that 
there is some contribution from spin-allowed 1MLCT transitions.  
When compared to the absorption spectra of the ligand, additional absorption bands are 
observed at over 500 nm, this can be seen more clearly in Figure 4.15 where the absorption 
spectrum of ligand HL1 has been overlaid with the absorption spectrum of complex C1. The weak 
absorption bands at long wavelengths are likely to possess some spin-forbidden 3MLCT 
character.25 As a result, a strong bathochromic shift is observed in the complexes in this study 
relative to the substituted complexes with quinoxaline ligands investigated in chapter 2.24 The 
reason for this is that the extended conjugation of the benzo[g]quinoxaline ligands lowers the 
energy of the MLCT transitions by stabilising the HOMO. The same small variations in absorption 
seen in the ligands, is also seen in the complexes; with complex C4 possessing the longest 
wavelength absorption just as ligand HL4 showed the lowest energy absorption of any ligand.  
 
Figure 4.14: UV-vis absorption spectra recorded for complexes C1-4. Recorded as solutions in chloroform 
at 1x10-5 M. 
Complex C1 has previously been reported in study from 2006 by Chen et al. and again, in 2017 
by Wang et al.22,18 Table 4.3 shows a comparison of the absorption data from each literature 
report in comparison with the data reported herein.  
Table 4.3: Comparison of literature UV-vis absorption spectra with data recorded in this study for 
complex C1. 
Complex λabs/ nm (ε/ M-1cm-1) 
C1 (CHCl3) 
286 (33200), 329 (24200), 415 (10700), 490 
(3900), 554 (2100) 
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Complex 1 (CH2Cl2) , Wang et  al., 201718 
327 (66000), 412 (29000), 486 (11000), 550 
(6000), 673 (120), 742 (40) 
Complex 3 (CH2Cl2) , Chen et al., 200622 412 (26000), 484 (9000), 540 (5000) 
 
Each study is in agreement with absorption features at around 412, 490 and 550 nm, however 
the molar extinction coefficients reported in literature are around triple those found in this 
study. In addition to this, there is no report in the literature of features below 300 nm, 
contradictory to the absorption observed at 289 nm. Furthermore, in addition to all the peaks 
observed in this report, Wang et al. also observed very weak, broad absorptions at 673 and 742 
nm which are not observed in the spectra reported here; in fact, no absorption above 600 nm is 
observed for any complex in this study. 
 
Figure 4.15: Overlaid absorption spectra of complex C1 (black) and ligand HL1 (red) showing additional 
bands observed in complex. 
Luminescence spectra were recorded for each complex at room temperature in aerated 
chloroform solutions using an excitation wavelength of 470 nm. This wavelength was chosen as 
it corresponds to a strong absorption band in all of the complexes in this study. Emission spectra 
were first recorded in the 250 – 750 nm region and then repeated in the 850 – 1300 nm region.   
The emission spectra shown in Figure 4.16 were the recorded for the visible region of the 
spectrum and show emission between 490 – 750 nm with vibronic structure in the peak shape 
of each complex. The spectra show almost no variation in the position of the emission peak with 
the four spectra being virtually superimposable. These observations do not correlate with the 
luminescent properties of the cationic iridium(III) phenyl quinoxaline complexes discussed in 
chapter 2, which showed phosphorescent emission between 620 – 650 nm from a 3MLCT state. 
24  It is also worth noting that the shape and position of these peaks differ from those of the free 
ligand, ruling out the possibility of decomposition in solution. The lifetime measurements for 
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these peaks were also measured and recorded at less than 10 ns, which suggests that these 
features may be due to intraligand transitions in the complexes.  
As mentioned previously, complex C1 has twice been reported in literature yet neither study 
reports emission below 790 nm for this complex. In addition to this, a paper published by Chen 
et al. in 2019 reports cationic bis-cyclometallated complexes with ligands L2 and L4 with a series 
of different ancillary ligands.17 This paper also reports no emission in the visible region of the 
spectrum. It appears likely that these reports did not scan the visible region of the spectrum for 
emission. 
 
Figure 4.16: Visible emission spectra for complexes C1-4. Recorded in aerated CHCl3, λex = 470 nm. 
The steady state experiments were then repeated to observe the near-IR region of the spectrum. 
These spectra were  also recorded in aerated chloroform at room temperature using an 
excitation wavelength of 505 nm and collected at between 850 – 1300 nm. The emission spectra 
recorded are shown in Figure 4.17 and a compilation of the data recorded in both the visible and 
near-IR regions is recorded in Table 4.4. 
Each of the complexes was excited using 505 nm light and, as Figure 4.17 shows, emission in the 
near-IR region was observed. Each complex exhibits a very broad emission profile which peaks 
between 915 – 950 nm and tails to around 1250 nm. The peak observed at around 1274 nm in 
each spectra is attributed to the spin relaxation of singlet oxygen (1O2  3O2). The presence of 
this feature not only confirms that the solvent used was aerated, but also suggests that there is 
an excited triplet state on a sensitiser molecule. This is further supported by lifetime 
measurements recorded for the complexes which all show values in the range of 116 – 162 ns 
which are concordant with triplet emission.  
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Figure 4.17: Steady state near-IR emission spectra pf the complexes. The peak at 1274 nm is due to the 
photogeneration of, and subsequent emission from, 1O2. (Aerated CHCl3, λex = 505 nm) 
These observations reported here are in good agreement with previous reports on related 
complexes with similar benzo[g]quinoxaline ligands.17,18,22  Table 4.5 shows a comparison of the 
data recorded for complex C1 in this study with that reported for the same complex previously. 
Table 4.4: Photophysical data recorded for ligands HL1-4 and complexes C1-4. [a] Recorded in aerated 
CHCl3; [b] λex = 405 nm; [c] λex = 295 nm; [d] λex = 505 nm; [e] λex = 355 nm 
 
Table 4.5: Comparison of data recorded for complex C1 with data previously recorded for the same 
complex. * Lifetime stated is intrinsic lifetime, τ0. 
900 1000 1100 1200 1300
 C1
 C2
 C3
 C4
Wavelength/ nm
Compound λabs / nm [a] λem / nm[a,b] (τ / ns[c]) λem / nm[a,d] (τ / ns[e]) 
HL1 386, 309, 276 485 (1.4) - 
HL2 391, 323, 312, 276 480 (1.1) - 
HL3 393, 318, 280 490 (1.8) - 
HL4 402, 332, 319, 276 480 (1.1) - 
C1 554, 490, 415, 329, 286 520 (4.9) 915 (119) 
C2 
554, 491, 445, 420, 388, 367, 
334, 283 
520 (7.0) 912 (148) 
C3 554, 500, 439, 415, 340, 287 520 (2.9) 928 (116) 
C4 554, 455, 348, 285 520 (<1) 949 (162) 
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Complex λem / nm (τ/ ns) 
C1 (CHCl3) 520 (4.9), 915 (119) 
Complex 1 (CH2Cl2) , Wang et al., 201718 794, 911, 965 (440)* 
Complex 3 (CH2Cl2), Chen et al., 200622 922 (245) 
 
4.3.4. Density Functional Theory Calculations 
The calculations discussed in this section were carried out by Thomas Stonelake and Dr Joseph 
Beames (Cardiff University) and can be found in more detail in the publication at the end of this 
thesis.26 The geometries of the complexes were optimised, and calculations included solvent 
effects. Also, the first five singlet excited states for each complex were determined using TD-DFT 
calculations on the stationary points and in addition to this, the phosphorescence and spin 
forbidden absorption bands were calculated. 
 
Figure 4.18: A comparison of the calculated geometries of the singlet and triplet excited states for 
complex C3 (left, RMSD = 0.185 Ǻ) and C4 (right, RMSD = 0.149 Ǻ). 
Figure 4.18 shows the superimposed calculated structures of the complexes C3 and C4 in both 
the singlet and triplet excited states where it can be seen that there are slightly different degrees 
of distortion in the cyclometallated ligand in each excited state. Table 4.6 shows the composition 
of the HOMO and LUMO in each complex. 
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Table 4.6: Calculated HOMO and LUMO contributions for each complex. 
 HOMO 
Compound Ir (5d) C^N (1) C^N (2) Bpy 
C1 26 % 36 % 36 % 1 % 
C2 26 % 37 % 36 % 1 % 
C3 13 % 44 % 42 % 0 % 
C4 16 % 40 % 43 % 1 % 
 LUMO 
C1 3 % 48 % 47 % 1 % 
C2 3 % 47 % 48 % 2 % 
C3 3 % 49 % 46 % 3 % 
C4 3 % 47 % 49 % 2 % 
 
From the above table, it is seen that the cyclometallated ligands are predicted to have the largest 
contribution to the HOMO, with the contribution of the iridium centre varying between 13 – 26 
%. This suggests that the emission is not purely 3MLCT in character but consists of both MLCT 
and intraligand transitions. It is also worth noting that the 2,2’-bipyridine ligand has very little 
contribution to these molecular orbitals. 
The vertical transitions for the complexes were calculated and are collated in Table 4.7. It was 
suggested that benzo[g]quinoxaline ligand centred transitions are responsible for the visible 
complex emission which is consistent with the similarity observed between the vibronic band 
shapes in the free ligand emission and in the complex emission. 
Table 4.7: Calculated vertical transitions for complexes C1-4 
Compound S1  S0 / nm T1  S0 / nm T1  S0 / nm 
C1 433 557 993 
C2 434 602 980 
C3 428 590 1019 
C4 428 583 962 
 
The electronic emission spectrum for the free ligand, HL1, was simulated as part of this study 
and Figure 4.19 shows this in comparison to the experimental emission spectra recorded for L1 
and its corresponding complex C1. 
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Figure 4.19: Franck - Condon simulation of the L1 A-X transition (blue), overlaid against the experimental 
emission spectra of the free ligand L1 (red) and the complex C1 (black). The spectra are offset by their 
respective vibronic origin, and are displayed as emission energy (cm-1) relative to zero. The grey bars 
show different vibronic features. 
The spectra show excellent agreement between simulation and experiment. In addition to 
confirming the assignment of the vibronic features, this figure shows the large similarity 
between the free ligand L1 and the same ligand in the complex. 
Table 4.7 shows the calculated wavelengths for selected transitions. The data corelates very well 
with the experimental observations, but most importantly, the calculations predict near-IR 
emission from the complexes at between 962 – 1019 nm. The absorption spectra recorded also 
align well with the calculated spin-allowed and spin-forbidden transitions. Interestingly, the DFT 
calculations also predicted that differences in ligand structure should lead to significant 
differences in the emission energy, but only a small variation of 37 nm was observed over the 
series. 
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4.4. Conclusion 
In this study, it has been shown that extending the conjugation of the cyclometallating ligand in 
a bis-cyclometallated iridium(III) complex system can result in large bathochromic shifts in 
emission wavelength, leading to near-IR emission. Ligands based upon benzo[g]quinoxaline 
have been shown to be excellent choice for Ir(III) complexes and DFT calculations have been 
able to reliably predict the transitions that dominate the lowest energy absorptions and 
phosphorescent emission properties of these complexes. 
In addition to this, this study has also shown that these complexes simultaneously show 
emission in the visible region of the spectrum, centred at around 520 nm. This is in contrast with 
a number of recent publications which feature an identical complex along with several closely 
related complexes. These reports omit the visible feature in each case, instead focusing upon 
the near-infrared. 
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4.5. Experimental 
All reactions were performed with the use of vacuum line and Schlenk techniques. Reagents 
were commercial grade and were used without further purification. 1H and 13C{1H} NMR spectra 
were run on NMR-FT Bruker 300 or 400 spectrometers and recorded in CDCl3. 1H and 13C{1H} 
NMR chemical shifts () were determined relative to internal TMS and are given in ppm. Low-
resolution mass spectra were obtained by the staff at Cardiff University. High-resolution mass 
spectra were carried out by at the EPSRC National Mass Spectrometry Service at Swansea 
University. UV-Vis studies were performed on a Shimadzu UV-1800 as chloroform solutions (10-
5 M). Photophysical data were obtained on a JobinYvon-Horiba Fluorolog spectrometer fitted 
with a JY TBX picosecond photodetection module as MeCN solutions. A Hamamatsu R5509-73 
detector (cooled to -80 ˚ C using a C9940 housing) was usedfor NIR luminescence measurements. 
For the NIR lifetimes the pulsed laser source was a Continuum Minilite Nd:YAG configured for 
355 nm output. For all NIR emission data, a 850 nm band pass filter was used. Emission spectra 
were uncorrected and excitation spectra were instrument corrected. The pulsed source was a 
Nano-LED configured for 372 nm output operating at 1 MHz. Luminescence lifetime profiles 
were obtained using the JobinYvon-Horiba FluoroHub single photon counting module and the 
data fits yielded the lifetime values using the provided DAS6 deconvolution software.  
Synthesis of HL1 To a stirred solution of benzil (322 mg, 1.6 mmol) in ethanol (15 mL) was added 
2,3-diaminonaphthalene (250 mg, 1.6 mmol) and acetic acid (0.5 mL). The reaction mixture was 
heated at reflux under a nitrogen atmosphere for 24 hours. The reaction mixture was cooled to 
room temperature and a precipitate collected by filtration to give L1 as a brown solid (Yield = 
0.34 g, 64%). 1H NMR (300 MHz, CDCl3): δH 8.68 (s, 2H, CH), 8.05 (dd, JHH  = 3.21, 6.39 Hz, 2H), 
7.50 (m, 6H), 7.30 (m, 6H) ppm. 13C{1H} NMR (101 MHz, CDCl3): δC 154.2, 139.2, 138.0, 134.1, 
129.8, 129.0, 128.6, 128.3, 127.6, 126.8 ppm. HRMS (ESI) found m/z 333.1387; calcd m/z 
333.1386 for C24H16N2+H . UV-vis. (CHCl3) λmax (ε / dm3 mol-1 cm-1): 386 (25200), 309 (71500), 276 
(114100) nm. Selected IR (solid) υmax = 1607, 1508, 1441, 1346, 1248, 1175, 1013, 976, 876, 836, 
760, 741, 691, 552, 500.0, 490, 467 cm-1. 
Synthesis of HL2 As HL1 but with 4,4’-dimethylbenzil (376 mg, 1.6 mmol) and 2,3-
diaminonaphthalene (250 mg, 1.6 mmol). Product collected as a brown solid (Yield = 0.41 g, 
71%). 1H NMR (300 MHz, CDCl3) δH 8.73 (s, 2H), 8.12 (dd, JHH = 3.2, 6.5 Hz, 2H), 7.57 (dd, JHH = 
3.1, 6.7 Hz, 2H), 7.49 (d, JHH  = 8.0 Hz, 4H), 7.19 (d, JHH = 8.0 Hz, 4H), 2.41 (s, 6H) ppm. 13C{1H} 
NMR (101 MHz, CDCl3) δC 154.3, 139.0, 138.0, 136.5, 134.0, 129.8, 129.0, 128.6, 127.4, 126.6, 
21.4 ppm. HRMS (ESI) m/z found 361.1699; calcd m/z 361.1699 for C26H20N2+H . UV-vis. (CHCl3) 
λmax (ε / dm3 mol-1 cm-1): 391 (24800), 323 (48600), 312 (54200), 276 (134500) nm. Selected IR 
(solid) υmax = 1607, 1508, 1445, 1346, 1247, 1174, 1109, 1013, 972, 878, 835, 819, 760, 559, 500, 
490, 471, 421 cm-1. 
Synthesis of HL3 As HL1 but with 4,4’-dibromobenzil (581 mg, 1.6 mmol) and 2,3-
diaminonaphthalene (250 mg, 1.6 mmol). Product collected as a light brown solid (Yield = 0.56 
g, 72%). 1H NMR (400 MHz, CDCl3) δH 8.66 (s, 2H), 8.05 (dd, JHH = 3.2, 6.5 Hz, 2H), 7.52 (m, 2H), 
7.46 (d, JHH = 8.4 Hz, 4H), 7.38 (d, JHH = 8.4 Hz, 4H) ppm. 13C{1H} NMR (101 MHz, CDCl3) C 152.6, 
137.9, 137.8, 134.3, 131.7, 131.4, 128.6, 127.7, 127.0, 123.9 ppm. HRMS (ESI) found m/z 
490.9569; calcd m/z 490.9576 for C24H15Br2N2+H. UV-vis. (CHCl3) λmax (ε / dm3mol-1cm-1): 393 
(11400), 318 (34300), 280 (46400) nm.  Selected IR (solid) υmax = 1605, 1510, 1445, 1344, 1246, 
1173, 1109, 1053, 1011, 972, 880, 833, 795, 758, 745, 723, 656, 646, 623, 573, 557, 548, 532, 
498, 471, 409 cm-1. 
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Synthesis of HL4 As HL1 but with anisil (427 mg, 1.6 mmol) and 2,3-diaminonaphthalene (250 
mg, 1.6 mmol). Product collected as a light brown solid (Yield = 0.50 g, 80%). 1H NMR (300 MHz, 
CDCl3) δH  8.61 (s, 2H, CH), 8.02 (dd, JHH = 3.0, 6.4 Hz, 2H), 7.48 (m, 6H), 6.83 (d, JHH = 8.4, 4H), 
3.78 (s, 6H) ppm. 13C{1H} (101 MHz, CDCl3) C 160.4, 153.8, 138.0, 133.9, 131.8, 131.3, 128.5, 
127.2, 126.5, 113.8, 55.4 ppm. HRMS (ESI) found m/z 393.1593; calcd m/z 393.1598 for 
C26H21N2O2+H. UV-vis. (CHCl3) λmax (ε / dm3mol-1cm-1):  402 (16900), 332 (24200), 319 (25600), 
276 (110300) nm. Selected IR (solid) υmax = 1605, 1578, 1541, 1508, 1445, 1414, 1344, 1275, 
1246, 1173, 1109, 1051, 1015, 976, 891, 880, 853, 833, 795, 756, 747, 656, 646, 623, 592, 573, 
557, 532, 525, 496, 474, 421 cm-1. 
Synthesis of [Ir(C^N)2Cl2]2 IrCl3.xH2O (1 eq.) and ligand, L (2 eq.) were dissolved in 2-
ethoxyethanol (10 mL) and the reaction mixture heated at reflux for 48 hours. The reaction was 
then cooled to room temperature and water (30 mL) was added to form a dark brown 
precipitate. The solid was collected by filtration to yield [(L)2Ir(µ-Cl2)Ir(L)2]. 
Synthesis of C1 [{Ir(L1)2(µ-Cl)}2] (195 mg, 0.11 mmol) and 2,2’-bipyridyl (36 mg, 0.23 mmol) were 
dissolved in 2-ethoxyethanol (10 mL) and heated at reflux for 24 hours under a nitrogen 
atmosphere. The reaction mixture was then cooled to room temperature and a saturated 
solution of aqueous ammonium hexafluorophosphate was added. Upon formation of a red 
precipitate, the mixture was filtered, and the precipitate washed with water and diethyl ether. 
The crude solid was purified by column chromatography using DCM followed by DCM/MeOH 
(9:1). Product collected as first red band with DCM/MeOH and dried in vacuo to give 
[Ir(L1)2(bipy)][PF6] as a red solid (Yield = 38 mg, 15%). 1H NMR (400 MHz, CDCl3): H 8.65 (d, JHH 
= 5.6 Hz, 2H), 8.55 (s, 2H), 8.31 (d, JHH = 8.8 Hz, 2H), 8.12 (app. t, JHH = 8.8 Hz, 2H), 7.91 (d, JHH = 
8.4 Hz, 2H), 7.89-7.77 (m, 6H), 7.75 (s, 2H), 7.64-7.60 (m, 6H), 7.44 (app. t, JHH = 8.8 Hz, 2H), 7.36 
(app. t, JHH = 6.4 Hz, 2H), 7.17 (s, 2H), 6.98 (d, JHH = 8.8 Hz, 2H), 6.70 (app. t, JHH = 5.6 Hz, 2H), 6.61 
(app. t, JHH = 7.2 Hz, 2H), 6.50 (d, JHH = 7.2 Hz, 2H) ppm. 13C{1H} NMR (101 MHz, CDCl3): C 164.5, 
155.8, 154.3, 153.8, 147.9, 144.3, 139.6, 134.6, 133.7, 132.5, 131.5, 130.4, 129.4, 129.4, 128.9, 
128.8, 128.2, 128.0, 127.6, 125.4, 122.0, 119.5, 114.4, 77.4, 76.7 ppm. HRMS (ESI) found m/z 
1011.2777; calcd m/z 1011.2786 for C58H38IrN8. UV-vis. (CHCl3) λmax (ε / dm3 mol-1 cm-1): 554 
(2100), 490 (3900), 415 (10700), 329 (24200), 286 (33200) nm. Selected IR (solid) υmax = 1607, 
1445, 1350, 1253, 835, 760, 738, 696, 574, 557, 500, 468 cm-1. 
Synthesis of C2 As C1 but with [{Ir(L2)2(µ-Cl)}2] (56 mg, 0.03 mmol) and 2,2’-bipyridyl (10 mg, 
0.07 mmol). Product collected as a red solid (Yield = 44 mg, 62%) 1H NMR (400 MHz, CDCl3): H 
8.67 (d, JHH = 6.60 Hz, 2H), 8.59 (s, 2H), 8.53 (d, JHH = 8.8 Hz, 2H), 8.21 (dd, JHH = 7.72, 8.80 Hz, 
2H), 7.98 (d, JHH = 8.80 Hz, 2H), 7.78 (m, 8H), 7.50 (m, 6H), 7.42 (app. t, JHH = 7.70, 2H), 7.24 (d, 
JHH = 7.72 Hz, 2H), 7.03 (d, JHH = 7.72 Hz, 2H), 6.65 (d, JHH = 8.84 Hz, 2H), 6.43 (s, 2H), 2.57 (s, 6H), 
1.94 (s, 6H) ppm. 13C{1H} NMR (101 MHz, CDCl3): C 164.8, 156.0, 148.0, 142.5, 141.7, 141.1, 
140.5, 136.9, 136.3, 135.1, 134.0, 133.4, 132.3, 130.0, 129.1, 128.8, 128.5, 128.1, 128.0, 127.7, 
127.5, 125.8, 123.8, 122.0, 21.8, 21.7 ppm. HRMS (ESI) found m/z 1067.3406; calcd m/z 
1067.3413 for C62H46IrN6. UV-vis. (CHCl3) λmax (ε / dm3 mol-1 cm-1): 554 (2500), 491 (4900), 445 
(9700), 420 (11000), 388 (14900), 367 (16900), 334 (28300), 283 (69500) nm. Selected IR (solid) 
υmax = 1586, 1503, 1445, 1398, 1359, 1314, 1257, 1211, 1177, 1138, 1069, 1042, 978, 833, 772, 
635, 579, 556, 513, 471, 424, 407 cm-1. 
Synthesis of C3 As C1 but with [{Ir(L3)2(µ-Cl)}2] (150 mg, 0.06 mmol) and 2,2’-bipyridyl (20 mg, 
0.13 mmol). Product collected as a red solid (Yield = 75 mg, 61%). 1H NMR (400 MHz, CDCl3): H 
8.82 (d, JHH = 8.80 Hz, 2H), 8.56 (s, 2H), 8.52 (d, JHH = 6.40 Hz, 2H), 8.21 (app. t, JHH = 8.40 Hz, 2H), 
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7.94 (d, JHH = 7.20 Hz, 3H), 7.77 – 7.68 (m, 5H), 7.62 (s, 2H), 7.49 (app. t, JHH = 8.40 Hz, 3H), 7.39 
(app. t, JHH = 6.00 Hz, 3H), 7.11 (d, JHH = 7.20 Hz, 3H), 6.97 (m, 5H), 6.62 (s, 2H) ppm. 13C{1H} NMR 
(101 MHz, d6-acetone): C 164.5, 155.8, 153.4, 149.6, 144.1, 141.0, 138.8, 137.5, 137.4, 136.8, 
134.1, 133.7, 133.6, 132.3, 131.5, 129.3, 129.1, 128.5, 128.3, 127.9, 127.5, 126.5, 126.0, 124.8, 
124.2, 122.4, 78.3 ppm. HRMS (ESI) found m/z 1326.9109; calcd m/z 1326.9162 for C58H34Br4IrN6. 
UV-vis. (CHCl3) λmax (ε / dm3 mol-1 cm-1): 554 (2400),  500 (5100), 439 (10700), 415 (11500), 340 
(26000), 287 (34800) nm. Selected IR (solid) υmax = 1607, 1512, 1445, 1348, 1248, 1174, 1109, 
1013, 878, 835, 760, 559, 500 cm-1. 
Synthesis of C4 As C1 but with [{Ir(L4)2(µ-Cl)}2] (100 mg, 0.09 mmol) and 2,2’-bipyridyl (16 mg, 
0.11 mmol). Product collected as a red solid (Yield = 27 mg, 21%). 1H NMR (400 MHz, CDCl3) H 
8.63 (d, JHH = 4.64 Hz, 2H), 8.45 (s, 2H), 8.43 (d, JHH = 8.00 Hz, 2H), 8.14 (app. t, JHH = 9.28 Hz, 2H), 
7.87 (d, JHH = 8.12 Hz, 2H), 7.76 (m, 6H), 7.62 (s, 2H), 7.40 (dd, JHH = 6.96, 8.12 Hz, 2H), 7.32 (dd, 
JHH = 5.80, 9.28 Hz, 2H), 7.27 (s, 2H), 7.24 (s, 4H), 7.11 (d, JHH = 8.52 Hz, 2H), 6.94 (d, JHH = 8.16 
Hz, 2H), 5.99 (s, 2H), 3.91 (s, 6H), 3.26 (s, 6H) ppm. 13C{1H} NMR (101 MHz, CDCl3) C 164.2, 161.4, 
156.0, 148.2, 141.1, 137.2, 136.7, 136.2, 134.4, 134.0, 133.1 132.1, 130.5, 128.9, 128.4, 128.1, 
127.5, 125.6, 121.6, 119.8, 114.7, 108.3, 55.6, 54.8 ppm. HRMS (ESI) found m/z 1131.3193; calcd 
m/z 1131.3209 for C62H46IrN6O4. UV-vis. (CHCl3) λmax (ε / dm3 mol-1 cm-1): 554 (10000), 455 
(31700), 348 (55200), 285 (120700) nm. Selected IR (solid) υmax = 1580, 1503, 1447, 1400, 1358, 
1246, 1224, 1173, 1134, 1020, 978, 870, 837, 810, 772, 687, 519, 471 cm-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Crystal data collection parameters 
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Formula C24H14Br2N2 Z' 1 
Dcalc./ g cm-3 1.699 Wavelength/Å 0.71075 
µ/mm-1 4.243 Radiation type MoKα 
Formula Weight 490.19 Θmin/° 2.687 
Colour orange Θmax/° 27.483 
Shape blade Measured Refl. 19907 
Size/mm3 0.360×0.140×0.040 Independent Refl. 
4396 
T/K 100(2) Reflections Used 3812 
Crystal System monoclinic Rint 
0.0501 
Space Group P21/n Parameters 253 
a/Å 5.7963(2) Restraints 0 
b/Å 21.8021(9) Largest Peak 1.511 
c/Å 15.1661(6) Deepest Hole -0.916 
α/° 90 GooF 1.057 
β/° 91.211(3) wR2 (all data) 0.1219 
γ/° 90 wR2 0.1166 
V/Å3 1916.15(13) R1 (all data) 0.0567 
Z 4 R1 0.0491 
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5. Exploratory Synthesis: Toward the synthesis of dicyanodibenzodioxin 
ligands and their rhenium(I) coordination chemistry 
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5.1. Introduction 
The previous three chapters have focussed upon the synthesis and characterisation of 
cyclometallated  iridium(III) complexes [Ir(C^N)2(N^L)]n. As discussed, the nature of the 
cyclometallated ligand can strongly influence the resultant electronics and thus luminescence  
properties of the complex in question. The following chapter takes a slightly different approach 
and considers the design and synthesis of a series of ligands based upon a rigid, conjugated 
dicyanodibenzodioxin core structure. These compounds are designed to act as chelating ligands 
in a wide range of metal complex systems including iridium(III) (see further discussion in Chapter 
6), but within Chapter 5 the focus will be upon exploring their coordination chemistry with 
rhenium(I).  
5.1.1. Dicyanodibenzodioxin Derivatives 
Large, planar heterocyclic aromatic compounds have applications as biological luminescent 
sensors as well as in materials science.1,2 This is because their large pi-systems lead to 
delocalisation of electron density and can give rise to multi-band optical spectra.3  
Dibenzodioxins are a branch of organic compounds that are known to have cytotoxic effects 
against certain tumour cell lines. It is understood that the dioxin core, which acts as a hydrogen-
bond acceptor, and the planar geometry of these compounds are responsible for their strong 
DNA intercalation behaviour.4–6 
 
Figure 5.1: Left) Dibenzodioxin structure. Right) Cytotoxic derivative of dibenzodioxin.5 
Dicycanobenzodioxins are similar in structure to dibenzodioxins, but as their name suggests, 
they possess two nitrile groups. These nitrile groups are electron withdrawing and can extend 
the pi-system which can alter the photophysical properties of the molecule, although these 
effects have not thoroughly been investigated.7,8 In addition to this, dicyanodibenzodioxins 
could potentially have advantageous biological applications as they have exhibited cytotoxicity 
against the HeLa cell line and glioma cell line C6.9 
 
Figure 5.2: Examples of dicyanodibenzodioxin based compounds.3 
The synthesis of these complexes is shown in Scheme 5.1. The reaction proceeds via a 
nucleophilic aromatic substitution reaction and means that many different analogues may be 
synthesised from di-hydroxy aromatic starting materials. 
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Scheme 5.1: Synthesis of dicyanodibenzodioxins.1 
There are numerous reports in the literature of the use of this aromatic motif in the synthesis of 
polymeric chains using the compound tetrafluoroterephthalonitrile, also known as 2,3,5,6-
tetrafluoro-1,4-dicyanobenzene, as a starting material.10,11 These reports typically use potassium 
carbonate as the base instead of sodium hydride which suggests that formation of a second 
dioxin bridge is relatively facile due to the preorganised nature of the reacting functional groups. 
Scheme 5.2 shows a proposed route to how the use of tetrafluoroterephthalonitrile could form 
a compound with a second dioxin bridge. 
 
Scheme 5.2: Proposed route to formation of second dioxin bridge. Where A is an aromatic diol and B is 
tetrafluoroterephthalonitrile. 
At present, there are no reports of the dicyanodibenzodioxin structure having been 
incorporated into a ligand system for transition metal chemistry. Thus, the aim of this work was 
to consider the introduction of a metal chelating site into this aromatic structure. As discussed 
later, one way to achieve this is by the use of 1,10-phenanthroline-5,6-diol as a dihydroxy 
starting material in the synthesis of the dicyanodibenzodioxins. Interestingly, the resulting target 
compound would have a similar structure to the known chelating ligand dipyridophenazine, 
dppz, and the use of a second 1,10-phenanthroline moiety would hypothetically result in a 
bridging ligand similar tetraazatetrapyridopentacene, tatpp. The structures of these known 
ligands along with the proposed dicyanodibenzodioxin based ligands are shown in Figure 5.3. 
 
Figure 5.3: Structures of chelating ligands dppz and tatpp alongside the hypothetical structures of 
dicyanodibenzodioxin ligands. 
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The ligands dppz and tatpp have been very well reported in the literature, particularly in the 
context of ruthenium(II) coordination chemistry. Examples of ruthenium(II) complexes with 
these ligands are shown in Figure 5.4. As shown in the figure, the ligand tatpp can be used to 
bridge two ruthenium(II) complexes, something which may also be possible with the 
dicyanodibenzodioxin analogue. The complexes shown were reported in 2017 as part of a series 
of ruthenium(II) polypyridyl complexes investigated for their biological activity.12 Polypyridyl 
dppz complexes of ruthenium(II) are of particular interest as these species have previously been 
shown to exhibit selective cytotoxicity toward cancer cell lines and have shown antitumor 
activity in vivo.13 Importantly, these complexes can also act as luminescent probes for DNA as 
they show enhanced luminescence when intercalated into the DNA double-helix or when in 
organic solvents, but do not luminesce in water in the absence of DNA.14,15 
 
Figure 5.4: Examples of ruthenium(II) complexes with dppz and tatpp ligands.12 
The ligand dppz has also been reported as a ligand in a tricarbonyl rhenium(I) complex. In 2008, 
the complex fac-[Re(CO)3(dppz)Cl] was synthesised as part of a series of rhenium(I) tricarbonyl 
complexes with functionalised dppz ligands.16 There are currently no reports of tatpp used as a 
ligand in mononuclear or dinuclear rhenium(I) tricarbonyl complexes in the primary literature, 
however their structures are also shown in Figure 5.5 for illustration. 
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Figure 5.5: Rhenium(I) tricarbonyl complexes bearing dppz and hypothetical  tatpp based structures. 
 
 
5.1.2. Rhenium(I) 
Like iridium(III) and ruthenium(II), rhenium(I) has a d6 electron configuration.17 Literature has 
shown that complexes of the form fac-[Re(N^N)(CO)3(L)]n+ (where N^N = a diimine ligand, L = 
monodentate ligand and n = 0 or 1) can exhibit phosphorescence at room temperature.18–20 
Emission from these complexes is typically assigned as arising from a 3MLCT state.21 The energy 
gap between the d orbitals of the rhenium centre and the π* orbitals from the ligands is 
relatively small due to the large amount of back-bonding from the carbonyl ligands.17 As a result 
of this, emission from this state is generally low in energy with emission usually occurring in the 
yellow-orange-red range of the visible spectrum. The lifetimes observed have been found to be 
in the range of 102 – 10-1 µs range, which is consistent with a triplet emitting state.17 
Some of the simplest complexes of the formula fac-[Re(N^N)(CO)3(L)]n+ are shown below in 
Figure 5.6 along with some of their photophysical properties. The diimine used in the complex 
on the left is 2,2’-bipyridine, bpy, and when used as a ligand in a tricarbonylrhenium(I) complex 
results in an emission wavelength of 642 nm in DCM.22 The complex in the centre of the figure 
has a 1,10-phenanthroline, phen, ligand. This complex has a shorter emission wavelength of 573 
nm in acetonitrile, but has a much longer luminescent lifetime than the analogous bpy 
complex.23 The final complex in the figure possesses a dipyridophenazine, dppz, ligand and has 
an emission wavelength of 600 nm and a luminescent lifetime of 0.04 µs, in degassed DCM, 
which is almost identical to that observed for the bpy complex.24,25 From this, it can be 
determined that small changes to the structure of the diimine ligand can have a significant 
impact upon the photophysical properties of the complex as a whole. 
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Figure 5.6: Structures and photophysical properties of simple tricarbonylrhenium(I) complexes. From left 
to right: [Re(bpy)(CO)3Cl],22 [Re(phen)(CO)3Cl],23 and [Re(dppz)(CO)3Cl]24,25.  
 
 
5.1.3. Rhenium Complexes in OLED Devices 
Complexes of rhenium(I) have become of interest in many different applications. One of which 
is as a dopant in OLED devices. Rhenium complexes are not only attractive as dopants for their 
luminescent properties, but the neutral complexes can also be sublimed quite easily during the 
manufacturing process. The design of OLED devices has previously been discussed in detail in 
chapter three, but presented here are examples of rhenium(I) complexes designed for this 
purpose. The complex on the left of Figure 5.7 was reported by Chu et al. in 2014, which has a 
1,10-phenanthroline diimine ligand and an axial [CNB(C6F5)3] ligand, was used as a dopant in an 
electrochemical device that showed “sky-blue” emission at a wavelength of 538 nm.26 The 
complex in the centre of the figure uses a functionalised 1,10-phenanthroline derivative as the 
diimine ligand to give a complex that has an emission wavelength of 570 nm.27 The complex on 
the right of the figure was reported in 2006 and has a functionalised benzimidazole ligand and 
shows emission at 590 nm.28 
 
Figure 5.7: Examples of rhenium(I) complexes designed as OLED dopants. 
5.1.4. Rhenium Complexes in Photocatalysis 
Another application gathering extensive interest is the use of rhenium complexes as 
homogeneous catalysts in the reduction of CO2 to CO. The photocatalytic activity of fac-
[Re(bpy)(CO)3Cl] was first reported by Hawecker et al. in 1986. The complex was found to be 
photocatalytic active after induction with visible light irradiation. The complex was also found 
to selectively reduce CO2 to CO with the use of a tertiary amine as an electron donor.29 Since 
then, other photocatalysts have been developed based upon similar complex structures. In 
1996, Hori et al. reported that the complex fac-[Re(bpy)(CO)3{P(OEt)3}]+ showed improved 
Chapter 5  
134 
 
efficiency in the reduction of CO2 compared to earlier catalysts which is believed to be due to 
the stability of the one-electron-reduced species fac-[Re(bpy·-)(CO)3{P(OEt)3}].30 A study in 2016 
replaced the 2,2’-bipyridine ligand of the benchmark species fac-[Re(bpy)(CO)3Br] with a series 
of pyridyl N-heterocyclic carbene ligands. The results showed that the complex fac-[Re(PyNHC-
PhCF3)(CO)3Br] was able to outperform the benchmark species in the reduction of CO2 both in 
the presence and in the absence of a photosensitiser species.31 
 
Figure 5.8: Structures of complexes used as photocatalysts for the reduction of CO2 to CO. From left to 
right: [Re(bpy)(CO)3Cl],29 [Re(bpy)(CO)3{P(OEt)3}],30 and [Re(PyNHC-PhCF3)(CO)3Br].31 
In recent years, the area of rhenium photocatalysts has diverged from the traditional 2,2’-
bipyridine and 1,10-phenanthroline diimine ligands. Shown on the left of Figure 5.9 is part of a 
nanographene-rhenium complex synthesised in 2016 as a selective CO2 reductant. The electron 
density is spread over the whole of the diimine ligand which lowers the electrical potential 
needed to drive the reaction. In addition to this, no photosensitiser is needed as the ligand 
absorbs a large range of the spectrum.32 In 2019, a study published reports of a ruthenium(II)-
rhenium(I) supramolecular photocatalyst for the reduction of CO2. The bimetallic species used 
as part of the catalyst is shown on the right-hand side of Figure 5.9.33 
 
Figure 5.9: Recently published complexes for photocatalytic applications. Left) Nanographene-complexes 
reported by Qiao et al.32 Right) Bimetallic Ru(II)-Re(I) complex used as part of a supramolecular 
photocatalyst by Kamata et al.33 
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5.1.5.  Rhenium Complexes in Bioimaging 
The field of bioimaging has also benefitted greatly from the development of luminescent 
rhenium(I) complexes. The large Stokes shift associated with these complexes overcomes the 
issue of auto fluorescence, while the low spin d6 nature of tricarbonylrhenium(I) complexes 
makes them kinetically inert and so unlikely to interact with DNA. The first major study of 
tricarbonylrhenium(I) bisimine complexes as imaging agents was published in 2007 by Amoroso 
and Coogan et al.34 A series of complexes of the form fac-[Re(bisim)L(CO)3]+ were synthesised, 
where bisim is a bisimine and L is pyridine or a derivative. Two examples of the complexes 
studied are shown in Figure 5.10. The complexes showed emission at around 550 nm which 
allows autofluorescence to be filtered out when imaging. In addition to this, the sulfonated 
complex shown in the figure showed very low toxicity, showing that complexes of this type may 
be promising future imaging agents. 
 
Figure 5.10: Some of the first examples of tricarbonylrhenium(I) complexes studied as biological imaging 
agents reported.34 
Other developments in the field of bioimaging include the incorporation of biological substrates 
into the structure of the rhenium(I) complex. Work published by Lo et al. in 2015 describes three 
examples of cationic tricarbonylrhenium(I) complexes that incorporate the biological substrates 
into the structure through functionalisation of the axial pyridine ligand.35 The biological 
substrates incorporated into the structure include estradiol, indole and biotin (Figure 5.11, 
clockwise from top). The aim of the study was to investigate how the photophysical properties 
of these complexes change upon binding of the biological substrate to its receptor. Common 
organic biotin-fluorophore compounds exhibit self-quenching upon binding to the avidin 
receptor, but this was not observed in the biotin-rhenium complex shown in Figure 5.11. In 
addition to this, it was found that the estradiol complex showed increased luminescence 
intensity and longer luminescent lifetime upon binding to estrogen receptors. As estrogen 
receptor content helps to provide accurate information on the index of hormone-dependent 
breast cancer,36  this complex could have applications as an imaging agent for estrogen receptor-
positive breast cancer. 
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Figure 5.11: Biological imaging agents of Re(I) incorporating biological substrates. 
More recent examples of tricarbonylrhenium(I) complexes are shown in Figure 5.12. The 
complex on the left was reported in 2017 by Langdon-Jones et al. The complex features an un-
substituted 1,10-phenanthroline diimine ligand and has a 1,8-naphthalimide derivative in the 
axial position. The 1,8-naphthalimide-based ligand is fluorescent and depending upon the 
substituents, the emission from the complex as a whole can be modulated between 3MLCT 
centred and ligand centred processes. This complex was found to be a viable cell imaging agent 
when tested with fission yeast cells.37 The complex on the right of the figure was reported in 
2019 and was found to have anti-cancer properties in addition to bioimaging applications. The 
complex was part of a study using non-steroidal anti-inflammatory drugs as the axial ligands in 
tricarbonylrhenium(I) complex systems. The complex shown uses aspirin as the axial ligand and 
was the only complex in the study that showed activity against cancer cell lines. The complex 
also showed no activity against non-tumorous mouse cells. Once inside the HeLa cell, the 
complex dissociates and produces the phosphorescent species [Re(CO)3(phen)]+ which 
accumulates in the mitochondria and was found to reversibly bind to hen egg white lysozyme 
(HEWL). The dissociated aspirin then inhibits the enzyme COX-2.38 
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Figure 5.12: Rhenium(I) complexes developed as bioimaging agents.37,38 
This work discussed here sets a precedent for the inclusion of biologically active compounds into 
the structure of luminescent inorganic complexes. Further work in this field could therefore 
include the incorporation of potentially cytotoxic compounds such as dicyanodibenzodioxins 
into rhenium complexes, and the possibility of dual action therapeutic and luminescence 
properties. 
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5.2. Aims 
The aim of this work was to investigate synthetic pathways to a series of fluorescent 
dicyanobenzodioxin compounds that also demonstrate an ability to act as ligands. A metal 
coordination site was incorporated into these ligands by use of a conjugated 1,10-
phenanthroline moiety to give a series of compounds with proposed structures of close 
similarity to ligands based upon dppz. 
These new dicyanobenzodioxin-based ligands were then to be coordinated to rhenium(I) to give 
complexes of the formulation fac-[Re(CO)3(L)Br] and to fully investigate the photophysical 
properties of these complexes. In addition to this, exchange of the axial bromide ligand in these 
complexes was to be carried out in order to form cationically charged species that optimise 
solubility characteristics. 
  
Chapter 5  
139 
 
5.3. Results and Discussion 
5.3.1. Synthesis and characterisation of dicyanobenzodioxins  
In this study, a series of four target compounds based upon the dicyanobenzodioxin core were 
synthesised and their photophysical properties investigated. 
The first step in the synthesis of these compounds was the oxidation of 1,10-phenanthroline to 
1,10-phenanthroline-5,6-dione following a procedure from literature.39 This step was followed 
by a reduction to the corresponding diol form using hydrazine as the reductant (Scheme 5.3). 
This species can quickly oxidise in air and so is immediately used in the following step without 
further characterisation. 
 
Scheme 5.3: Synthesis of 1,10-phenanthroline-5,6-diol from 1,10-phenanthroline. 
In the next step, 1,10-phenanthroline-5,6-diol, was then dissolved in DMF and reacted with 
tetrafluoroterephthalonitrile (TFTPN) in the presence of potassium carbonate to form ligand L1 
(Scheme 5.4) as a bright green solid in 80% yield The product precipitated out of solution and so 
was collected by filtration and washed with water to remove excess K2CO3 with no further 
purification necessary. L1 is a ligand in its own right, but also a valuable precursor to asymmetric 
dicyanobenzodioxin based ligands.  
 
Scheme 5.4: Synthesis of ligand L1 from 1,10-phenanthroline-5,6-diol. 
L1 was fully characterised by proton, carbon and fluorine NMR spectroscopy in addition to HRMS 
and IR spectroscopy. This section will discuss the analysis in detail. Figure 5.13 shows the proton 
NMR spectrum recorded for L1 in deuterated DMSO, with the proton assignments shown 
circled. The proton environment nearest to the nitrogen heteroatoms appears most downfield 
as a doublet at around 9.2 ppm. The splitting of the signal at around 8.0 ppm suggests it arises 
from the proton environment circled in red on the ligand, with the doublet at around 8.45 ppm 
arising from the final proton environment. When comparing these observations with the 
spectrum recorded for the 1,10-phenanthroline-5,6-dione precursor, a downfield shift of each 
proton environment is seen. The largest of these shifts occurs for the environment circled in red, 
which appears at 7.59 ppm in the dione species but is centred around 7.95 ppm in L1. As both 
the precursor and the product have the same number of protons and proton environments, the 
downfield shifts observed are indicative of the formation of the product.  
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Figure 5.13: Proton NMR spectrum recorded for ligand L1 in deuterated DMSO with assignments for each 
proton (400 MHz). 
The fluorine NMR spectrum shows a single signal at -132.30 ppm in deuterated DMSO. The signal 
is shifted upfield from that of the free tetrafluoroterephthalonitrile, which shows a single signal 
at -131.09 ppm in the same solvent. This shows that only one fluorinated species is present and 
that it is not the fluorinated starting material. 
 
Figure 5.14: Fluorine NMR spectrum recorded for ligand L1 in deuterated DMSO (376 MHz). 
The carbon NMR is shown in Figure 5.15, but was difficult to record due to the relatively poor 
solubility of L1 in organic solvents and as a result, the spectrum produced is very weak. The 
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number of peaks observed is consistent with the number of unique carbon environments in the 
compound, also a signal is observed at around 120 ppm which is consistent with a nitrile carbon 
environment. 
 
Figure 5.15: Carbon NMR spectrum recorded for ligand L1 in deuterated DMSO (126 MHz). 
The IR spectrum recorded for ligand L1 is shown in Figure 5.16. The most distinctive feature in 
the spectrum is the relatively weak stretch at 2241 cm-1 is indicative of a  C≡N stretch. 
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Figure 5.16: FTIR ATR spectrum recorded for ligand L1. Inset) HRMS (ASAP) data for L1 showing the 
molecular ion peak at 337.1096 amu. 
The mass spectrometry data also correspond to synthesis of the desired compound L1. The inset 
of Figure 5.16 shows the high-resolution mass spectrometry data recorded for L1 showing the 
molecular ion peak present at 337.1096 amu. Therefore the characterisation is consistent with 
the proposed structure of  ligand L1. 
L1 was then used as the precursor for the synthesis of L2, L3 and L4. These were obtained by 
reacting L1 with the aromatic diols: catechol, 4-tert-butylcatechol and 2,3-
dihydroxynaphthalene, respectively.  Again, reaction in DMF with potassium carbonate yielded 
the ligands. The product of each reaction crashed out of a solution as a brightly coloured 
precipitate. Compounds L2 and L4 were green in colour, while ligand L3 was isolated as an 
orange solid. 
Chapter 5  
143 
 
N
N
O
O
CN
CN
O
O
N
N
O
O
CN
CN
O
O
N
N
O
O
CN
CN
O
O
N
N
O
O
CN
F
F
CN
HO
HO
K2CO3
DMF N
N
O
O
CN
CN
O
O
L2 L3 L4  
Scheme 5.5: Synthesis of ligands L2, L3 and L4. 
The prepared compounds (Scheme 5.5), L1-4, each exhibited very poor solubility in common 
organic solvents. The planar structure of each molecule suggests that pi-stacking is most likely 
responsible for this property; this is also supported by L4, the most aromatic ligand, showing the 
least solubility. One impact of this limiting solubility is that it has not been possible to record 
good quality proton or carbon NMR data for L2, L3 and L4.  
Figure 5.17 shows the proton NMR spectrum recorded for ligand L2 in deuterated DMSO. As the 
peaks do not rise significantly above the baseline, the integration of these signals is unreliable. 
The spectrum shows the same three signals as seen in the spectrum of L1, as expected, along 
with an additional multiplet signal at 7.19 ppm arising from the catechol moiety. It can be 
assumed that both starting materials, L1 and catechol, have been consumed in the reaction as 
they exhibit good solubility in DMSO and would result in much more intense peaks in the NMR 
spectrum. In addition to this, the absence of signals in the fluorine NMR spectrum suggests that 
there is no residual L1 remaining. 
 
Figure 5.17: Proton NMR spectrum recorded for ligand L2 in deuterated DMSO. 
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It was not possible to obtain a proton NMR spectrum for ligand L3, however a very weak 
spectrum was recorded for ligand L4 using a 600 MHz instrument and recorded over 1024 scans. 
The spectrum showed no sign of excess starting material, however a number of very weak 
signals are present near the baseline which are possibly due to the formation of aggregates. A 
more intense set of signals is present in the aromatic region of the spectrum which together 
integrate correctly to the target compound. The proton NMR spectrum alone does not confirm 
confidently that the desired product has been synthesised, however in combination with the 
absence of signals in the fluorine NMR, it provides evidence that the starting materials, L1 and 
2,3-dihydroxynaphthalene, have been consumed.  
Therefore, in addition to NMR spectroscopy, high resolution mass spectrometry was employed 
to confirm the presence of the molecular ion peak. This was found to be present in the cases of 
L1, L2 and L3. The mass spectrum of ligand L2 is shown in Figure 5.18, where the [M + H] peak 
can be seen, it is also worth noting the absence of peaks corresponding to the starting material, 
L1. 
 
Figure 5.18: High resolution mass spectrum recorded for ligand L2 showing [M + H] peak. Peak for 
starting material is absent. 
The poor solubility of ligand L4 also made recording mass spectrometry data difficult. The high-
resolution mass spectrum recorded showed that the molecular ion peak is not present, but the 
starting material is also absent from the spectrum. A number of peaks with a higher mass value 
than that of the molecular ion were present, suggesting that the ligand may form adducts with 
other species in the spectrometer. 
From this data it is possible to confirm the synthesis of ligands L1, L2 and L3. The data recorded 
for ligand L4 suggets that the starting materials are not present in the final product, however 
NMR spectroscopy and mass spectrometry have proved unsuccessful in confirming the presence 
of target compound L4. 
Infra-red spectroscopy was used to identify the position of the nitrile stretches in each 
compound. These stretches are typically observed at between 2260 – 2220 cm-1 and appear with 
medium intensity. Table 5.1 lists the position of these signals for each ligand L1 - L4. It was not 
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possible to observe a nitrile stretch in the IR spectrum of ligand L3, however the mass 
spectrometry data is consistent with formation of the target product. Meanwhile, a nitrile 
stretch is present in the IR spectrum of ligand L4, meaning that while it is not possible to be 
certain of the structure of this compound, there are clearly nitrile groups present. 
 
 
Table 5.1: Positions of nitrile stretch in infrared spectrum for ligands L1 - L4. 
Ligand CN Stretch/ cm-1 
L1 2241 
L2 2237 
L3 n/a 
L4 2241 
 
As discussed previously, the aim of this chapter was also to synthesise ligands with similar 
structure to the well-studied ligands dppz and tattp. The ligands L1 – L4 have a related structure 
to dppz, but to synthesise a ligand analogous to tattp, two metal coordination sites are required. 
Synthesis of a such a ligand was attempted using two equivalents of 1,10-phenanthroline-5,6-
diol and one equivalent of tetrafluoroterephthalonitrile (Scheme 5.6). Analysis of the product of 
the reaction showed that only one equivalent of the diol species had reacted to give L1. 
 
Scheme 5.6: Proposed synthetic route to tattp dicyanodibenzodioxin analogue. 
A second attempt was made to isolate the bridging dicyanodibenzodioxin ligand using L1 as a 
starting material with a further equivalent of 1,10-phenanthroline-5,6-diol (Scheme 5.7), but 
disappointingly no reaction was observed and L1 was recovered. Although the reasons for this 
are currently unclear it may be that the limiting solubility of L1 in the solvent conditions is 
preventing efficient reaction.  
 
Scheme 5.7: Alternative route to bridging dicyanodibenzodioxin ligand. 
As a result of this exploratory work, the focus of this work shifted to the coordination chemistry 
of ligands L1 - L4 only. 
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5.3.2. Coordination chemistry with rhenium(I) 
Although the poor solubility of L1-L4 was noted, these four compounds were further 
investigated as ligands in rhenium(I) coordination chemistry. Each ligand was reacted in toluene 
at reflux in the presence of [Re(CO)5Br] and yielded a final complex of the form [Re(CO)3(-
L)Br].The synthesis of these complexes is shown in Scheme 5.8. 
 
Scheme 5.8: Synthesis of rhenium complex from dioxin ligand. 
The Re(I) complexes precipitated out of the reaction solution and were obtained in high yield by 
filtration. The proposed structures of these complexes are shown in Figure 5.19. The complexes 
were collected as brightly coloured powders ranging from green to orange in appearance. 
 
Figure 5.19: Structures and yields of tricarbonylrhenium complexes synthesised. 
The four complexes were characterised by NMR spectroscopy, mass spectrometry and infrared 
spectroscopy. The NMR data collected from the complexes was of better quality than that 
collected for the free ligands due to improved solubility characteristics. The proton NMR 
spectrum shown in Figure 5.20 is that recorded for fac-[Re(CO)3(L3)Br]. The spectrum shows 
clear peaks which integrate correctly to the number of protons in the complex. This is in great 
contrast with the free ligand, for which it was not possible to record a proton spectrum. 
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Figure 5.20: Proton NMR spectrum recorded for [Re(CO)3(L3)Br]. 
The improved solubility of the complexes over their free ligands meant it was possible to obtain 
proton NMR data for every complex, however in the case of fac-[Re(CO)3(L4)Br] the spectrum 
was still very weak due the low solubility of the complex. It was not possible to obtain carbon 
NMR data for any of the four complexes synthesised. 
High resolution mass spectrometry was performed on each complex which was able to identify 
the sodium adduct of the molecular ion. Shown in Figure 5.21 is the high-resolution mass 
spectrum of complex fac-[Re(CO)3(L1)Br]. The parent peak corresponds to [M + Na] and the 
peaks at lower amu values are fragments which do not correspond to either starting material. 
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Figure 5.21: High-resolution mass spectrum of complex [Re(CO)3(L1)Br]  showing sodium adduct, [M + 
Na]. 
The complexes were also analysed using infrared spectroscopy. The nitrile stretch is no longer 
observable in the spectra, likely due to the much higher relative intensity of the carbonyl 
stretches in each complex. The position of the carbonyl stretches for each complex are shown 
in Table 5.2. 
Table 5.2: Position of metal carbonyl stretches in the neutral rhenium complexes with 
dicyanodibenzodioxin ligands. 
Complex CO stretch/ cm-1 
[Re(CO)3(L1)Br] 2031, 1929, 1877 
[Re(CO)3(L2)Br] 2019, 1902br 
[Re(CO)3(L3)Br] 2029, 1925, 1879 
[Re(CO)3(L4)Br] 2021, 1886br 
 
The data shows that the complexes with ligands L2 and L4 show two carbonyl stretches, while 
the complexes with ligands L1 and L3 show three stretches. The coordination sphere of each 
neutral complex has a Cs symmetry and therefore, three carbonyl stretches are predicted in the 
IR spectrum (2A’ + A’’). Three stretches are observed in the case of complexes fac-
[Re(CO)3(L1)Br] and fac-[Re(CO)3(L3)Br] with values that compare well with literature complexes 
of a similar structure.40 The complexes with ligands L2 and L4 show only two stretches. In each 
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case, the lower energy stretch is broader than the one higher in energy suggesting it is composed 
of two overlapping stretches. 
Full characterisation of the free ligands and of the neutral Re(I) complexes was not possible due 
to the limiting solubility of these species. In an attempt to further improve the solubility, the 
four neutral complexes were converted to their cationic analogues by exchanging the axial 
bromide ligand for an acetonitrile ligand following the synthesis route in Scheme 5.9. Here, 
acetonitrile was used as the solvent in the reaction; the silver tetrafloroborate, AgBF4, was used 
to abstract the bromide ion to form AgBr while the BF4- ion becomes the counter ion for the 
cationic rhenium complex. 
 
Scheme 5.9: Ligand exchange to give cationic complexes. 
Following this route, four novel cationic complexes were isolated. The structures and yields of 
these complexes are shown in Figure 5.22. The isolated yields of these complexes were much 
lower than those of their neutral counterparts and vary largely between complexes. Higher 
yields were observed in cases where the neutral complex had better solubility in acetonitrile, as 
seen in the cases of complexes fac-[Re(CO)3(L1)(MeCN)][BF4] and fac-[Re(CO)3(L3)(MeCN)][BF4]. 
 
Figure 5.22: Structures and yields of cationic complexes with ligands L1 – L4. 
This increased solubility resulted in higher quality proton NMR spectra and also meant it was 
possible to record carbon NMR data. Figure 5.23 shows the proton NMR recorded for complex 
fac-[Re(CO)3(L4)(MeCN)][BF4]. 
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Figure 5.23: Proton NMR data for cationic complex [Re(CO)3(L4)(MeCN)][BF4]. 
Carbon NMR data was collected for all complexes and the spectrum recorded for complex fac-
[Re(CO)3(L3)(MeCN)][BF4] is shown in Figure 5.24. The signal at 39.52 ppm is due to the 
deuterated DMSO. The t-butyl peaks can be clearly observed at 30.81 (C(CH3)3) and 34.29 (C(CH-
3)3) ppm respectively. Other signals of interest include the coordinated acetonitrile signals at 
1.32 ppm and 93.58 ppm as well as a carbonyl peak arising at 195.72 ppm. 
 
Figure 5.24: Carbon NMR spectrum recorded for complex [Re(CO)3(L3)(MeCN)][BF4] in deuterated DMSO. 
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It was also possible to grow a good quality crystal for single crystal diffraction for the complex 
[Re(CO)3(L3)(MeCN)][BF4]. This crystal was grown via vapour diffusion of diisopropyl ether into 
a saturated acetonitrile solution of the complex.  
 
Figure 5.25: Crystal structure of complex [Re(CO)3(L3)(MeCN)][BF4]. 
 
The structure recorded confirms that the target complex was synthesised. The following data 
tables show the bond lengths and bond angles of the coordination sphere. The rhenium – 
carbonyl bond lengths are around 1.91 – 1.94 Å and the rhenium – diimine bond lengths are 
between 2.17 – 2.18 Å which are consistent with literature reports of similar complexes.40–42 In 
addition to this, the bite angle of the diimine ligand was measured at 76.20(8)˚ which compares 
closely with that measured for a phen ligand in a similar complex reported by Lo et al. in 2006.41 
It is also worth noting that the dicyanodibenzodioxin ligand is not completely planar, with the 
CCO-Re-N angles measured at 172.19(9)˚ and 172.60(10)˚, making the geometry of the complex 
a distorted octahedron. This non-planarity has also been reported in tricarbonylrhenium(I) phen 
complexes.42 
Table 5.3: Data collection parameters for complex [Re(CO)3(L3)(MeCN)][BF4]. 
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Formula C39H27B0.95Br0.06F3.77N7O7Re Z' 1 
Dcalc./ g cm-3 1.699 Wavelength/Å 0.71075 
m/mm-1 3.314 Radiation type MoKa 
Formula Weight 978.21 Qmin/° 2.323 
Colour yellow Qmax/° 27.483 
Shape block Measured Refl. 88085 
Size/mm3 0.251×0.168×0.084 Independent Refl. 8767 
T/K 100(2) Reflections with I > 2(I) 8428 
Crystal System triclinic Rint 0.0237 
Space Group P-1 Parameters 548 
a/Å 8.68880(10) Restraints 84 
b/Å 14.54320(10) Largest Peak 2.158 
c/Å 16.6700(2) Deepest Hole -0.549 
a/° 106.8550(10) GooF 1.092 
b/° 100.2890(10) wR2 (all data) 0.0600 
g/° 101.4630(10) wR2 0.0595 
V/Å3 1912.07(4) R1 (all data) 0.0244 
Z 2 R1 0.0231 
 
Table 5.4: Selected bond lengths for the coordination sphere or complex [Re(CO)3(L3)(MeCN)][BF4] 
Atom Atom Length/Å 
Re(1) N(1) 2.169(2) 
Re(1) N(2) 2.177(2) 
Re(1) N(41) 2.131(2) 
Re(1) C(31) 1.935(3) 
Re(1) C(32) 1.922(3) 
Re(1) C(33) 1.908(3) 
 
 
Table 5.5: Selected bond angles in the coordination sphere of [Re(CO)3(L3)(MeCN)][BF4] 
Atom Atom Atom Angle/° 
N(1) Re(1) N(2) 76.20(8) 
N(41) Re(1) N(1) 82.64(8) 
N(41) Re(1) N(2) 81.43(8) 
C(31) Re(1) N(1) 172.19(9) 
C(31) Re(1) N(2) 96.14(10) 
C(31) Re(1) N(41) 94.83(11) 
C(32) Re(1) N(1) 97.66(10) 
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C(32) Re(1) N(2) 172.60(10) 
C(32) Re(1) N(41) 93.79(11) 
C(32) Re(1) C(31) 89.87(12) 
C(33) Re(1) N(1) 92.92(10) 
C(33) Re(1) N(2) 95.72(10) 
C(33) Re(1) N(41) 175.18(10) 
C(33) Re(1) C(31) 89.33(12) 
C(33) Re(1) C(32) 88.64(13) 
 
These compounds were also analysed by IR spectroscopy and the  results are shown in Table 
5.6. The number of carbonyl stretches observed in each cationic complex is the same as in each 
neutral precursor. The coordination sphere of each of these complexes is pseudo C3v in 
symmetry and as such, a total of two IR active stretches is predicted for each complex (A1 + E). 
As observed in the neutral complexes, the cationic complexes with ligands L1 and L3 exhibit 
three IR carbonyl absorptions, which is likely due to the retention of the Cs symmetry exhibited 
by those complexes. The carbonyl stretches observed in the cationic complexes are higher in 
energy than those in the neutral complexes. This is because the d-orbitals in the cationic species 
are more diffuse resulting in a poorer overlap between the metal d orbitals and the antibonding 
orbital of the carbonyl ligand. The backbonding is weakened which strengthens the carbon – 
oxygen bond. 
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Table 5.6: Carbonyl infrared stretches for cationic rhenium complexes. 
Complex CO stretch/ cm-1 
[Re(CO)3(L1)(MeCN)][BF4] 2039, 1948, 1913 
[Re(CO)3(L2)(MeCN)][BF4] 2035, 1902 
[Re(CO)3(L3)(MeCN)][BF4] 2037, 1950, 1917 
[Re(CO)3(L4)(MeCN)][BF4] 2033, 1906 
 
5.3.3. Photophysical Data 
The compound dipyridophenazine is similar in structure to the ligands synthesised in this work, 
however no photophysical data for this compound is available in the primary literature for 
comparison. Dicyanodibenzodioxin compounds with similar structures to ligands L1 – L4 have 
previously been reported in literature with photophysical data. Figure 5.26 shows three simple 
compounds with a dicyanodibenzodioxin core along with some of their photophysical 
properties. The absorption and emission maxima of compounds a and b are very similar despite 
a change in structure. However, the absorption maximum of compound c is longer than that 
recorded for a and b suggesting that larger structural changes can influence the photophysical 
properties of these types of compound. 
 
Figure 5.26: Examples of similar dioxin compounds from literature along with relevant photophysical 
data.3,43,44 
Figure 5.27 shows the UV-vis absorption spectra of ligands L1-4.  Each compound exhibits 
absorption features between 250 – 300 nm arising from π-π* and also n-π* transitions 
associated with the phenanthroline moiety and, in the cases of L2-4, the aryl moiety.  Each 
species also shows a feature at between 400 and 450 nm. This feature is assigned to a charge 
transfer transition involving the accepting nitrile groups in each ligand. It appears that the aryl 
substituents have little to no effect upon the wavelength of this feature, however the intensity 
does differ between species, with the naphthyl substituted species, L4, having the highest molar 
extinction coefficient and the fluoro- substituted species having the lowest.  
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Figure 5.27: UV-vis absorption spectra recorded for ligands L1-4. Measured in CHCl3 at a concentration of 
1x10-5 M. 
Literature compounds a and b both have absorption maxima of around 390 nm, which is also 
very close to the value of 400 nm recorded for ligand L1, suggesting that the phenanthroline 
moiety has little to no influence upon the absorption wavelength. Compound c has an additional 
aryl moiety in comparison to a and b and shows a red-shifted absorption wavelength of 428 nm. 
This is similar to the results observed for ligands L2-4 in respect to ligand L1. The effects 
discussed above are a result of the fact that dibenzodioxins and their related compounds contain 
oxygen atoms para- to one another separating aromatic parts of the compound and so there is 
no through-bond conjugation across the whole molecule. It is for this reason that the 
phenanthroline moiety exercises no influence over absorption. In addition to this, it has been 
observed that the use of electron withdrawing and electron donating groups can shift the 
absorption maxima of charge transfer transitions as is seen when replacing the fluoro 
substituents with an aryl dioxin substituent.1  
The emission spectrum for each ligand is shown in Figure 5.28. The emission feature is broad 
and without any vibronic features.  Across the series, there is minimal variation in emission 
wavelength maxima which suggests that the charge transfer transition responsible for this 
emission is unperturbed by the nature of the conjugated groups. The quantum yields and 
luminescent lifetimes of each ligand were also recorded. The lifetimes are all < 10 ns and suggest 
that a fluorescence process dominates emission. The data shows that ligands L2-4 have a 
quantum yield value that is over 10x that recorded for L1. Also, ligand L1 has a much shorter 
lifetime than ligands L2-4. 
Table 5.7: Photophysical data for ligands L1-4. 
Ligand Absorption wavelength λabs/ nm 
Emission 
Wavelength λem/ nm 
Quantum yield, 
Φ/ % Lifetime, τ/ ns 
L1 400, 353, 277 490 0.2 2.2 
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L2 441, 350, 271 485 2.2 7.2 
L3 445, 350, 273 489 2.9 8.1 
L4 436 485 2.3 6.4 
 
 
Figure 5.28: Normalised emission spectra recorded for ligands L1-4. Spectra recorded on CHCl3 at room 
temperature. 
The UV-vis absorption profiles for the neutral complexes of the form fac-[Re(CO)3(L)Br] are 
shown in Figure 5.29. The spectra have the same general features as seen in the ligands, 
however the feature previously observed between 380 - 460 nm in the ligands now has a much 
broader profile of 340 – 460 nm. This can be ascribed to the overlapping metal-to-ligand charge 
transfer (MLCT) feature that is typically present in this region. This corresponds well with the 
absorption profile of the literature known complex fac-[Re(CO)3(phen)Br] (where phen = 1,10-
phenanthroline), which shows an 1MLCT absorption maximum of 370 nm.23 Also worthy of note 
is the large changes in intensity observed for the higher energy features. The molar extinction 
coefficient of the absorptions occurring around 280 nm for the complexes with ligands L1, L2 
and L3 are around half of those observed in the free ligand. Interestingly, the molar extinction 
coefficient of this absorption in the complex fac-[Re(CO)3(L4)Br] is over 5 times higher than that 
of the free ligand, rising from around 10000 M-1cm-1 in the free ligand to over 50000 M-1cm-1 in 
the complex. 
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Figure 5.29: UV-vis absorption spectra recorded for neutral complexes fac-[Re(CO)3(L)Br]. Samples 
recorded in CHCl3 at concentration of 1x10 -5 M.  
The UV-vis absorption data of the complex fac-[Re(CO)3(dppz-F2)Cl] is also available in the 
literature for comparison. The most notable feature is that the longest wavelength absorption 
in the literature complex is around 40 nm shorter than that observed in fac-[Re(CO)3(L1)Br]. The 
molar extinction coefficients are also much higher in the dppz-F2 complex.  
 
Figure 5.30: Left) UV/vis absorption data recorded for complex [Re(CO)3(L1)Br]. Right) UV-vis data from 
literature for complex [Re(CO)3(dppz-F2)Cl].16 
The emission spectra of the synthesised complexes are shown in Figure 5.31. Two distinct 
emission peaks are seen for each complex, one centred around 490 nm and another centred at 
around 610 nm. The higher energy emission matches the emission observed from the free 
ligand, while the emission peak at 610 nm is in a similar range to the typical 3MLCT emission 
observed from species such as fac-[Re(CO)3(phen)Br]: λem = 570 nm, fac-[Re(CO)3(phen)Cl]: λem 
= 573 nm and the complex fac-[Re(CO)3(ephen)Cl]: λem = 585 nm (where ephen = 5,6-epoxy-
1,10-phenanthroline).23,42 The lack of through-bond conjugation in the ligand appears to 
effectively separate the molecule into two sections, with the central dicyanobenzodioxin moiety 
responsible for intraligand charge transfer, and the rhenium(I)-phenanthroline moiety 
responsible for the metal-to-ligand charge transfer. The result of this is dual emission in the 
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visible region of the spectrum. Furthermore, the intensity of the 3MLCT emission relative to the 
ICT emission varies depending upon the aryl moiety used at the opposite end of the ligand to 
coordination. This creates the possibility of selectively tuning the relative intensity for desired 
applications. 
 
 
Figure 5.31: Steady state emission spectra recorded for complexes fac-[Re(CO)3(L)Br] in CHCl3. 
The luminescence lifetime and quantum yield values were measured for the 3MLCT emission 
peak and are reported in Table 5.8. This peak exhibits a much longer lifetime than the intraligand 
charge transfer peak of the free ligand with each complex showing a lifetime of over 80 ns and 
the longest emission lifetime recorded for the complex fac-[Re(CO)3(L4)Br] at 131.6 ns. The 
quantum yield values were lower than those recorded for the free ligands, with the biggest 
difference observed for ligand L4. The free ligand shows a quantum yield of 2.3 % which 
decreases to only 0.38 % in the complex fac-[Re(CO)3(L4)Br]. 
Table 5.8: Photophysical data for fac-[Re(CO)3(L)Br] complexes. 
Complex 
Absorption 
wavelength λabs/ 
nm 
Emission 
wavelength 
λem/ nm 
Quantum 
yield, Φ/ % Lifetime, τ/ ns 
[Re(CO)3(L1)Br] 442, 382, 300 477, 618 0.90 81.5 
[Re(CO)3(L2)Br] 427, 301, 264 462, 612 0.94 85.8 
[Re(CO)3(L3)Br] 434, 304, 265 464, 613 1.23 97.6 
[Re(CO)3(L4)Br] 417, 263 456 0.38 131.6 (95%), 6.6 (5%) 
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Comparative studies were then carried out for the corresponding cationic complexes of the form 
fac-[Re(CO)3(L)(MeCN)][BF4]. The UV-vis absorption spectra are shown in Figure 5.32. When 
comparing this data with that recorded for the neutral complexes it can be observed that molar 
extinction coefficient values for complexes fac-[Re(CO)3(L2)(MeCN)][BF4] and fac-
[Re(CO)3(L3)(MeCN)][BF4] has decreased significantly for the feature between 370 – 460 nm 
while the values for fac[Re(CO)3(L1)(MeCN)][BF4] and fac-[Re(CO)3(L4)(MeCN)][BF4] remain 
similar. 
Work published in 1982 by Caspar and Meyer directly compared the photophysical properties 
of the complexes fac-[Re(CO)3(bpy)Cl] and fac-[Re(CO)3(bpy)(MeCN)][PF6]. Their results showed 
that the cationic complex showed a slightly higher energy MLCT absorption wavelength than the 
neutral complex.45 A similar effect is not observed in the data recorded for the 
dicyanodibenzodioxin complexes, however this is likely due to the overlap between the MLCT 
absorption and the CT absorption of the ligand. 
 
 
Figure 5.32: UV-vis absorption spectra recorded for cationic complexes fac-[Re(CO)3(L)(MeCN)][BF4]. 
Recorded in MeCN at concentration 1x10-5 M. 
However, a much greater difference is present in the steady state emission data recorded for 
the cationic complexes. This data is presented in Figure 5.33 and shows that the emission peak 
assigned to a 3MLCT transition in the neutral complexes is no longer present in the cationic 
complexes. Instead, the spectra recorded bare a strong resemblance to those recorded for the 
free ligand.  
The work published by Caspar and Meyer in 1982 showed similar results when comparing the 
emission wavelengths of the complexes fac-[Re(CO)3(bpy)Cl] and fac-
[Re(CO)3(bpy)(MeCN)][PF6]. The chloride complex showed an emission wavelength of around 
622 nm, but this shifted to 535 nm when the chloride was exchanged for an acetonitrile ligand.45 
This suggests that the peak observed in the cationic rhenium complex emission spectra may be 
two overlapping 3MLCT and intraligand CT emission peaks.  
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Figure 5.33:  Steady state emission spectra recorded for complexes fac-[Re(CO)3(L)(MeCN)][BF4]. 
Measured in MeCN at room temperature. 
The lifetime of each species was recorded in acetonitrile and the results are tabulated below. 
Unlike the free ligands, the lifetimes recorded for this emission peak are bi-exponential which 
may suggest two overlapping emission features. The lifetimes recorded are very short with both 
exponents being shorter than that of the neutral complex. The report by Caspar and Meyer 
suggests that a much longer emission lifetime should be observed in the cationic complex 
compared to the neutral complex, but as their measurements were recorded in deoxygenated 
solvents it may be that quenching by triplet oxygen is responsible for the shorter lifetimes 
observed in this study. 
 
 
 
 
Table 5.9: Luminescence lifetimes recorded for complexes fac-[Re(CO)3(L)(MeCN)][BF4].Measurements 
recorded in MeCN at room temperature, λex = 295 nm. 
Complex Lifetime/ ns 
[Re(CO)3(L1)(MeCN)][BF4] 1.5 (43 %), 4.5 (57 %) 
[Re(CO)3(L2)(MeCN)][BF4] 2.0 
[Re(CO)3(L3)(MeCN)][BF4] 4.8 (54 %), 1.5 (46 %) 
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[Re(CO)3(L4)(MeCN)][BF4] 1.8 (66 %), 5.1 (34 %) 
 
Further to this, one sample was chosen and the emission spectra re-recorded using a series of 
different excitation wavelengths. Figure 5.34 shows the results produced when the same sample 
of complex fac-[Re(CO)3(L3)(MeCN)]+ was excited at different wavelengths. When shorter 
excitation wavelengths are used, the most prominent peak is observed at between 370 – 420 
nm. This peak corresponds to the phenanthroline moiety and matches well with literature 
reports of the emission spectrum of free 1,10-phenanthroline.46 
 
Figure 5.34: Steady state emission spectra recorded for complex fac-[Re(CO)3(L3)(MeCN)][BF4] in MeCN 
using different excitation wavelengths. 
Figure 5.35 shows the emission spectrum of complex [Re(CO)3(L3)(MeCN)]+ recorded in different 
solvents to show the effect of solvatochromism upon the complex. The emission wavelength 
varies widely depending upon the solvent used, from around 470 nm in tetrahydrofuran (THF) 
to almost 540 nm in the absence of solvent. With the exception of water, the more polar 
solvents, THF and methanol, resulted in the shorter wavelength emission; while non-polar 
solvents, chloroform and toluene, produced longer wavelength emission. This suggests that the 
compound may exhibit negative solvatochromism, implying a less dipolar excited state following 
the redistribution of electron density. 
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Figure 5.35: Steady state emission specta of complex fac-[Re(CO)3(L3)(MeCN)][BF4] recorded in different 
solvents using an excitation wavelength of 420 nm. 
The luminescence lifetimes of complex [Re(CO)3(L3)(MeCN)]+ were re-recorded in each solvent 
and the results are shown in Table 5.10. It is clear from these results that the solvent has a large 
effect upon the lifetime of this species. The least polar solvent, chloroform and toluene, result 
in the longest-lived emission, whilst the shortest emission was recorded in the absence of 
solvent, with the next shortest lifetime recorded in methanol which is a polar, protic solvent.  
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Table 5.10: Luminescence lifetimes recorded for complex fac-[Re(CO)3(L3)(MeCN)][PF6]  in different 
solvents. Measurements ecorded at room temperature, λex = 295 nm. 
Solvent Lifetime/ ns 
Methanol 0.06 (19 %), 1.8 (81 %) 
Chloroform 0.7 (69 %), 9.1 (31 %) 
Water 0.09 (85 %), 3.7 (15 %) 
THF 0.06 (25 %), 5.9 (75 %) 
Toluene 1.0 (22 %), 0.2 (52 %), 9.4 (26 %) 
None 0.6 
 
It is clear from the photophysical data recorded that the ligand centred transition is always 
present and is not altered in position or intensity by complexation or substitution of other 
ligands in the complex. This provides evidence that the charge transfer transition is isolated 
upon the dicyanodibenzodioxin core of the ligand and independent of the phenanthroline and 
aryl substituents. Further to this, the intraligand charge transfer transition does not appear to 
influence the MLCT transition arising from the phenanthroline moiety, with the red emission 
peak in the neutral complexes bearing a large similarity to the literature known species fac-
[Re(CO)3(phen)Cl]. It is also likely that substitution of the axial chloride ligand with an acetonitrile 
ligand increases the energy of the 3MLCT emission to match that of the intraligand charge 
transfer transition. 
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5.4. Conclusion 
In this chapter, four novel ligands have been synthesised based upon dicyanodibenzodioxin 
derivatives. These were then used as ligands to synthesise eight novel rhenium complexes, four 
neutral and four cationic. Characterisation of the free ligands and of the neutral complexes 
proved difficult to complete due to low solubility, however, full characterisation was achieved 
for all cationic species with a crystal structure obtained for the complex fac-
[Re(CO)3(L3)(MeCN)][BF4].  
The photophysical properties of all species were studied in depth. The neutral complexes were 
found to have dual emission arising from the separation of the intraligand charge transfer 
moiety at around 490 nm, and metal-to-ligand charge transfer moiety in the complex at around 
610 nm. Exchange of the axial bromide ligand in the neutral complexes with an acetonitrile 
ligand gave the four cationic complexes. The emission peak of these complexes showed an 
increase in energy and coincided with the intraligand charge transfer peak resulting in green 
emission only. 
This work has shown that the biologically active dicyanodibenzodioxin motif can be incorporated 
into a diimine ligand. Successful coordination of this compound to a tricarbonylrhenium(I) 
complex that shows dual green and red emission could lead to the development of biologically 
active luminescent probes. 
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5.5. Experimental 
All reactions were performed with the use of vacuum line and Schlenk techniques. Reagents 
were commercial grade and were used without further purification. 1H and 13C{1H} NMR spectra 
were run on NMR-FT Bruker 300 or 400 spectrometers and recorded in CDCl3. 1H and 13C{1H} 
NMR chemical shifts () were determined relative to internal TMS and are given in ppm. Low-
resolution mass spectra were obtained by the staff at Cardiff University. High-resolution mass 
spectra were carried out by at the EPSRC National Mass Spectrometry Service at Swansea 
University. UV-Vis studies were performed on a Shimadzu UV-1800 as chloroform solutions (10-
5 M). Photophysical data were obtained on a JobinYvon-Horiba Fluorolog spectrometer fitted 
with a JY TBX picosecond photodetection module as MeCN solutions. Emission spectra were 
uncorrected and excitation spectra were instrument corrected. The pulsed source was a Nano-
LED configured for 372 nm output operating at 1 MHz. Luminescence lifetime profiles were 
obtained using the JobinYvon-Horiba FluoroHub single photon counting module and the data 
fits yielded the lifetime values using the provided DAS6 deconvolution software.  
Synthesis of 1,10-phenanthroline-5,6-dione To a solution of sulfuric acid (40 mL, conc) and nitric 
acid (20 mL, conc) on ice, was added 1,10-phenanthroline (4.0 g, 0.02 mol) and sodium bromide 
(4.0g, 0.04 mol). The ice was removed and the reaction flask heated at reflux for 4 hours. The 
reaction mixture was cooled to room temperature and poured over ice before neutralisation 
with sodium hydroxide pellets (18 g, 0.5 mol), followed by sodium hydroxide solution (100 mL, 
10 M). The crude product was then extracted into chloroform (3x 500 mL), dried over MgSO4 
and the solvent removed in vacuo. Purification was carried out by trituration in hot ethanol (10 
mL) to yield 1,10-phenanthroline-5,6-dione as a yellow solid. (Yield = 2.02 g, 48 %), 1H NMR (300 
MHz, CDCl3) δ H 9.12 (2 H, dd, JHH = 4.6, 1.8 Hz), 8.71 – 8.33 (2 H, m), 7.67 – 7.46 (2 H, m). 
Synthesis of 1,10-phenanthroline-5,6-diol To a stirred solution of 1,10-phenanthroline-5,6-
dione (1.0 g, 4.8 mmol) in degassed water (40 ml) was added hydrazine hydrate (432 mg, 14.4 
mmol) at room temperature. Once the evolution of gas had begun to subside, the reaction 
mixture was filtered and the precipitate collected was washed with diethyl ether (100 mL) and 
dried in vacuo. The yellow product was used in subsequent steps without further 
characterisation. 
Synthesis of Ligand L1 To a solution of tetrafluoroteraphthalonitrile (1.0 g, 5.0 mmol) 
in acetone (60 mL) was added 1,10-phenanthroline-5,6-diol (961 mg, 5.0 mmol) and 
K2CO3 (1.40 g, 10.0 mmol). The reaction mixture was heated at reflux for 24 hours, after 
which time a green precipitate formed. After cooling to room temperature, the precipitate 
was collected by filtration and washed with acetone (20 mL), water (20 mL) and diethyl 
ether (50 mL) to give compound 1 as a green solid. (Yield = 1.48 g, 80 %). 1H NMR (400 
MHz, DMSO) δ H 9.16 (1 H, s), 8.38 (1 H, s), 7.99 – 7.92 (1 H, m) ppm. 13C{1H} NMR 
(126 MHz, CDCl3): δC 149.98, 146.49, 144.27, 142.78, 139.65, 128.84, 127.87, 123.01, 
118.41, 106.31 ppm. 19F{1H} NMR (376 MHz, DMSO): δF -132.30 ppm. HRMS (ASAP) 
found m/z = 373.0533, calculated m/z = 373.0532 for C20H6F2N4O2. UV vis. (CHCl3) max 
(ε / dm3mol-1cm-1):  402 (2300), 339 (2300), 280 (10800), 252 (18500) nm. IR (solid)  / 
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cm-1: 3385, 2241, 1655, 1620, 1585, 1477, 1458, 1423, 1346, 1331, 1302, 1263, 1250, 
1144, 1113, 1063, 1032, 976, 957, 800, 737, 635, 480.  
Synthesis of Ligand L2 To a solution of compound 1 (120 mg, 0.33 mmol) in dimethylformamide 
(5 mL) was added catechol (43 mg, 0.39 mmol) and K2CO3 (136 mg, 0.98 mmol). The reaction 
mixture was heated at 60 ˚C for 24 hours. Upon cooling, water (30 mL) was added to form a 
brown precipitate. The precipitate was collected by filtration and washed with diethyl ether (25 
mL) to give compound 2 as a dark brown solid. (Yield = 80 mg, 55 %). HRMS (ASAP) found m/z = 
443.0771, calculated m/z = 443.0775 for C26H10N4O4+H. UV vis. (CHCl3) max (ε / dm3mol-1cm-1): 
436 (6300), 350 (2700), 273 (19400) nm. IR (solid)  / cm-1: 3383, 3013, 2237, 1661, 1632, 1587, 
1454, 1346, 1329, 1304, 1267, 1248, 1113, 1088, 1063, 1026, 962, 802, 752, 737, 635, 559, 503, 
419, 411. 
Synthesis of Ligand L3 As synthesis of compound 2, but with compound 1 (300 mg, 0.81 mmol) 
and tert-butylcatechol (147 mg, 0.89 mmol). Product collected as a brown solid. (Yield = 245 mg, 
61 %). HRMS (ASAP) found m/z = 499.1388, calculated m/z = 499.1401 for C30H18N4O4+H. UV vis. 
(CHCl3) max (ε / dm3mol-1cm-1): 448 (5000), 349 (2100), 295 (7100), 273 (16600) nm. IR (solid)  
/ cm-1: 3362, 2955, 1663, 1630, 1508, 1456, 1344, 1329, 1300, 1265, 1113, 1088, 1063, 1030, 
968, 864, 843, 804, 737, 627, 407. 
Synthesis of Ligand L4 As synthesis of compound 2, but with compound 1 (150 mg, 0.40 mmol) 
and 2,3-naphthalenediol (71 mg, 0.44 mmol). Product collected as a dark purple solid. (Yield = 
85 mg, 43 %) UV vis. (CHCl3) max (ε / dm3mol-1cm-1): 433 (9400), 342 (4300), 294 (17200), 284 
(33600), 267 (50700), 254 (56000) nm. IR (solid)  / cm-1: 3379, 2241, 1655, 1630, 1585, 1508, 
1450, 1346, 1329, 1271, 1252, 1171, 1115, 1086, 1063, 1030, 966, 899, 870, 802, 737, 619, 480, 
451, 411. 
Synthesis of complex [Re(CO)3(L1)Br] Compound 1 (100 mg, 0.25 mmol) and Re(CO)5Br (100 mg, 
0.27 mmol) were stirred in toluene (25 ml) and heated at reflux for 24 hours. The cooled reaction 
mixture was filtered to give complex 1 as a green solid. (Yield = 140 mg, 78 %). 1H NMR (500 
MHz, DMSO): δ H 9.53 (2 H, d, JHH = 4.3 Hz), 8.81 (2 H, d, JHH = 8.1 Hz), 8.31 – 8.18 (2 H, m). HRMS 
(ASAP) found m/z = 744.8910, calculated m/z = 744.8922 for C23H6BrF2N4O5Re+Na.. UV vis. 
(CHCl3) max (ε / dm3mol-1cm-1): 442 (2500), 382 (6200), 300 (10700), 289 (14300) nm. IR (solid) 
 / cm-1 : 2031.04, 1928.82, 1894.10, 1876.74, 1664.57, 1487.12, 1465.90, 1352.10, 1273.02, 
1091.71, 1072.42, 1049.28, 966.34, 817.82, 748.38, 725.23, 522.71, 414.70, 405.05. 
Synthesis of complex [Re(CO)3(L2)Br] Compound 2 (80 mg, 0.18 mmol) and Re(CO)5Br (73 mg, 
0.18 mmol) were stirred in toluene and heated at reflux for 24 hours. The cooled reaction 
mixture was filtered to give complex 2 as a green solid. (Yield = 105 mg, 76 %). 1H NMR (400 
MHz, DMSO): δ H 9.52 (2 H, m), 8.78 (2 H, m), 8.23 (2 H, m), 7.16 (4 H, m). HRMS (ASAP) found 
m/z = 791.9272, calculated m/z = 791.9274 for C29H10BrN4O7Re. UV vis. (CHCl3) max (ε / dm3mol-
1cm-1): 427 (10000), 301 (11200), 264 (39300) nm. IR (solid)  / cm-1 : 2019, 1902, 1659, 1634, 
1495, 1429, 1350, 1331, 1308, 1273, 1252, 1125, 1090, 1072, 1051, 997, 976, 812, 772, 739, 725, 
644, 627, 527, 484, 434, 424, 411, 401. 
Synthesis of complex [Re(CO)3(L3)Br] Compound 4 (100 mg, 0.20 mmol) and Re(CO)5Br (74 mg, 
0.18 mmol) were stirred in toluene (25 mL) and heated at reflux for 24 hours. The cooled 
reaction mixture was filtered to give complex 4 as an orange solid. (Yield = 125 mg, 82 %). 1H 
NMR (500 MHz, DMSO): δ H  9.51 (2 H, d, JHH = 5.0 Hz), 8.78 (2 H, d, JHH = 7.9 Hz), 8.22 (2 H, dd, 
Chapter 5  
167 
 
JHH = 8.1, 4.9 Hz), 7.20 – 7.07 (3 H, m), 1.28 (9 H, s). HRMS (ASAP) found m/z = 870.9780, 
calculated m/z = 870.9797 for C33H18BrN4O7Re+Na. UV vis. (CHCl3) max (ε / dm3mol-1cm-1):  434 
(16300), 304 (1400), 265 (68300) nm. IR (solid)  / cm-1 : 2029, 1924, 1879, 1661, 1634, 1462, 
1427, 1350, 1329, 1277, 1125, 1090, 1072, 1051, 995, 978, 814, 725, 640, 621, 523, 467, 403. 
Synthesis of complex [Re(CO)3(L4)Br] Compound 3 (70 mg, 0.14 mmol) and Re(CO)5Br (71 mg, 
0.14 mmol) were stirred in toluene (25 mL) and heated at reflux for 24 hours. The cooled 
reaction mixture was filtered to give complex 3 as a dark brown solid. (Yield = 111 mg, 94 %). 1H 
NMR (500 MHz, DMSO): δ H 8.50 (2 H, d, JHH = 3.4 Hz), 7.90 – 7.85 (2 H, m), 7.45 (2 H, m), 7.25 (2 
H, m), 7.16 (4 H, m). UV vis. (CHCl3) max (ε / dm3mol-1cm-1):  417 (3400), 263 (9300) nm. IR (solid) 
 / cm-1 : 2021, 1886, 1605, 1512, 1458, 1329, 1279, 1258, 1169, 1126, 1090, 1072, 1049, 980, 
908, 816, 772, 723, 523, 478, 414, 401. 
Synthesis of [Re(CO)3(L1)MeCN][BF4] A solution of Re(CO)3(L1)Br (300 mg, 0.42 mmol) and silver 
tetrafluoroborate, AgBF4, (1.5 eq., 121 mg, 0.62 mmol) in acetonitrile (50 mL) was heated at 
reflux for 24 hours in the absence of light. Upon cooling, the reaction mixture was filtered 
through Celite™ and the filtrate dried in vaccuo. The crude solid was taken up in acetonitrile and 
reprecipitated by addition of diethyl ether. A green precipitate was collected by filtration and 
washed with diethyl ether to give [Re(CO)3(L1)MeCN][BF4] (Yield = 128 mg, 40%). 1H NMR (400 
MHz, Acetone): δ H 9.69 (2 H, ddd, JHH = 5.1, 3.5, 1.3 Hz), 9.09 – 9.03 (2 H, m), 8.46 – 8.36 (1 H, 
m), 2.78 (3 H, s). HRMS (ESI) found m/z = 684.0151, calculated m/z = 684.0129 for 
C25H9F2N5O5Re+. UV vis. (CH3CN) max (ε / dm3mol-1cm-1): 375 (9800), 295 (19000), 248 (55000) 
nm. IR (solid) υmax = 2039, 1948, 913, 1663, 1589, 1481, 1468, 1431, 1356, 1265, 1070, 1051, 
989, 822, 727, 642, 625, 523, 478, 409 cm-1. 
Synthesis of [Re(CO)3(L2)MeCN][BF4] As [Re(CO)3(L1)MeCN][BF4] but with Re(CO)3(L2)Br (300 
mg, 0.38 mmol), and AgBF4 (1.5 eq, 110 mg, 0.57 mmol). Product collected as green/yellow solid 
(Yield = 56 mg, 18%). 1H NMR (300 MHz, DMSO): δ H 9.57 (2 H, d, JHH = 6.0 Hz), 8.89 (1 H, d, JHH = 
7.8 Hz), 8.30 (2 H, m), 7.19 (4 H, m), 2.16 (3 H, s). HRMS (ESI) found m/z = 754.0375, calculated 
m/z = 754.0372 for C31H13N5O7Re+. UV vis. (CH3CN) max (ε / dm3mol-1cm-1): 422 (5700), 261 
(36600) nm. IR (solid) υmax = 2035, 1902, 1663, 1634, 1460, 1433, 1354, 1306, 1275, 1250, 1130, 
1051, 976, 812, 762, 725, 644, 590, 532, 520, 419, 411, 403 cm-1. 
Synthesis of [Re(CO)3(L3)MeCN][BF4] As [Re(CO)3(L1)MeCN][BF4] but with Re(CO)3(L3)Br (300 
mg, 0.35 mmol) and AgBF4 (1.5 eq., 103 mg, 0.53 mmol). Product collected as an orange solid 
(Yield = 186 mg, 59%). 1H NMR (300 MHz, DMSO): δ H 9.56 (2 H, d, JHH = 4.8 Hz), 8.88 (2 H, d, JHH 
=  8.1 Hz), 8.37 – 8.23 (2 H, m), 7.18 (1 H, s), 7.13 (2 H, s), 2.15 (3 H, s), 1.28 (9 H, s) ppm. 13C{1H} 
NMR (126 MHz, DMSO): δ C 195.6, 154.2, 149.2, 142.9, 140.3, 140.2, 138.5, 137.4, 137.5, 136.7, 
132.7, 131.3, 127.7, 122.3, 121.4, 117.8, 115.9, 113.7, 109.1, 93.6, 93.5 34.2, 30.6, 0.9, 0.1 ppm. 
HRMS (ESI) found m/z = 810.0989, calculated m/z = 810.0998 for C35H21N5O7Re+. UV vis. (CH3CN) 
max (ε / dm3mol-1cm-1): 425 (4800), 283 (33900), 264 (47600) nm. IR (solid) υmax = 3553, 2037, 
1917, 1634, 1464, 1433, 1418, 1352, 1331, 1273, 1072, 1016, 980, 895, 816, 766, 725,  714, 644, 
627, 518.85, 433.98 cm-1. 
Synthesis of [Re(CO)3(L4)MeCN][BF4] As [Re(CO)3(L1)MeCN][BF4] but with Re(CO)3(L4)Br (300 
mg, 0.36 mmol) and AgBF4 (1.5 eq., 103 mg, 0.53 mmol). Product collected as a dark green solid 
(Yield = 14 mg, 5%). 1H NMR (300 MHz, DMSO): δ H 9.58 (2 H, m), 8.88 (2 H, m), 8.32 (2 H, m), 
7.79 (4 H, m), 7.41 (2 H, m), 2.07 (3 H, s). HRMS (ESI) found m/z = 804.0517, calculated m/z = 
804.0529 for C35H15N5O7Re+. UV vis. (CH3CN) max (ε / dm3mol-1cm-1): 425 (4500), 261 (46400), 
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234 (42200) nm. IR (solid) υmax = 2035, 1902, 1663, 1460, 1433, 1354, 1306, 1275, 1250, 1130, 
1051, 976, 812, 762, 725, 644, 590, 532, 521, 419, 411, 403 cm-1. 
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6.1. Summary 
This thesis has explored the synthesis and characterisation of luminescent transition metal 
complexes, beginning with the design of cyclometallating ligands in iridium(III) systems, followed 
by studying the effects of ancillary ligand upon emission and ending with the design of novel 
diimine ligands. 
The work of chapter 2 investigated the effects of cyclometallating ligand substituents upon the 
luminescent properties of cationic bis-cyclometallated iridium(III) complexes. It was found that 
these changes in ligand structure led to a tuning range of 30 nm across the series. Chapter 3 
then expanded upon this work by investigating the role of ancillary ligand in the bis-
cyclometallated iridium(III) systems developed in chapter 2. This work found that changing the 
ancillary ligand could further extend the range of emission wavelengths using the same 
cyclometallating ligands as the work in chapter 2. 
Bis-cyclometallated iridium(III) systems also formed the basis of chapter 4. Ligands with a 
benzo[g]quinoxaline structure were used to study how the extent of conjugation influences the 
emission properties of a complex. The results showed that each complex showed emission in 
the near infra-red region of the spectrum. 
Chapter 5 focussed upon the synthesis of a series of novel diimine compounds and their 
coordination chemistry with rhenium in a series of tricarbonylrhenium(I) complexes. From this 
work, a series of four novel diimine ligands were synthesised incorporating a 
dicyanodibenzodioxin segment into their structure, as well as eight novel rhenium(I) complexes. 
The results showed that the neutral series of complexes showed two emission peaks, with the 
longer wavelength peak varying in intensity depending upon the structure of the diimine ligand. 
6.2. Future Work 
Chapter 5 presented the synthesis of a series of novel diimine ligands with a structure based 
around dicyanodibenzodioxin and their coordination chemistry with rhenium(I). This work 
showed that incorporation of these ligands into a neutral tricarbonylrhenium(I) complex 
resulted in dual emission from the species, with the intensity of red emission varying with ligand 
structure. It is therefore of interest to investigate whether these novel diimine ligands could 
influence the photophysical properties of other luminescent transition metal complexes. The 
experiments presented in this chapter form the foundation of future work to this end. 
Chapter 2 reported series of iridium(III) complexes with quinoxaline-based cyclometallating 
ligands and the literature known diimine ligand 2,2’-bipyridine. Chapter 3 showed that 
substitution of 2,2’-bipyridine with picolinic acid or pyrazinoic acid further influenced the 
photophysical properties. As an extension of this work, the dicyanodibenzodioxin ligand L1 from 
chapter 5 was used as an ancillary ligand in one of these iridium complexes. The proposed 
synthetic route is shown in Scheme 6.1. 
The synthesis makes use of the bis-acetonitrile iridium(III) complex synthesised in chapter 3 as 
the iridium(III) starting material. This was chosen over the µ-chloro-bridged dimeric iridium 
species used in chapter 2 due to the increased lability of acetonitrile ligands over the bridging 
chloride ligands. To overcome the low solubility of ligand L1 in common organic solvents, 
nitromethane was used as the reaction solvent due to its high boiling point and is only weakly 
coordinating. 
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Scheme 6.1: Proposed synthesis of bis-cyclometallated iridium(III) complexes with dioxin-based ligands. 
The experimental procedure for this reaction is described below: 
[Ir(quin)2(MeCN)2][BF4] (200 mg, 0.23 mmol) and ligand L1 (96 mg, 0.25 mmol) were dissolved 
in nitromethane (10 mL) and heated at reflux for 48 hours under a nitrogen atmosphere. Upon 
cooling, the solvent was removed in vaccuo and the crude solid taken up in chloroform. The 
solution was filtered to remove a green precipitate and the dark red solution purified by column 
chromatography using DCM/MeOH (95:5) as the eluent. Small fractions were collected from a 
wide red band and two fractions were shown to contain one species by TLC. These were dried 
and recrystallised using vapour diffusion of diisopropyl ether into a saturated solution of the 
product in MeCN. The red coloured crystals grown were submitted for single crystal x-ray 
diffraction. The crystal structure of this complex is shown in Figure 6.1 with the crystal data in 
the appendix of this work. 
 
Figure 6.1: Crystal structure obtained by single crystal x-ray diffraction. 
The crystal data shows that the target complex was isolated, however, the low yield suggests 
that the reaction conditions require adjustment in order to give yields high enough for full 
analysis. 
The future of this work lies in using each diimine ligand from chapter 5 as ancillary ligands in 
iridium complexes, beginning with those systems outlaid in chapter 2 and then in the near-
infrared systems of chapter 4. The photophysical properties should then be fully investigated 
and, if appropriate, followed by cell imaging studies. 
Table 6.1: Crystal data collection parameters for iridium complex with dicyanodibenzodioxin ligand 
N
N
N
N
Ir
NCMe
NCMe
BF4
N
N
N
N
Ir
N
N O
O
CN
F
F
CN
BF4
MeNO2
N
N O
O
CN
F
F
CN
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Formula C62H53BF6IrN9O3 Z' 1 
Dcalc./ g cm-3 1.546 Wavelength/Å 0.71075 
µ/mm-1 2.487 Radiation type MoKα 
Formula Weight 1289.14 Θmin/° 1.688 
Colour red Θmax/° 27.483 
Shape block Measured Refl. 189143 
Size/mm3 0.140×0.120×0.040 Independent Refl. 12698 
T/K 100(2) Reflections with I > 2(I) 11479 
Crystal System monoclinic Rint 0.0485 
Space Group P21/n Parameters 872 
a/Å 12.1642(2) Restraints 587 
b/Å 12.8238(2) Largest Peak 1.704 
c/Å 35.8981(6) Deepest Hole -0.593 
α/° 90 GooF 1.064 
β/° 98.4850(10) wR2 (all data) 0.0797 
γ/° 90 wR2 0.0769 
V/Å3 5538.50(16) R1 (all data) 0.0352 
Z 4 R1 0.0303 
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